<!DOCTYPE html><html lang="en" class="bg-surface-base antialiased"><head><meta charSet="utf-8"/><meta name="viewport" content="width=device-width, initial-scale=1, interactive-widget=resizes-content"/><link rel="stylesheet" href="/_next/static/css/62c4caba71dfda84.css" nonce="YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/eb3d87f98fe1565f.css" nonce="YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/1b5e561215938d4d.css" nonce="YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/0227d069a630d414.css" nonce="YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/f87fff2ab93d05a7.css" nonce="YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm" data-precedence="next"/><link rel="preload" as="script" fetchPriority="low" nonce="YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm" href="/_next/static/chunks/webpack-e121ed42680f327e.js"/><script src="/_next/static/chunks/78a669d9-e7993486b22c4915.js" async="" nonce="YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm"></script><script src="/_next/static/chunks/40c4a5a7-abdabb07419d1cfc.js" async="" nonce="YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm"></script><script src="/_next/static/chunks/2230-f7c87dc9fa57c408.js" async="" nonce="YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm"></script><script src="/_next/static/chunks/main-app-536d4b8fca62396a.js" async="" nonce="YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm"></script><script src="/_next/static/chunks/63f0ec43-8ee6a76d70472249.js" async="" nonce="YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm"></script><script src="/_next/static/chunks/7670-7326298c9856172b.js" async="" nonce="YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm"></script><script src="/_next/static/chunks/282-691fffb366e24ca5.js" async="" nonce="YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm"></script><script src="/_next/static/chunks/7515-336759ef5dad2b52.js" async="" nonce="YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm"></script><script src="/_next/static/chunks/927-34e2a6da3e15e26b.js" async="" nonce="YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm"></script><script src="/_next/static/chunks/5855-243eeca8f0e4cabd.js" async="" nonce="YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm"></script><script src="/_next/static/chunks/4393-1c8dff25ec904469.js" async="" nonce="YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm"></script><script src="/_next/static/chunks/2225-454cf9f44775e7ce.js" async="" nonce="YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm"></script><script src="/_next/static/chunks/7618-43536a8fb0dd3bfe.js" async="" nonce="YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js" async="" nonce="YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm"></script><script src="/_next/static/chunks/7720-3a1e7e411adba2d3.js" async="" nonce="YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm"></script><script src="/_next/static/chunks/7086-1f1c4891d766e04f.js" async="" nonce="YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/not-found-69a3edc7db5749d6.js" async="" nonce="YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm"></script><script src="/_next/static/chunks/app/global-error-4d07d20223cd4b4c.js" async="" nonce="YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm"></script><script src="/_next/static/chunks/8208b75a-a48e5a4507a0de91.js" async="" nonce="YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm"></script><script src="/_next/static/chunks/5497-ab85ef3ea59dd353.js" async="" nonce="YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm"></script><script src="/_next/static/chunks/6281-c6e84786dade3614.js" async="" nonce="YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm"></script><script src="/_next/static/chunks/2660-d983a7f287e89f18.js" async="" nonce="YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm"></script><script src="/_next/static/chunks/5002-9735c25beda556ba.js" async="" nonce="YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm"></script><script src="/_next/static/chunks/3655-6717081f7512305a.js" async="" nonce="YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm"></script><script src="/_next/static/chunks/8945-e4e3cf487f5e27c7.js" async="" nonce="YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm"></script><script src="/_next/static/chunks/9214-a10614844a67ba31.js" async="" nonce="YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm"></script><script src="/_next/static/chunks/4789-2080f6497f78b5b6.js" async="" nonce="YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm"></script><script src="/_next/static/chunks/app/layout-226f2bd71acf9f9e.js" async="" nonce="YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm"></script><script src="/_next/static/chunks/24cf1b50-159cca90b09285e0.js" async="" nonce="YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm"></script><script src="/_next/static/chunks/9ffa21ba-c069766d809bd4c7.js" async="" nonce="YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm"></script><script src="/_next/static/chunks/600-9a9fcafaaa6c1c4c.js" async="" nonce="YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm"></script><script src="/_next/static/chunks/5448-2a3cfd853d899c9a.js" async="" nonce="YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm"></script><script src="/_next/static/chunks/8-8ca70ca619d8e099.js" async="" nonce="YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js" async="" nonce="YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm"></script><script src="/_next/static/chunks/app/error-4a29e9399afba038.js" async="" nonce="YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm"></script><script src="/_next/static/chunks/app/not-found-dd95690acf732f18.js" async="" nonce="YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm"></script><meta name="next-size-adjust" content=""/><title>Grokipedia</title><meta name="description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><link rel="icon" type="image/x-icon" href="/favicon.ico" sizes="48x48"/><link rel="icon" href="/images/icon-dark.png" media="(prefers-color-scheme: light)" type="image/png"/><link rel="icon" href="/images/icon-light.png" media="(prefers-color-scheme: dark)" type="image/png"/><link rel="apple-touch-icon" href="/icon-192x192.png"/><link rel="manifest" href="/manifest.webmanifest"/><meta name="robots" content="index, follow"/><meta name="googlebot" content="index, follow, max-snippet:-1"/><meta property="og:title" content="Grokipedia"/><meta property="og:description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><meta property="og:url" content="https://grokipedia.com"/><meta property="og:site_name" content="Grokipedia"/><meta property="og:locale" content="en_US"/><meta property="og:type" content="website"/><meta property="og:image" content="https://grokipedia.com/icon-512x512.png"/><meta property="og:image:width" content="512"/><meta property="og:image:height" content="512"/><meta property="og:image:alt" content="Grokipedia"/><meta name="twitter:card" content="summary"/><meta name="twitter:creator" content="@Grokipedia"/><meta name="twitter:title" content="Grokipedia"/><meta name="twitter:description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><meta name="twitter:image" content="https://grokipedia.com/icon-512x512.png"/><title>Barbital</title><meta name="description" content="Barbital, also known by the trade name Veronal, is a barbiturate compound chemically designated as 5,5-diethylbarbituric acid, recognized as the first barbiturate introduced for clinical use as a long-acting sedative and hypnotic agent. Synthesized in 1902 by Emil Fischer and Heinrich Dresler, its hypnotic properties were demonstrated in 1903 by pharmacologist Josef von Mering, leading to its patenting and marketing by Bayer starting in 1904. Barbital exerts its effects primarily by enhancing..."/><meta name="author" content="system"/><link rel="manifest" href="/manifest.webmanifest"/><meta name="keywords" content="Veronal"/><meta name="robots" content="index, follow"/><meta name="googlebot" content="index, follow, max-snippet:-1"/><link rel="canonical" href="https://grokipedia.com/page/Barbital"/><meta property="og:title" content="Barbital"/><meta property="og:description" content="Barbital, also known by the trade name Veronal, is a barbiturate compound chemically designated as 5,5-diethylbarbituric acid, recognized as the first barbiturate introduced for clinical use as a long-acting sedative and hypnotic agent. Synthesized in 1902 by Emil Fischer and Heinrich Dresler, its hypnotic properties were demonstrated in 1903 by pharmacologist Josef von Mering, leading to its patenting and marketing by Bayer starting in 1904. Barbital exerts its effects primarily by enhancing..."/><meta property="og:url" content="https://grokipedia.com/page/Barbital"/><meta property="og:site_name" content="Grokipedia"/><meta property="og:locale" content="en"/><meta property="og:image" content="https://grokipedia.com/icon-512x512.png"/><meta property="og:image:width" content="512"/><meta property="og:image:height" content="512"/><meta property="og:image:alt" content="Barbital"/><meta property="og:type" content="article"/><meta property="article:modified_time" content="1970-01-21T09:19:43.129Z"/><meta name="twitter:card" content="summary"/><meta name="twitter:creator" content="@Grokipedia"/><meta name="twitter:title" content="Barbital"/><meta name="twitter:description" content="Barbital, also known by the trade name Veronal, is a barbiturate compound chemically designated as 5,5-diethylbarbituric acid, recognized as the first barbiturate introduced for clinical use as a long-acting sedative and hypnotic agent. Synthesized in 1902 by Emil Fischer and Heinrich Dresler, its hypnotic properties were demonstrated in 1903 by pharmacologist Josef von Mering, leading to its patenting and marketing by Bayer starting in 1904. Barbital exerts its effects primarily by enhancing..."/><meta name="twitter:image" content="https://grokipedia.com/icon-512x512.png"/><link rel="icon" href="/favicon.ico" type="image/x-icon" sizes="16x16"/><meta name="sentry-trace" content="28b97e785f6756198304d5e928f04de9-69e13640464a4905-1"/><meta name="baggage" content="sentry-environment=production,sentry-public_key=5f2258f71198ee26a355127af230c3a6,sentry-trace_id=28b97e785f6756198304d5e928f04de9,sentry-org_id=4508179396558848,sentry-transaction=GET%20%2Fpage%2F%5Bslug%5D,sentry-sampled=true,sentry-sample_rand=0.6565073746679952,sentry-sample_rate=1"/><script src="/_next/static/chunks/polyfills-42372ed130431b0a.js" noModule="" nonce="YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm"></script></head><body class="flex h-[100svh] w-full flex-col __variable_13c637 __variable_8a0ba0 __variable_779740 __variable_2484fd __variable_525cc3 __variable_13486b"><div hidden=""><!--$--><!--/$--></div><script nonce="YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm">((a,b,c,d,e,f,g,h)=>{let i=document.documentElement,j=["light","dark"];function k(b){var c;(Array.isArray(a)?a:[a]).forEach(a=>{let c="class"===a,d=c&&f?e.map(a=>f[a]||a):e;c?(i.classList.remove(...d),i.classList.add(f&&f[b]?f[b]:b)):i.setAttribute(a,b)}),c=b,h&&j.includes(c)&&(i.style.colorScheme=c)}if(d)k(d);else try{let a=localStorage.getItem(b)||c,d=g&&"system"===a?window.matchMedia("(prefers-color-scheme: dark)").matches?"dark":"light":a;k(d)}catch(a){}})("class","theme","dark",null,["light","dark"],null,true,true)</script><header class="h-16 bg-surface-base fixed top-0 z-50 w-full"><div class="hidden h-full grid-cols-[1fr_3fr_1fr] items-center gap-4 !py-0 md:grid max-w-full py-6 px-4 w-full mx-auto"><div class="-ml-2 justify-self-start"><a class="cursor-pointer" href="/"><svg width="200" height="auto" viewBox="0 0 955 225" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M99.6937 159.214C90.008 159.214 81.5652 157.414 74.3652 153.814C67.1652 150.214 61.5509 144.986 57.5223 138.129C53.5794 131.271 51.608 123.043 51.608 113.443C51.608 103.843 53.5794 95.4857 57.5223 88.3714C61.5509 81.2572 67.1652 75.7286 74.3652 71.7857C81.6509 67.8429 90.1794 65.8714 99.9509 65.8714C103.208 65.8714 106.679 66.1286 110.365 66.6429C114.051 67.0714 117.222 67.6714 119.879 68.4429C121.508 68.8714 123.008 69.2572 124.379 69.6C125.751 69.9429 127.122 70.1143 128.494 70.1143C129.522 70.1143 130.551 69.9857 131.579 69.7286C131.751 73.5 131.922 77.4 132.094 81.4286C132.265 85.4572 132.522 89.6572 132.865 94.0286C131.065 94.2857 129.565 94.3714 128.365 94.2857C126.651 86.4 123.522 80.5714 118.979 76.8C114.437 72.9429 108.394 71.0143 100.851 71.0143C94.8509 71.0143 89.708 72.1286 85.4223 74.3572C81.2223 76.5 77.7937 79.4572 75.1366 83.2286C72.5652 87 70.6794 91.3714 69.4794 96.3429C68.2794 101.229 67.6794 106.457 67.6794 112.029C67.6794 120.171 68.9223 127.371 71.408 133.629C73.8937 139.886 77.6652 144.814 82.7223 148.414C87.8652 151.929 94.2937 153.686 102.008 153.686C104.408 153.686 107.065 153.471 109.979 153.043C112.894 152.529 115.679 151.757 118.337 150.729V134.529C118.337 131.871 118.208 129.814 117.951 128.357C117.779 126.814 117.222 125.7 116.279 125.014C115.422 124.329 114.008 123.857 112.037 123.6C110.151 123.257 107.537 122.957 104.194 122.7C103.937 121.329 103.937 119.957 104.194 118.586C105.994 118.586 108.179 118.629 110.751 118.714C113.322 118.714 115.894 118.757 118.465 118.843C121.122 118.843 123.308 118.843 125.022 118.843C127.679 118.843 130.722 118.8 134.151 118.714C137.665 118.629 140.665 118.586 143.151 118.586C143.322 119.871 143.322 121.2 143.151 122.571C139.637 123 137.108 123.429 135.565 123.857C134.022 124.286 133.079 125.143 132.737 126.429C132.394 127.714 132.222 129.9 132.222 132.986V137.1C132.222 141.129 132.308 144.514 132.479 147.257C132.737 150 132.951 151.971 133.122 153.171C121.208 157.2 110.065 159.214 99.6937 159.214ZM148.19 157.414C147.933 156.043 147.933 154.714 148.19 153.429C151.105 153.257 153.248 153 154.619 152.657C155.99 152.229 156.89 151.371 157.319 150.086C157.748 148.8 157.962 146.743 157.962 143.914V115.114C157.962 111.771 157.79 109.286 157.448 107.657C157.19 106.029 156.376 104.914 155.005 104.314C153.719 103.629 151.49 103.071 148.319 102.643C148.062 101.443 148.062 100.329 148.319 99.3C151.748 98.6143 155.09 97.8429 158.348 96.9857C161.605 96.0429 165.033 94.8429 168.633 93.3857L170.819 94.1572V105.471C176.819 97.8429 182.948 94.0286 189.205 94.0286C192.205 94.0286 194.433 94.8429 195.89 96.4714C197.348 98.0143 198.076 99.7714 198.076 101.743C198.076 104.057 197.305 105.857 195.762 107.143C194.219 108.343 192.462 108.943 190.49 108.943C188.862 108.943 187.233 108.514 185.605 107.657C184.062 106.8 182.905 105.471 182.133 103.671C179.219 103.671 176.605 104.829 174.29 107.143C172.062 109.371 170.948 111.986 170.948 114.986V142.629C170.948 145.971 171.119 148.371 171.462 149.829C171.89 151.286 172.919 152.229 174.548 152.657C176.262 153 179.005 153.257 182.776 153.429C182.948 154.629 182.948 155.957 182.776 157.414C179.862 157.414 176.862 157.371 173.776 157.286C170.69 157.2 167.519 157.157 164.262 157.157C161.09 157.157 158.262 157.2 155.776 157.286C153.376 157.371 150.848 157.414 148.19 157.414ZM229.285 158.829C223.028 158.829 217.542 157.5 212.828 154.843C208.199 152.1 204.599 148.371 202.028 143.657C199.457 138.857 198.171 133.371 198.171 127.2C198.171 120.514 199.499 114.686 202.157 109.714C204.899 104.743 208.714 100.886 213.599 98.1429C218.485 95.4 224.099 94.0286 230.442 94.0286C236.699 94.0286 242.142 95.4 246.771 98.1429C251.399 100.886 254.999 104.657 257.571 109.457C260.142 114.257 261.428 119.7 261.428 125.786C261.428 132.043 260.057 137.7 257.314 142.757C254.657 147.729 250.928 151.671 246.128 154.586C241.328 157.414 235.714 158.829 229.285 158.829ZM212.699 125.657C212.699 134.4 214.114 141.343 216.942 146.486C219.857 151.543 224.185 154.071 229.928 154.071C235.414 154.071 239.614 151.671 242.528 146.871C245.442 141.986 246.899 135.471 246.899 127.329C246.899 118.671 245.442 111.771 242.528 106.629C239.614 101.486 235.371 98.9143 229.799 98.9143C224.314 98.9143 220.071 101.271 217.071 105.986C214.157 110.7 212.699 117.257 212.699 125.657ZM267.394 157.414C267.308 157.071 267.265 156.729 267.265 156.386C267.265 156.043 267.265 155.7 267.265 155.357C267.265 155.014 267.265 154.714 267.265 154.457C267.265 154.114 267.308 153.771 267.394 153.429C270.308 153.257 272.451 153 273.822 152.657C275.194 152.229 276.094 151.371 276.522 150.086C276.951 148.8 277.165 146.743 277.165 143.914V79.5C277.165 76.8429 276.908 74.8714 276.394 73.5857C275.965 72.2143 274.979 71.2714 273.437 70.7572C271.979 70.1572 269.751 69.7286 266.751 69.4714C266.665 69.1286 266.622 68.8286 266.622 68.5714C266.622 68.3143 266.622 68.0572 266.622 67.8C266.622 67.4572 266.622 67.1572 266.622 66.9C266.622 66.6429 266.665 66.3429 266.751 66C270.179 65.5714 273.694 64.9286 277.294 64.0714C280.894 63.1286 284.579 61.8429 288.351 60.2143L290.537 60.9857C290.451 62.8714 290.365 65.0143 290.279 67.4143C290.279 69.8143 290.279 72.4286 290.279 75.2572V122.957C291.308 122.957 292.165 122.786 292.851 122.443C293.537 122.1 294.094 121.757 294.522 121.414C294.694 121.243 295.037 120.943 295.551 120.514C296.065 120 296.965 119.1 298.251 117.814C299.537 116.529 301.379 114.6 303.779 112.029C306.008 109.543 307.765 107.614 309.051 106.243C310.422 104.786 311.108 103.586 311.108 102.643C311.108 101.957 310.508 101.4 309.308 100.971C308.194 100.457 306.651 100.157 304.679 100.071C304.594 99.7286 304.551 99.3857 304.551 99.0429C304.551 98.7 304.551 98.3572 304.551 98.0143C304.551 97.6714 304.551 97.3286 304.551 96.9857C304.551 96.6429 304.594 96.3 304.679 95.9572C306.394 95.9572 308.537 96 311.108 96.0857C313.765 96.1714 316.122 96.2143 318.179 96.2143C319.208 96.2143 320.665 96.2143 322.551 96.2143C324.522 96.1286 326.494 96.0857 328.465 96.0857C330.437 96.0857 331.894 96.0857 332.837 96.0857C332.922 96.4286 332.965 96.7714 332.965 97.1143C333.051 97.4572 333.094 97.8 333.094 98.1429C333.094 98.4857 333.051 98.8286 332.965 99.1714C332.965 99.4286 332.922 99.7286 332.837 100.071C328.379 100.157 324.608 101.271 321.522 103.414C318.437 105.471 315.479 107.914 312.651 110.743L303.394 120L321.137 143.4C323.022 145.886 324.565 147.857 325.765 149.314C327.051 150.686 328.422 151.671 329.879 152.271C331.337 152.871 333.351 153.257 335.922 153.429C336.094 154.629 336.094 155.957 335.922 157.414C334.808 157.414 333.137 157.371 330.908 157.286C328.765 157.2 325.379 157.157 320.751 157.157C320.065 157.157 319.037 157.157 317.665 157.157C316.294 157.157 315.008 157.243 313.808 157.414C313.808 156.471 313.294 155.186 312.265 153.557C311.237 151.843 310.422 150.6 309.822 149.829C309.565 149.4 308.922 148.5 307.894 147.129C306.865 145.671 305.622 144 304.165 142.114C302.794 140.143 301.379 138.171 299.922 136.2C298.465 134.143 297.137 132.343 295.937 130.8C294.994 129.514 294.094 128.529 293.237 127.843C292.465 127.071 291.479 126.686 290.279 126.686V142.629C290.279 145.971 290.408 148.371 290.665 149.829C291.008 151.286 291.737 152.229 292.851 152.657C294.051 153 295.851 153.257 298.251 153.429C298.422 154.714 298.422 156.043 298.251 157.414C296.022 157.414 293.665 157.371 291.179 157.286C288.779 157.2 286.165 157.157 283.337 157.157C280.594 157.157 277.894 157.2 275.237 157.286C272.579 157.371 269.965 157.414 267.394 157.414ZM369.34 157.414C366.94 157.414 364.454 157.371 361.883 157.286C359.311 157.2 356.526 157.157 353.526 157.157C350.783 157.157 347.997 157.2 345.169 157.286C342.426 157.371 339.769 157.414 337.197 157.414C336.94 156.043 336.94 154.714 337.197 153.429C340.111 153.257 342.254 153 343.626 152.657C344.997 152.229 345.897 151.371 346.326 150.086C346.754 148.8 346.969 146.743 346.969 143.914V115.114C346.969 111.771 346.84 109.286 346.583 107.657C346.326 106.029 345.511 104.914 344.14 104.314C342.854 103.629 340.583 103.071 337.326 102.643C337.069 101.443 337.069 100.329 337.326 99.3C341.097 98.6143 344.697 97.7572 348.126 96.7286C351.554 95.7 354.854 94.5857 358.026 93.3857L360.211 94.1572C360.126 96.8143 360.04 99.3 359.954 101.614C359.954 103.929 359.954 106.114 359.954 108.171V142.629C359.954 145.971 360.126 148.371 360.469 149.829C360.897 151.286 361.754 152.229 363.04 152.657C364.411 153 366.511 153.257 369.34 153.429C369.597 154.714 369.597 156.043 369.34 157.414ZM343.626 71.5286C343.626 69.0429 344.483 66.9429 346.197 65.2286C347.997 63.5143 350.14 62.6572 352.626 62.6572C355.026 62.6572 357.083 63.5143 358.797 65.2286C360.597 66.9429 361.497 69 361.497 71.4C361.497 73.6286 360.64 75.6857 358.926 77.5715C357.211 79.3714 355.026 80.2714 352.369 80.2714C349.969 80.2714 347.911 79.4143 346.197 77.7C344.483 75.9857 343.626 73.9286 343.626 71.5286ZM372.678 188.914C372.592 187.543 372.592 186.214 372.678 184.929C375.678 184.757 377.864 184.457 379.235 184.029C380.607 183.6 381.464 182.743 381.807 181.457C382.235 180.257 382.45 178.286 382.45 175.543V115.114C382.45 111.771 382.278 109.286 381.935 107.657C381.678 106.029 380.864 104.914 379.492 104.314C378.207 103.629 375.978 103.071 372.807 102.643C372.635 101.443 372.635 100.329 372.807 99.3C376.321 98.6143 379.75 97.8 383.092 96.8572C386.435 95.9143 389.907 94.7572 393.507 93.3857L395.307 94.2857C395.221 96.4286 395.178 98.2714 395.178 99.8143C395.178 101.271 395.178 102.686 395.178 104.057C398.521 100.543 401.821 98.0143 405.078 96.4714C408.335 94.8429 411.807 94.0286 415.492 94.0286C420.892 94.0286 425.435 95.4429 429.121 98.2714C432.892 101.1 435.764 104.786 437.735 109.329C439.707 113.871 440.692 118.8 440.692 124.114C440.692 130.371 439.321 136.157 436.578 141.471C433.921 146.7 430.192 150.9 425.392 154.071C420.592 157.243 415.021 158.829 408.678 158.829C406.192 158.829 403.835 158.614 401.607 158.186C399.378 157.843 397.278 157.329 395.307 156.643V174C395.307 177.343 395.564 179.743 396.078 181.2C396.592 182.657 397.707 183.557 399.421 183.9C401.135 184.329 403.835 184.629 407.521 184.8C407.607 186.171 407.607 187.543 407.521 188.914C404.607 188.914 401.65 188.871 398.65 188.786C395.735 188.7 392.521 188.657 389.007 188.657C385.664 188.657 382.792 188.7 380.392 188.786C377.992 188.871 375.421 188.914 372.678 188.914ZM395.178 146.1C398.864 151.414 403.75 154.071 409.835 154.071C414.121 154.071 417.507 152.871 419.992 150.471C422.564 148.071 424.407 144.943 425.521 141.086C426.721 137.229 427.321 133.157 427.321 128.871C427.321 124.586 426.764 120.386 425.65 116.271C424.535 112.157 422.692 108.771 420.121 106.114C417.635 103.371 414.207 102 409.835 102C404.607 102 399.721 104.529 395.178 109.586V146.1ZM477.335 158.829C471.25 158.829 466.107 157.414 461.907 154.586C457.707 151.757 454.493 147.986 452.264 143.271C450.121 138.471 449.05 133.2 449.05 127.457C449.05 121.543 450.164 116.057 452.393 111C454.707 105.943 458.05 101.871 462.421 98.7857C466.793 95.6143 472.107 94.0286 478.364 94.0286C485.907 94.0286 491.778 96.3 495.978 100.843C500.264 105.3 502.407 111.086 502.407 118.2C502.407 119.057 502.364 119.829 502.278 120.514C502.278 121.114 502.235 121.629 502.15 122.057L461.65 121.671C461.65 122.014 461.65 122.314 461.65 122.571C461.65 130.971 463.578 137.571 467.435 142.371C471.293 147.171 476.693 149.571 483.635 149.571C489.464 149.571 495.207 147.686 500.864 143.914C501.721 144.943 502.364 145.929 502.793 146.871C495.507 154.843 487.021 158.829 477.335 158.829ZM462.035 116.914L488.65 116.4C488.735 116.229 488.778 116.014 488.778 115.757C488.778 115.414 488.778 115.2 488.778 115.114C488.778 110.486 487.75 106.629 485.693 103.543C483.721 100.457 480.764 98.9143 476.821 98.9143C473.135 98.9143 469.921 100.414 467.178 103.414C464.435 106.414 462.721 110.914 462.035 116.914ZM559.644 158.957L557.587 158.057L557.073 149.186C554.073 152.443 550.987 154.886 547.816 156.514C544.73 158.057 541.302 158.829 537.53 158.829C532.216 158.829 527.544 157.414 523.516 154.586C519.573 151.671 516.53 147.9 514.387 143.271C512.244 138.643 511.173 133.629 511.173 128.229C511.173 121.971 512.502 116.271 515.159 111.129C517.902 105.986 521.716 101.871 526.602 98.7857C531.573 95.6143 537.359 94.0286 543.959 94.0286C545.93 94.0286 547.987 94.2 550.13 94.5429C552.273 94.8 554.502 95.2714 556.816 95.9572V79.5C556.816 76.8429 556.559 74.8714 556.044 73.5857C555.53 72.2143 554.502 71.2714 552.959 70.7572C551.502 70.1572 549.273 69.7286 546.273 69.4714C546.016 68.3572 546.016 67.2 546.273 66C549.702 65.5714 553.216 64.9286 556.816 64.0714C560.416 63.1286 564.102 61.8429 567.873 60.2143L570.059 60.9857C569.973 62.8714 569.887 65.0143 569.802 67.4143C569.802 69.8143 569.802 72.4286 569.802 75.2572V139.029C569.802 142.286 569.93 144.729 570.187 146.357C570.445 147.986 571.216 149.143 572.502 149.829C573.787 150.429 575.973 150.986 579.059 151.5C579.316 152.614 579.316 153.771 579.059 154.971C575.63 155.486 572.287 156.043 569.03 156.643C565.773 157.243 562.644 158.014 559.644 158.957ZM556.944 106.886C553.259 101.829 548.416 99.3 542.416 99.3C536.502 99.3 532.044 101.486 529.044 105.857C526.044 110.143 524.544 116.1 524.544 123.729C524.544 128.186 525.144 132.471 526.344 136.586C527.544 140.7 529.516 144.086 532.259 146.743C535.002 149.4 538.644 150.729 543.187 150.729C548.93 150.729 553.516 148.243 556.944 143.271V106.886ZM615.699 157.414C613.299 157.414 610.813 157.371 608.242 157.286C605.67 157.2 602.885 157.157 599.885 157.157C597.142 157.157 594.356 157.2 591.527 157.286C588.785 157.371 586.127 157.414 583.556 157.414C583.299 156.043 583.299 154.714 583.556 153.429C586.47 153.257 588.613 153 589.985 152.657C591.356 152.229 592.256 151.371 592.685 150.086C593.113 148.8 593.327 146.743 593.327 143.914V115.114C593.327 111.771 593.199 109.286 592.942 107.657C592.685 106.029 591.87 104.914 590.499 104.314C589.213 103.629 586.942 103.071 583.685 102.643C583.427 101.443 583.427 100.329 583.685 99.3C587.456 98.6143 591.056 97.7572 594.485 96.7286C597.913 95.7 601.213 94.5857 604.385 93.3857L606.57 94.1572C606.485 96.8143 606.399 99.3 606.313 101.614C606.313 103.929 606.313 106.114 606.313 108.171V142.629C606.313 145.971 606.485 148.371 606.827 149.829C607.256 151.286 608.113 152.229 609.399 152.657C610.77 153 612.87 153.257 615.699 153.429C615.956 154.714 615.956 156.043 615.699 157.414ZM589.985 71.5286C589.985 69.0429 590.842 66.9429 592.556 65.2286C594.356 63.5143 596.499 62.6572 598.985 62.6572C601.385 62.6572 603.442 63.5143 605.156 65.2286C606.956 66.9429 607.856 69 607.856 71.4C607.856 73.6286 606.999 75.6857 605.285 77.5715C603.57 79.3714 601.385 80.2714 598.727 80.2714C596.327 80.2714 594.27 79.4143 592.556 77.7C590.842 75.9857 589.985 73.9286 589.985 71.5286ZM665.837 158.571C660.18 158.571 656.623 155.743 655.165 150.086C649.08 155.914 642.865 158.829 636.523 158.829C632.151 158.829 628.423 157.543 625.337 154.971C622.337 152.314 620.837 148.671 620.837 144.043C620.837 132.729 632.365 125.614 655.423 122.7C655.423 120.643 655.423 118.543 655.423 116.4C655.508 114.257 655.551 111.986 655.551 109.586C655.551 106.586 654.437 104.271 652.208 102.643C650.065 100.929 647.451 100.071 644.365 100.071C642.137 100.071 640.251 100.414 638.708 101.1C638.708 103.071 638.28 105.086 637.423 107.143C636.565 109.2 635.365 110.957 633.823 112.414C632.365 113.786 630.565 114.471 628.423 114.471C626.537 114.471 625.037 113.957 623.923 112.929C622.894 111.814 622.38 110.486 622.38 108.943C622.38 106.886 623.323 104.957 625.208 103.157C627.18 101.271 629.665 99.6857 632.665 98.4C635.665 97.0286 638.794 95.9572 642.051 95.1857C645.308 94.4143 648.223 94.0286 650.794 94.0286C653.965 94.0286 656.88 94.6286 659.537 95.8286C662.28 96.9429 664.465 98.6572 666.094 100.971C667.808 103.2 668.665 105.986 668.665 109.329C668.665 111.386 668.623 114.086 668.537 117.429C668.451 120.686 668.365 124.2 668.28 127.971C668.28 131.657 668.237 135.171 668.151 138.514C668.065 141.857 668.023 144.557 668.023 146.614C668.023 149.357 669.223 150.729 671.623 150.729C673.165 150.729 675.523 150.214 678.694 149.186C679.037 149.614 679.251 150.086 679.337 150.6C679.508 151.114 679.637 151.586 679.723 152.014C677.58 154.329 675.308 156 672.908 157.029C670.594 158.057 668.237 158.571 665.837 158.571ZM655.165 146.614L655.423 127.329C647.537 128.357 642.094 130.029 639.094 132.343C636.18 134.657 634.723 137.614 634.723 141.214C634.723 144.214 635.494 146.529 637.037 148.157C638.665 149.7 640.68 150.471 643.08 150.471C644.623 150.471 646.337 150.129 648.223 149.443C650.194 148.757 652.508 147.814 655.165 146.614Z" fill="currentColor"></path><rect x="715" y="65" width="195" height="105" rx="52.5" fill="currentColor" fill-opacity="0.05"></rect><path d="M767.529 142.875L754.049 107.938H762.552L769.309 127.582C769.705 128.812 770.078 130.032 770.43 131.24C770.781 132.449 771.078 133.559 771.32 134.569H771.616C771.858 133.559 772.144 132.449 772.473 131.24C772.825 130.032 773.198 128.812 773.594 127.582L780.186 107.938H788.689L775.472 142.875H767.529ZM810.856 143.633C806.901 143.633 803.528 142.71 800.737 140.865C797.969 138.997 795.871 136.305 794.442 132.79C793.014 129.252 792.3 124.989 792.3 120.001V118.255C792.3 113.245 793.014 108.982 794.442 105.467C795.871 101.929 797.969 99.2373 800.737 97.3916C803.528 95.5239 806.901 94.5901 810.856 94.5901C814.789 94.5901 818.129 95.5129 820.875 97.3586C823.644 99.2043 825.731 101.907 827.138 105.467C828.566 109.004 829.28 113.267 829.28 118.255V120.001C829.28 124.989 828.577 129.252 827.171 132.79C825.764 136.327 823.677 139.019 820.908 140.865C818.162 142.71 814.811 143.633 810.856 143.633ZM810.889 136.382C813.064 136.382 814.877 135.789 816.327 134.602C817.799 133.416 818.898 131.658 819.623 129.329C820.348 126.978 820.711 124.066 820.711 120.595V117.694C820.711 114.223 820.337 111.311 819.59 108.96C818.865 106.609 817.777 104.84 816.327 103.654C814.877 102.445 813.064 101.841 810.889 101.841C808.714 101.841 806.879 102.434 805.385 103.621C803.912 104.785 802.792 106.554 802.023 108.927C801.276 111.278 800.902 114.201 800.902 117.694V120.595C800.902 124.044 801.287 126.945 802.056 129.296C802.825 131.647 803.945 133.416 805.418 134.602C806.89 135.789 808.714 136.382 810.889 136.382ZM838.988 143.205C838 143.205 837.099 142.985 836.286 142.545C835.495 142.106 834.879 141.491 834.44 140.7C834.001 139.909 833.781 139.019 833.781 138.03C833.781 137.019 834.001 136.118 834.44 135.327C834.879 134.536 835.495 133.921 836.286 133.482C837.099 133.042 838 132.823 838.988 132.823C839.977 132.823 840.867 133.042 841.658 133.482C842.449 133.921 843.064 134.536 843.504 135.327C843.943 136.118 844.163 137.019 844.163 138.03C844.163 139.019 843.943 139.909 843.504 140.7C843.064 141.491 842.449 142.106 841.658 142.545C840.867 142.985 839.977 143.205 838.988 143.205ZM857.365 142.875V104.511L846.39 111.663V103.357L858.453 95.3481H865.802V142.875H857.365Z" fill="currentColor"></path></svg></a></div><div class="mx-auto flex w-full"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 border-input text-primary hover:border-primary/15 border hover:bg-overlay-hover py-2 max-w-full px-3 shadow-none sm:w-80 focus-visible:z-1 mx-auto h-full w-full rounded-full bg-surface-l1" type="button"><div class="flex items-center justify-between sm:w-full gap-4"><div class="flex items-center justify-start gap-2"><span class="inline-flex items-center justify-center p-0 m-0 w-4 h-4 text-muted" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-4 h-4" focusable="false" style="fill:currentColor"><path d="m18.031 16.617 4.283 4.282-1.415 1.415-4.282-4.283A8.96 8.96 0 0 1 11 20c-4.968 0-9-4.032-9-9s4.032-9 9-9 9 4.032 9 9a8.96 8.96 0 0 1-1.969 5.617m-2.006-.742A6.98 6.98 0 0 0 18 11c0-3.867-3.133-7-7-7s-7 3.133-7 7 3.133 7 7 7a6.98 6.98 0 0 0 4.875-1.975z"></path></svg></span><p class="text-sm text-muted hidden sm:block">Search</p></div><span class="hidden sm:block"><div class="bg-foreground/10 text-muted inline-flex items-center rounded-md px-1 py-0.5 text-center font-sans text-xs font-normal tracking-widest rtl:space-x-reverse"><span>âŒ˜</span><span class="text-xs">K</span></div></span></div></button></div><div class="flex items-center gap-2 justify-self-end"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover px-4 py-2 w-9 h-9 flex-shrink-0" type="button" id="radix-_R_7apfiumdb_" aria-haspopup="menu" aria-expanded="false" data-state="closed"><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 rotate-0 scale-100 transition-all dark:-rotate-90 dark:scale-0" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M12 18a6 6 0 1 1 0-12 6 6 0 0 1 0 12m0-2a4 4 0 1 0 0-8 4 4 0 0 0 0 8M11 1h2v3h-2zm0 19h2v3h-2zM3.515 4.929l1.414-1.414L7.05 5.636 5.636 7.05zM16.95 18.364l1.414-1.414 2.121 2.121-1.414 1.414zm2.121-14.85 1.414 1.415-2.121 2.121-1.414-1.414zM5.636 16.95l1.414 1.414-2.121 2.121-1.414-1.414zM23 11v2h-3v-2zM4 11v2H1v-2z"></path></svg></span><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 absolute rotate-90 scale-0 transition-all dark:rotate-0 dark:scale-100" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M10 7a7 7 0 0 0 12 4.9v.1c0 5.523-4.477 10-10 10S2 17.523 2 12 6.477 2 12 2h.1A6.98 6.98 0 0 0 10 7m-6 5a8 8 0 0 0 15.062 3.762A9 9 0 0 1 8.238 4.938 8 8 0 0 0 4 12"></path></svg></span><span class="sr-only">Toggle theme</span></button></div></div><div class="flex h-full items-center md:hidden justify-between max-w-full py-6 px-4 w-full mx-auto pt-8"><div class="flex items-center"><div class="-ml-2"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover h-9 w-9" type="button" aria-label="Toggle table of contents"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-list h-6 w-6"><path d="M3 12h.01"></path><path d="M3 18h.01"></path><path d="M3 6h.01"></path><path d="M8 12h13"></path><path d="M8 18h13"></path><path d="M8 6h13"></path></svg></button></div><a class="cursor-pointer" href="/"><svg width="160" height="auto" viewBox="0 0 955 225" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M99.6937 159.214C90.008 159.214 81.5652 157.414 74.3652 153.814C67.1652 150.214 61.5509 144.986 57.5223 138.129C53.5794 131.271 51.608 123.043 51.608 113.443C51.608 103.843 53.5794 95.4857 57.5223 88.3714C61.5509 81.2572 67.1652 75.7286 74.3652 71.7857C81.6509 67.8429 90.1794 65.8714 99.9509 65.8714C103.208 65.8714 106.679 66.1286 110.365 66.6429C114.051 67.0714 117.222 67.6714 119.879 68.4429C121.508 68.8714 123.008 69.2572 124.379 69.6C125.751 69.9429 127.122 70.1143 128.494 70.1143C129.522 70.1143 130.551 69.9857 131.579 69.7286C131.751 73.5 131.922 77.4 132.094 81.4286C132.265 85.4572 132.522 89.6572 132.865 94.0286C131.065 94.2857 129.565 94.3714 128.365 94.2857C126.651 86.4 123.522 80.5714 118.979 76.8C114.437 72.9429 108.394 71.0143 100.851 71.0143C94.8509 71.0143 89.708 72.1286 85.4223 74.3572C81.2223 76.5 77.7937 79.4572 75.1366 83.2286C72.5652 87 70.6794 91.3714 69.4794 96.3429C68.2794 101.229 67.6794 106.457 67.6794 112.029C67.6794 120.171 68.9223 127.371 71.408 133.629C73.8937 139.886 77.6652 144.814 82.7223 148.414C87.8652 151.929 94.2937 153.686 102.008 153.686C104.408 153.686 107.065 153.471 109.979 153.043C112.894 152.529 115.679 151.757 118.337 150.729V134.529C118.337 131.871 118.208 129.814 117.951 128.357C117.779 126.814 117.222 125.7 116.279 125.014C115.422 124.329 114.008 123.857 112.037 123.6C110.151 123.257 107.537 122.957 104.194 122.7C103.937 121.329 103.937 119.957 104.194 118.586C105.994 118.586 108.179 118.629 110.751 118.714C113.322 118.714 115.894 118.757 118.465 118.843C121.122 118.843 123.308 118.843 125.022 118.843C127.679 118.843 130.722 118.8 134.151 118.714C137.665 118.629 140.665 118.586 143.151 118.586C143.322 119.871 143.322 121.2 143.151 122.571C139.637 123 137.108 123.429 135.565 123.857C134.022 124.286 133.079 125.143 132.737 126.429C132.394 127.714 132.222 129.9 132.222 132.986V137.1C132.222 141.129 132.308 144.514 132.479 147.257C132.737 150 132.951 151.971 133.122 153.171C121.208 157.2 110.065 159.214 99.6937 159.214ZM148.19 157.414C147.933 156.043 147.933 154.714 148.19 153.429C151.105 153.257 153.248 153 154.619 152.657C155.99 152.229 156.89 151.371 157.319 150.086C157.748 148.8 157.962 146.743 157.962 143.914V115.114C157.962 111.771 157.79 109.286 157.448 107.657C157.19 106.029 156.376 104.914 155.005 104.314C153.719 103.629 151.49 103.071 148.319 102.643C148.062 101.443 148.062 100.329 148.319 99.3C151.748 98.6143 155.09 97.8429 158.348 96.9857C161.605 96.0429 165.033 94.8429 168.633 93.3857L170.819 94.1572V105.471C176.819 97.8429 182.948 94.0286 189.205 94.0286C192.205 94.0286 194.433 94.8429 195.89 96.4714C197.348 98.0143 198.076 99.7714 198.076 101.743C198.076 104.057 197.305 105.857 195.762 107.143C194.219 108.343 192.462 108.943 190.49 108.943C188.862 108.943 187.233 108.514 185.605 107.657C184.062 106.8 182.905 105.471 182.133 103.671C179.219 103.671 176.605 104.829 174.29 107.143C172.062 109.371 170.948 111.986 170.948 114.986V142.629C170.948 145.971 171.119 148.371 171.462 149.829C171.89 151.286 172.919 152.229 174.548 152.657C176.262 153 179.005 153.257 182.776 153.429C182.948 154.629 182.948 155.957 182.776 157.414C179.862 157.414 176.862 157.371 173.776 157.286C170.69 157.2 167.519 157.157 164.262 157.157C161.09 157.157 158.262 157.2 155.776 157.286C153.376 157.371 150.848 157.414 148.19 157.414ZM229.285 158.829C223.028 158.829 217.542 157.5 212.828 154.843C208.199 152.1 204.599 148.371 202.028 143.657C199.457 138.857 198.171 133.371 198.171 127.2C198.171 120.514 199.499 114.686 202.157 109.714C204.899 104.743 208.714 100.886 213.599 98.1429C218.485 95.4 224.099 94.0286 230.442 94.0286C236.699 94.0286 242.142 95.4 246.771 98.1429C251.399 100.886 254.999 104.657 257.571 109.457C260.142 114.257 261.428 119.7 261.428 125.786C261.428 132.043 260.057 137.7 257.314 142.757C254.657 147.729 250.928 151.671 246.128 154.586C241.328 157.414 235.714 158.829 229.285 158.829ZM212.699 125.657C212.699 134.4 214.114 141.343 216.942 146.486C219.857 151.543 224.185 154.071 229.928 154.071C235.414 154.071 239.614 151.671 242.528 146.871C245.442 141.986 246.899 135.471 246.899 127.329C246.899 118.671 245.442 111.771 242.528 106.629C239.614 101.486 235.371 98.9143 229.799 98.9143C224.314 98.9143 220.071 101.271 217.071 105.986C214.157 110.7 212.699 117.257 212.699 125.657ZM267.394 157.414C267.308 157.071 267.265 156.729 267.265 156.386C267.265 156.043 267.265 155.7 267.265 155.357C267.265 155.014 267.265 154.714 267.265 154.457C267.265 154.114 267.308 153.771 267.394 153.429C270.308 153.257 272.451 153 273.822 152.657C275.194 152.229 276.094 151.371 276.522 150.086C276.951 148.8 277.165 146.743 277.165 143.914V79.5C277.165 76.8429 276.908 74.8714 276.394 73.5857C275.965 72.2143 274.979 71.2714 273.437 70.7572C271.979 70.1572 269.751 69.7286 266.751 69.4714C266.665 69.1286 266.622 68.8286 266.622 68.5714C266.622 68.3143 266.622 68.0572 266.622 67.8C266.622 67.4572 266.622 67.1572 266.622 66.9C266.622 66.6429 266.665 66.3429 266.751 66C270.179 65.5714 273.694 64.9286 277.294 64.0714C280.894 63.1286 284.579 61.8429 288.351 60.2143L290.537 60.9857C290.451 62.8714 290.365 65.0143 290.279 67.4143C290.279 69.8143 290.279 72.4286 290.279 75.2572V122.957C291.308 122.957 292.165 122.786 292.851 122.443C293.537 122.1 294.094 121.757 294.522 121.414C294.694 121.243 295.037 120.943 295.551 120.514C296.065 120 296.965 119.1 298.251 117.814C299.537 116.529 301.379 114.6 303.779 112.029C306.008 109.543 307.765 107.614 309.051 106.243C310.422 104.786 311.108 103.586 311.108 102.643C311.108 101.957 310.508 101.4 309.308 100.971C308.194 100.457 306.651 100.157 304.679 100.071C304.594 99.7286 304.551 99.3857 304.551 99.0429C304.551 98.7 304.551 98.3572 304.551 98.0143C304.551 97.6714 304.551 97.3286 304.551 96.9857C304.551 96.6429 304.594 96.3 304.679 95.9572C306.394 95.9572 308.537 96 311.108 96.0857C313.765 96.1714 316.122 96.2143 318.179 96.2143C319.208 96.2143 320.665 96.2143 322.551 96.2143C324.522 96.1286 326.494 96.0857 328.465 96.0857C330.437 96.0857 331.894 96.0857 332.837 96.0857C332.922 96.4286 332.965 96.7714 332.965 97.1143C333.051 97.4572 333.094 97.8 333.094 98.1429C333.094 98.4857 333.051 98.8286 332.965 99.1714C332.965 99.4286 332.922 99.7286 332.837 100.071C328.379 100.157 324.608 101.271 321.522 103.414C318.437 105.471 315.479 107.914 312.651 110.743L303.394 120L321.137 143.4C323.022 145.886 324.565 147.857 325.765 149.314C327.051 150.686 328.422 151.671 329.879 152.271C331.337 152.871 333.351 153.257 335.922 153.429C336.094 154.629 336.094 155.957 335.922 157.414C334.808 157.414 333.137 157.371 330.908 157.286C328.765 157.2 325.379 157.157 320.751 157.157C320.065 157.157 319.037 157.157 317.665 157.157C316.294 157.157 315.008 157.243 313.808 157.414C313.808 156.471 313.294 155.186 312.265 153.557C311.237 151.843 310.422 150.6 309.822 149.829C309.565 149.4 308.922 148.5 307.894 147.129C306.865 145.671 305.622 144 304.165 142.114C302.794 140.143 301.379 138.171 299.922 136.2C298.465 134.143 297.137 132.343 295.937 130.8C294.994 129.514 294.094 128.529 293.237 127.843C292.465 127.071 291.479 126.686 290.279 126.686V142.629C290.279 145.971 290.408 148.371 290.665 149.829C291.008 151.286 291.737 152.229 292.851 152.657C294.051 153 295.851 153.257 298.251 153.429C298.422 154.714 298.422 156.043 298.251 157.414C296.022 157.414 293.665 157.371 291.179 157.286C288.779 157.2 286.165 157.157 283.337 157.157C280.594 157.157 277.894 157.2 275.237 157.286C272.579 157.371 269.965 157.414 267.394 157.414ZM369.34 157.414C366.94 157.414 364.454 157.371 361.883 157.286C359.311 157.2 356.526 157.157 353.526 157.157C350.783 157.157 347.997 157.2 345.169 157.286C342.426 157.371 339.769 157.414 337.197 157.414C336.94 156.043 336.94 154.714 337.197 153.429C340.111 153.257 342.254 153 343.626 152.657C344.997 152.229 345.897 151.371 346.326 150.086C346.754 148.8 346.969 146.743 346.969 143.914V115.114C346.969 111.771 346.84 109.286 346.583 107.657C346.326 106.029 345.511 104.914 344.14 104.314C342.854 103.629 340.583 103.071 337.326 102.643C337.069 101.443 337.069 100.329 337.326 99.3C341.097 98.6143 344.697 97.7572 348.126 96.7286C351.554 95.7 354.854 94.5857 358.026 93.3857L360.211 94.1572C360.126 96.8143 360.04 99.3 359.954 101.614C359.954 103.929 359.954 106.114 359.954 108.171V142.629C359.954 145.971 360.126 148.371 360.469 149.829C360.897 151.286 361.754 152.229 363.04 152.657C364.411 153 366.511 153.257 369.34 153.429C369.597 154.714 369.597 156.043 369.34 157.414ZM343.626 71.5286C343.626 69.0429 344.483 66.9429 346.197 65.2286C347.997 63.5143 350.14 62.6572 352.626 62.6572C355.026 62.6572 357.083 63.5143 358.797 65.2286C360.597 66.9429 361.497 69 361.497 71.4C361.497 73.6286 360.64 75.6857 358.926 77.5715C357.211 79.3714 355.026 80.2714 352.369 80.2714C349.969 80.2714 347.911 79.4143 346.197 77.7C344.483 75.9857 343.626 73.9286 343.626 71.5286ZM372.678 188.914C372.592 187.543 372.592 186.214 372.678 184.929C375.678 184.757 377.864 184.457 379.235 184.029C380.607 183.6 381.464 182.743 381.807 181.457C382.235 180.257 382.45 178.286 382.45 175.543V115.114C382.45 111.771 382.278 109.286 381.935 107.657C381.678 106.029 380.864 104.914 379.492 104.314C378.207 103.629 375.978 103.071 372.807 102.643C372.635 101.443 372.635 100.329 372.807 99.3C376.321 98.6143 379.75 97.8 383.092 96.8572C386.435 95.9143 389.907 94.7572 393.507 93.3857L395.307 94.2857C395.221 96.4286 395.178 98.2714 395.178 99.8143C395.178 101.271 395.178 102.686 395.178 104.057C398.521 100.543 401.821 98.0143 405.078 96.4714C408.335 94.8429 411.807 94.0286 415.492 94.0286C420.892 94.0286 425.435 95.4429 429.121 98.2714C432.892 101.1 435.764 104.786 437.735 109.329C439.707 113.871 440.692 118.8 440.692 124.114C440.692 130.371 439.321 136.157 436.578 141.471C433.921 146.7 430.192 150.9 425.392 154.071C420.592 157.243 415.021 158.829 408.678 158.829C406.192 158.829 403.835 158.614 401.607 158.186C399.378 157.843 397.278 157.329 395.307 156.643V174C395.307 177.343 395.564 179.743 396.078 181.2C396.592 182.657 397.707 183.557 399.421 183.9C401.135 184.329 403.835 184.629 407.521 184.8C407.607 186.171 407.607 187.543 407.521 188.914C404.607 188.914 401.65 188.871 398.65 188.786C395.735 188.7 392.521 188.657 389.007 188.657C385.664 188.657 382.792 188.7 380.392 188.786C377.992 188.871 375.421 188.914 372.678 188.914ZM395.178 146.1C398.864 151.414 403.75 154.071 409.835 154.071C414.121 154.071 417.507 152.871 419.992 150.471C422.564 148.071 424.407 144.943 425.521 141.086C426.721 137.229 427.321 133.157 427.321 128.871C427.321 124.586 426.764 120.386 425.65 116.271C424.535 112.157 422.692 108.771 420.121 106.114C417.635 103.371 414.207 102 409.835 102C404.607 102 399.721 104.529 395.178 109.586V146.1ZM477.335 158.829C471.25 158.829 466.107 157.414 461.907 154.586C457.707 151.757 454.493 147.986 452.264 143.271C450.121 138.471 449.05 133.2 449.05 127.457C449.05 121.543 450.164 116.057 452.393 111C454.707 105.943 458.05 101.871 462.421 98.7857C466.793 95.6143 472.107 94.0286 478.364 94.0286C485.907 94.0286 491.778 96.3 495.978 100.843C500.264 105.3 502.407 111.086 502.407 118.2C502.407 119.057 502.364 119.829 502.278 120.514C502.278 121.114 502.235 121.629 502.15 122.057L461.65 121.671C461.65 122.014 461.65 122.314 461.65 122.571C461.65 130.971 463.578 137.571 467.435 142.371C471.293 147.171 476.693 149.571 483.635 149.571C489.464 149.571 495.207 147.686 500.864 143.914C501.721 144.943 502.364 145.929 502.793 146.871C495.507 154.843 487.021 158.829 477.335 158.829ZM462.035 116.914L488.65 116.4C488.735 116.229 488.778 116.014 488.778 115.757C488.778 115.414 488.778 115.2 488.778 115.114C488.778 110.486 487.75 106.629 485.693 103.543C483.721 100.457 480.764 98.9143 476.821 98.9143C473.135 98.9143 469.921 100.414 467.178 103.414C464.435 106.414 462.721 110.914 462.035 116.914ZM559.644 158.957L557.587 158.057L557.073 149.186C554.073 152.443 550.987 154.886 547.816 156.514C544.73 158.057 541.302 158.829 537.53 158.829C532.216 158.829 527.544 157.414 523.516 154.586C519.573 151.671 516.53 147.9 514.387 143.271C512.244 138.643 511.173 133.629 511.173 128.229C511.173 121.971 512.502 116.271 515.159 111.129C517.902 105.986 521.716 101.871 526.602 98.7857C531.573 95.6143 537.359 94.0286 543.959 94.0286C545.93 94.0286 547.987 94.2 550.13 94.5429C552.273 94.8 554.502 95.2714 556.816 95.9572V79.5C556.816 76.8429 556.559 74.8714 556.044 73.5857C555.53 72.2143 554.502 71.2714 552.959 70.7572C551.502 70.1572 549.273 69.7286 546.273 69.4714C546.016 68.3572 546.016 67.2 546.273 66C549.702 65.5714 553.216 64.9286 556.816 64.0714C560.416 63.1286 564.102 61.8429 567.873 60.2143L570.059 60.9857C569.973 62.8714 569.887 65.0143 569.802 67.4143C569.802 69.8143 569.802 72.4286 569.802 75.2572V139.029C569.802 142.286 569.93 144.729 570.187 146.357C570.445 147.986 571.216 149.143 572.502 149.829C573.787 150.429 575.973 150.986 579.059 151.5C579.316 152.614 579.316 153.771 579.059 154.971C575.63 155.486 572.287 156.043 569.03 156.643C565.773 157.243 562.644 158.014 559.644 158.957ZM556.944 106.886C553.259 101.829 548.416 99.3 542.416 99.3C536.502 99.3 532.044 101.486 529.044 105.857C526.044 110.143 524.544 116.1 524.544 123.729C524.544 128.186 525.144 132.471 526.344 136.586C527.544 140.7 529.516 144.086 532.259 146.743C535.002 149.4 538.644 150.729 543.187 150.729C548.93 150.729 553.516 148.243 556.944 143.271V106.886ZM615.699 157.414C613.299 157.414 610.813 157.371 608.242 157.286C605.67 157.2 602.885 157.157 599.885 157.157C597.142 157.157 594.356 157.2 591.527 157.286C588.785 157.371 586.127 157.414 583.556 157.414C583.299 156.043 583.299 154.714 583.556 153.429C586.47 153.257 588.613 153 589.985 152.657C591.356 152.229 592.256 151.371 592.685 150.086C593.113 148.8 593.327 146.743 593.327 143.914V115.114C593.327 111.771 593.199 109.286 592.942 107.657C592.685 106.029 591.87 104.914 590.499 104.314C589.213 103.629 586.942 103.071 583.685 102.643C583.427 101.443 583.427 100.329 583.685 99.3C587.456 98.6143 591.056 97.7572 594.485 96.7286C597.913 95.7 601.213 94.5857 604.385 93.3857L606.57 94.1572C606.485 96.8143 606.399 99.3 606.313 101.614C606.313 103.929 606.313 106.114 606.313 108.171V142.629C606.313 145.971 606.485 148.371 606.827 149.829C607.256 151.286 608.113 152.229 609.399 152.657C610.77 153 612.87 153.257 615.699 153.429C615.956 154.714 615.956 156.043 615.699 157.414ZM589.985 71.5286C589.985 69.0429 590.842 66.9429 592.556 65.2286C594.356 63.5143 596.499 62.6572 598.985 62.6572C601.385 62.6572 603.442 63.5143 605.156 65.2286C606.956 66.9429 607.856 69 607.856 71.4C607.856 73.6286 606.999 75.6857 605.285 77.5715C603.57 79.3714 601.385 80.2714 598.727 80.2714C596.327 80.2714 594.27 79.4143 592.556 77.7C590.842 75.9857 589.985 73.9286 589.985 71.5286ZM665.837 158.571C660.18 158.571 656.623 155.743 655.165 150.086C649.08 155.914 642.865 158.829 636.523 158.829C632.151 158.829 628.423 157.543 625.337 154.971C622.337 152.314 620.837 148.671 620.837 144.043C620.837 132.729 632.365 125.614 655.423 122.7C655.423 120.643 655.423 118.543 655.423 116.4C655.508 114.257 655.551 111.986 655.551 109.586C655.551 106.586 654.437 104.271 652.208 102.643C650.065 100.929 647.451 100.071 644.365 100.071C642.137 100.071 640.251 100.414 638.708 101.1C638.708 103.071 638.28 105.086 637.423 107.143C636.565 109.2 635.365 110.957 633.823 112.414C632.365 113.786 630.565 114.471 628.423 114.471C626.537 114.471 625.037 113.957 623.923 112.929C622.894 111.814 622.38 110.486 622.38 108.943C622.38 106.886 623.323 104.957 625.208 103.157C627.18 101.271 629.665 99.6857 632.665 98.4C635.665 97.0286 638.794 95.9572 642.051 95.1857C645.308 94.4143 648.223 94.0286 650.794 94.0286C653.965 94.0286 656.88 94.6286 659.537 95.8286C662.28 96.9429 664.465 98.6572 666.094 100.971C667.808 103.2 668.665 105.986 668.665 109.329C668.665 111.386 668.623 114.086 668.537 117.429C668.451 120.686 668.365 124.2 668.28 127.971C668.28 131.657 668.237 135.171 668.151 138.514C668.065 141.857 668.023 144.557 668.023 146.614C668.023 149.357 669.223 150.729 671.623 150.729C673.165 150.729 675.523 150.214 678.694 149.186C679.037 149.614 679.251 150.086 679.337 150.6C679.508 151.114 679.637 151.586 679.723 152.014C677.58 154.329 675.308 156 672.908 157.029C670.594 158.057 668.237 158.571 665.837 158.571ZM655.165 146.614L655.423 127.329C647.537 128.357 642.094 130.029 639.094 132.343C636.18 134.657 634.723 137.614 634.723 141.214C634.723 144.214 635.494 146.529 637.037 148.157C638.665 149.7 640.68 150.471 643.08 150.471C644.623 150.471 646.337 150.129 648.223 149.443C650.194 148.757 652.508 147.814 655.165 146.614Z" fill="currentColor"></path><rect x="715" y="65" width="195" height="105" rx="52.5" fill="currentColor" fill-opacity="0.05"></rect><path d="M767.529 142.875L754.049 107.938H762.552L769.309 127.582C769.705 128.812 770.078 130.032 770.43 131.24C770.781 132.449 771.078 133.559 771.32 134.569H771.616C771.858 133.559 772.144 132.449 772.473 131.24C772.825 130.032 773.198 128.812 773.594 127.582L780.186 107.938H788.689L775.472 142.875H767.529ZM810.856 143.633C806.901 143.633 803.528 142.71 800.737 140.865C797.969 138.997 795.871 136.305 794.442 132.79C793.014 129.252 792.3 124.989 792.3 120.001V118.255C792.3 113.245 793.014 108.982 794.442 105.467C795.871 101.929 797.969 99.2373 800.737 97.3916C803.528 95.5239 806.901 94.5901 810.856 94.5901C814.789 94.5901 818.129 95.5129 820.875 97.3586C823.644 99.2043 825.731 101.907 827.138 105.467C828.566 109.004 829.28 113.267 829.28 118.255V120.001C829.28 124.989 828.577 129.252 827.171 132.79C825.764 136.327 823.677 139.019 820.908 140.865C818.162 142.71 814.811 143.633 810.856 143.633ZM810.889 136.382C813.064 136.382 814.877 135.789 816.327 134.602C817.799 133.416 818.898 131.658 819.623 129.329C820.348 126.978 820.711 124.066 820.711 120.595V117.694C820.711 114.223 820.337 111.311 819.59 108.96C818.865 106.609 817.777 104.84 816.327 103.654C814.877 102.445 813.064 101.841 810.889 101.841C808.714 101.841 806.879 102.434 805.385 103.621C803.912 104.785 802.792 106.554 802.023 108.927C801.276 111.278 800.902 114.201 800.902 117.694V120.595C800.902 124.044 801.287 126.945 802.056 129.296C802.825 131.647 803.945 133.416 805.418 134.602C806.89 135.789 808.714 136.382 810.889 136.382ZM838.988 143.205C838 143.205 837.099 142.985 836.286 142.545C835.495 142.106 834.879 141.491 834.44 140.7C834.001 139.909 833.781 139.019 833.781 138.03C833.781 137.019 834.001 136.118 834.44 135.327C834.879 134.536 835.495 133.921 836.286 133.482C837.099 133.042 838 132.823 838.988 132.823C839.977 132.823 840.867 133.042 841.658 133.482C842.449 133.921 843.064 134.536 843.504 135.327C843.943 136.118 844.163 137.019 844.163 138.03C844.163 139.019 843.943 139.909 843.504 140.7C843.064 141.491 842.449 142.106 841.658 142.545C840.867 142.985 839.977 143.205 838.988 143.205ZM857.365 142.875V104.511L846.39 111.663V103.357L858.453 95.3481H865.802V142.875H857.365Z" fill="currentColor"></path></svg></a></div><div class="flex items-center gap-1"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover px-4 py-2 w-9 h-9 flex-shrink-0 [&amp;_svg]:!w-5" type="button" id="radix-_R_aipfiumdb_" aria-haspopup="menu" aria-expanded="false" data-state="closed"><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 rotate-0 scale-100 transition-all dark:-rotate-90 dark:scale-0" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M12 18a6 6 0 1 1 0-12 6 6 0 0 1 0 12m0-2a4 4 0 1 0 0-8 4 4 0 0 0 0 8M11 1h2v3h-2zm0 19h2v3h-2zM3.515 4.929l1.414-1.414L7.05 5.636 5.636 7.05zM16.95 18.364l1.414-1.414 2.121 2.121-1.414 1.414zm2.121-14.85 1.414 1.415-2.121 2.121-1.414-1.414zM5.636 16.95l1.414 1.414-2.121 2.121-1.414-1.414zM23 11v2h-3v-2zM4 11v2H1v-2z"></path></svg></span><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 absolute rotate-90 scale-0 transition-all dark:rotate-0 dark:scale-100" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M10 7a7 7 0 0 0 12 4.9v.1c0 5.523-4.477 10-10 10S2 17.523 2 12 6.477 2 12 2h.1A6.98 6.98 0 0 0 10 7m-6 5a8 8 0 0 0 15.062 3.762A9 9 0 0 1 8.238 4.938 8 8 0 0 0 4 12"></path></svg></span><span class="sr-only">Toggle theme</span></button><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover h-9 w-9" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-search h-5 w-5"><circle cx="11" cy="11" r="8"></circle><path d="m21 21-4.3-4.3"></path></svg></button></div></div></header><div class="bg-surface-base fixed right-0 top-16 z-50 h-[calc(100vh-4rem)] w-full transform border-l transition-transform duration-300 ease-in-out sm:w-1/2 md:hidden translate-x-full"><div class="flex flex-col gap-4 p-4"><div class="flex flex-row gap-2"><button class="focus-visible:ring-ring inline-flex items-center gap-x-2 whitespace-nowrap text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 border-input text-primary hover:border-primary/15 border hover:bg-overlay-hover py-2 max-w-full shadow-none sm:w-80 h-10 w-full justify-start rounded-full bg-surface-l1 px-4" type="button"><div class="flex items-center justify-between sm:w-full gap-4"><div class="flex items-center justify-start gap-2"><span class="inline-flex items-center justify-center p-0 m-0 w-4 h-4 text-muted" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-4 h-4" focusable="false" style="fill:currentColor"><path d="m18.031 16.617 4.283 4.282-1.415 1.415-4.282-4.283A8.96 8.96 0 0 1 11 20c-4.968 0-9-4.032-9-9s4.032-9 9-9 9 4.032 9 9a8.96 8.96 0 0 1-1.969 5.617m-2.006-.742A6.98 6.98 0 0 0 18 11c0-3.867-3.133-7-7-7s-7 3.133-7 7 3.133 7 7 7a6.98 6.98 0 0 0 4.875-1.975z"></path></svg></span><p class="text-sm text-muted hidden sm:block">Search</p></div><span class="hidden sm:block"><div class="bg-foreground/10 text-muted inline-flex items-center rounded-md px-1 py-0.5 text-center font-sans text-xs font-normal tracking-widest rtl:space-x-reverse"><span>âŒ˜</span><span class="text-xs">K</span></div></span></div></button></div></div></div><div><div class="min-[1350px]:grid min-[1350px]:grid-cols-[1fr_3fr_1fr]"><nav class="bg-surface-base hidden h-[calc(100vh-4rem)] overflow-y-auto px-6 pb-32 min-[1350px]:sticky min-[1350px]:top-16 min-[1350px]:block scrollbar-none [-ms-overflow-style:none] [scrollbar-width:none] [&amp;::-webkit-scrollbar]:hidden [overscroll-behavior:contain] pt-8"><ul class="space-y-2 text-sm"><li style="padding-left:0rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#barbital" class="transition-opacity hover:opacity-100 opacity-50">Barbital</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#history" class="transition-opacity hover:opacity-100 opacity-50">History</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#discovery-and-synthesis" class="transition-opacity hover:opacity-100 opacity-50">Discovery and Synthesis</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#early-medical-adoption-and-marketing" class="transition-opacity hover:opacity-100 opacity-50">Early Medical Adoption and Marketing</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#decline-in-use-and-regulatory-shifts" class="transition-opacity hover:opacity-100 opacity-50">Decline in Use and Regulatory Shifts</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#chemistry" class="transition-opacity hover:opacity-100 opacity-50">Chemistry</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#chemical-structure-and-properties" class="transition-opacity hover:opacity-100 opacity-50">Chemical Structure and Properties</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#laboratory-synthesis-methods" class="transition-opacity hover:opacity-100 opacity-50">Laboratory Synthesis Methods</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#pharmacology" class="transition-opacity hover:opacity-100 opacity-50">Pharmacology</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#mechanism-of-action" class="transition-opacity hover:opacity-100 opacity-50">Mechanism of Action</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#pharmacokinetics-and-metabolism" class="transition-opacity hover:opacity-100 opacity-50">Pharmacokinetics and Metabolism</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#therapeutic-applications" class="transition-opacity hover:opacity-100 opacity-50">Therapeutic Applications</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#historical-indications" class="transition-opacity hover:opacity-100 opacity-50">Historical Indications</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#modern-clinical-uses" class="transition-opacity hover:opacity-100 opacity-50">Modern Clinical Uses</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#risks-and-adverse-effects" class="transition-opacity hover:opacity-100 opacity-50">Risks and Adverse Effects</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#short-term-side-effects" class="transition-opacity hover:opacity-100 opacity-50">Short-Term Side Effects</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#overdose-and-toxicity" class="transition-opacity hover:opacity-100 opacity-50">Overdose and Toxicity</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#dependence-tolerance-and-withdrawal" class="transition-opacity hover:opacity-100 opacity-50">Dependence, Tolerance, and Withdrawal</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#legal-status-and-regulation" class="transition-opacity hover:opacity-100 opacity-50">Legal Status and Regulation</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#classification-and-controls" class="transition-opacity hover:opacity-100 opacity-50">Classification and Controls</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#international-variations-and-recent-changes" class="transition-opacity hover:opacity-100 opacity-50">International Variations and Recent Changes</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#non-medical-applications" class="transition-opacity hover:opacity-100 opacity-50">Non-Medical Applications</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#use-in-biochemical-buffers" class="transition-opacity hover:opacity-100 opacity-50">Use in Biochemical Buffers</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#cultural-and-historical-impact" class="transition-opacity hover:opacity-100 opacity-50">Cultural and Historical Impact</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#references-in-fiction-and-media" class="transition-opacity hover:opacity-100 opacity-50">References in Fiction and Media</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#references" class="transition-opacity hover:opacity-100 opacity-50">References</a></li></ul></nav><div class="relative top-16 pb-32 pt-8 px-4 md:px-8"><div class="mx-auto max-w-[850px]"><button data-state="closed" type="button" class="flex items-center"><div class="text-fg-tertiary mb-2 flex cursor-help items-center gap-2 text-sm"><span class="inline-flex items-center justify-center p-0 m-0" data-namespace="@xai/icons" data-slot="icon" style="height:16px;width:16px"><svg xmlns="http://www.w3.org/2000/svg" fill="none" viewBox="0 0 33 33" aria-hidden="true" class="" focusable="false" style="fill:currentColor;height:16px;width:16px"><path fill="currentColor" d="m13.237 21.04 11.082-8.19c.543-.4 1.32-.244 1.578.38 1.363 3.288.754 7.241-1.957 9.955-2.71 2.714-6.482 3.31-9.93 1.954l-3.765 1.745c5.401 3.697 11.96 2.782 16.059-1.324 3.251-3.255 4.258-7.692 3.317-11.693l.008.009c-1.365-5.878.336-8.227 3.82-13.031q.123-.17.247-.345l-4.585 4.59v-.014L13.234 21.044M10.95 23.031c-3.877-3.707-3.208-9.446.1-12.755 2.446-2.449 6.454-3.448 9.952-1.979L24.76 6.56c-.677-.49-1.545-1.017-2.54-1.387A12.465 12.465 0 0 0 8.675 7.901c-3.519 3.523-4.625 8.94-2.725 13.561 1.42 3.454-.907 5.898-3.251 8.364-.83.874-1.664 1.749-2.335 2.674l10.583-9.466"></path></svg></span><span>Fact-checked by Grok<!-- --> <!-- -->4 days ago</span></div></button><article class="text-[16px]"><h1 id="barbital" class="group relative mb-2 scroll-mt-24 font-serif text-[2.125em] font-semibold tracking-[-1px] [&amp;:not(:first-child)]:mt-14" node="[object Object]">Barbital<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h1>
<span class="mb-4 block break-words text-[1em] leading-7">
Barbital, also known by the trade name Veronal, is a barbiturate compound chemically designated as 5,5-diethylbarbituric acid, recognized as the first barbiturate introduced for clinical use as a long-acting sedative and hypnotic agent. Synthesized in 1902 by Emil Fischer and Heinrich Dresler, its hypnotic properties were demonstrated in 1903 by pharmacologist Josef von Mering, leading to its patenting and marketing by Bayer starting in 1904.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_60qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_80qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Barbital exerts its effects primarily by enhancing the activity of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) at GABA_A receptors in the central nervous system, resulting in generalized depression of neuronal activity that manifests as sedation, hypnosis, and anticonvulsant action. Initially employed for treating insomnia, anxiety, and as a preoperative sedative, its use expanded broadly in the early 20th century but was limited by a narrow therapeutic index, rapid development of tolerance, and severe risks including respiratory depression, dependence, and overdose lethality.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_41abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_61abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The drug&#x27;s historical significance lies in pioneering the barbiturate class, which dominated sedative-hypnotic therapy for decades until safer alternatives like benzodiazepines supplanted it amid growing recognition of abuse potential and adverse outcomes, including contribution to iatrogenic addiction and intentional overdoses.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_41qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_61qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup></span>
<h2 id="history" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">History<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="discovery-and-synthesis" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Discovery and Synthesis<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">
Barbituric acid, the parent compound of barbital, was first synthesized in 1864 by Adolf von Baeyer through the condensation of urea and malonic acid.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_63abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> This reaction yielded a cyclic structure with no initial pharmacological activity, serving as a foundational scaffold for later derivatives.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a3abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In 1903, Emil Fischer, a chemist at Bayer, and physician Joseph von Mering developed diethylbarbituric acid (barbital), the first barbiturate with hypnotic properties, by condensing diethylmalonic acid diethyl ester with urea.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_43qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup> Fischer patented the compound in January 1903, followed by publication of initial findings in March.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_83qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> Von Mering&#x27;s animal experiments demonstrated that oral administration induced prolonged sleep in dogs without significant toxicity, distinguishing it from prior sedatives like chloral hydrate.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c3qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[6]</sup> This synthesis method enabled scalable production due to barbital&#x27;s relative stability and solubility in alkaline solutions, facilitating its isolation as a crystalline solid.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_g3qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The discovery marked the inaugural application of substituted barbituric acids for medical use, building on Baeyer&#x27;s earlier work but innovating through alkyl substitution at the 5-position to confer sedative effects.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_44abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> Bayer named the compound Veronal, evoking the serene associations of Verona, Italy, in recognition of its calming action observed in preclinical tests.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_84abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[7]</sup></span>
<h3 id="early-medical-adoption-and-marketing" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Early Medical Adoption and Marketing<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7"></span>
<span class="mb-4 block break-words text-[1em] leading-7">Barbital, marketed by Bayer as Veronal starting in 1904 following its patent by Emil Fischer in 1903, was introduced as a novel hypnotic agent for treating insomnia and anxiety. The drug was licensed to Winthrop Chemical Company for distribution in the United States. Initial clinical evaluation began with self-experiments by psychiatrist Hermann von Husen in 1904, who administered doses of 0.5 g and 1 g, achieving 8-9 hours of deep sleep with minimal side effects, thereby establishing its efficacy as a sedative.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_45qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Contemporary observations highlighted Veronal&#x27;s advantages over prior sedatives like bromides and chloral hydrate, noting its greater potency, broader therapeutic range, and reduced toxicity profile, which facilitated rapid integration into psychiatric practice for calming manic and melancholic states. By the 1910s, barbital had achieved widespread prescription across Europe and the United States for sedation and neurological disorders, supported by early reports of reliable, dose-dependent hypnotic induction.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_46abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">During World War I, Veronal emerged as the most commonly prescribed sedative for managing shell shock symptoms such as mental confusion and excitement, administered to approximately 37.5% of affected patients at facilities like the Royal Edinburgh Asylum, demonstrating its practical value in frontline psychiatric care despite the onset of reported overdose incidents.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_46qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup></span>
<h3 id="decline-in-use-and-regulatory-shifts" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Decline in Use and Regulatory Shifts<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">By the 1920s, reports of barbiturate-related suicides and accidental overdoses began accumulating, with the first documented overdose death appearing in medical literature as early as 1912; from that decade onward, these agents were increasingly employed in intentional self-poisoning due to their accessibility and potent sedative effects.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_47qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> In the United States, barbiturates were linked to more poisoning deaths than any other pharmaceutical drug except possibly alcohol by the mid-1950s, exacerbated by their narrow therapeutic index, where small dosage excesses could precipitate respiratory failure and lethality.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_87qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup> United Kingdom data illustrate the trend&#x27;s severity: barbiturate suicides rose from 104 cases in 1941â€“1950 to 735 in 1958â€“1962, while accidental overdose deaths climbed from 60 to 285 over the same periods, reflecting both intentional misuse and errors in therapeutic administration.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c7qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[10]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The introduction of benzodiazepines in the early 1960s, starting with chlordiazepoxide in 1960, accelerated the decline in barbiturate prescriptions, as these newer agents demonstrated a wider therapeutic window and reduced risk of fatal respiratory depression owing to a ceiling effect on central nervous system suppression.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_48abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup> Clinical studies highlighted benzodiazepines&#x27; superior safety profile for anxiolysis and hypnosis, with overdose lethality requiring far higher doses or combinations with other depressants, prompting a rapid shift in medical practice away from barbiturates for routine sedative-hypnotic use by the late 1960s.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_88abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Regulatory responses formalized these concerns: the U.S. Controlled Substances Act of 1970 classified barbiturates based on abuse potential and dependence risk, placing short-acting variants like secobarbital in Schedule II, intermediate ones like amobarbital in Schedule III, and long-acting types including barbital in Schedule IV.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_48qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[12]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_68qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup> Internationally, the 1971 United Nations Convention on Psychotropic Substances imposed controls on 12 barbiturates, including barbital, aligning with World Health Organization assessments of their high misuse liability and endorsing restrictions on non-essential hypnotic applications.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a8qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[14]</sup> These measures, grounded in epidemiological data on overdoses and dependence, curtailed over-the-counter and liberal prescription availability, further diminishing barbital&#x27;s clinical prominence.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_e8qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup></span>
<h2 id="chemistry" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Chemistry<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="chemical-structure-and-properties" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Chemical Structure and Properties<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">
Barbital, systematically named 5,5-diethylpyrimidine-2,4,6(1H,3H,5H)-trione, possesses the molecular formula Câ‚ˆHâ‚â‚‚Nâ‚‚Oâ‚ƒ and a molecular weight of 184.19 g/mol. It is a barbituric acid derivative characterized by two ethyl groups substituted at the 5-position of the barbituric acid core, which enhances its lipophilicity relative to the unsubstituted parent compound.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6aabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[15]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8aabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[16]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">As a white, odorless crystalline powder, barbital has a melting point of 188â€“192 Â°C and is poorly soluble in water (1 g dissolves in approximately 130 mL at 25 Â°C) but more readily soluble in organic solvents, including ethanol (1 g per 14 mL), diethyl ether (1 g per 35 mL), and chloroform (1 g per 75 mL). Its pKâ‚ value is 7.43 at 25 Â°C, indicating weak acidity that permits buffering capacity around neutral pH values.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4aqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[17]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6aqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[18]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8aqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[15]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Barbital demonstrates chemical stability under neutral and acidic conditions but degrades via hydrolysis in alkaline media, yielding products such as urea and diethylmalonic acid derivatives, as observed in empirical degradation studies of barbiturates. This pH-dependent instability influences pharmaceutical storage recommendations, favoring dry, acidic or neutral environments to minimize breakdown.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4babav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[19]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6babav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[20]</sup></span>
<h3 id="laboratory-synthesis-methods" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Laboratory Synthesis Methods<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7"></span>
<span class="mb-4 block break-words text-[1em] leading-7">Barbital, or 5,5-diethylbarbituric acid, is synthesized in the laboratory through the condensation of diethyl 2,2-diethylmalonate with urea in the presence of sodium ethoxide as a base catalyst.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4cqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[21]</sup> This method, originally described by Emil Fischer in 1903, involves dissolving sodium (16 g) in absolute ethanol (300 g) to generate sodium ethoxide, followed by addition of diethyl 2,2-diethylmalonate (50 g) and urea (24 g), with the mixture heated under reflux for several hours to facilitate cyclization and elimination of two equivalents of ethanol.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8cqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[21]</sup> The reaction intermediate is then acidified with hydrochloric acid to precipitate the barbital product, which is purified by recrystallization from water or ethanol.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ccqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[21]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The procedure yields barbital as white crystals with a typical laboratory efficiency of around 70-80% when conducted under anhydrous conditions and controlled temperatures (typically 78-80Â°C during reflux).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4dabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[22]</sup> Variations for scalability include using pre-formed sodium ethoxide solutions to enhance reproducibility, though the core malonic ester-urea condensation remains standard due to its simplicity and high atom economy.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8dabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[23]</sup> Industrial adaptations by Bayer, which commercialized barbital as Veronal starting in 1904, employed analogous ester condensations optimized for larger batches, often incorporating malonic acid derivatives to minimize side products like alkylated ureas.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cdabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In modern laboratory practice, adaptations prioritize safety by avoiding excessive sodium metal handling through commercial sodium ethoxide, and product purity is confirmed via spectroscopic methods such as Â¹H NMR (characteristic signals at Î´ 1.0-1.2 ppm for ethyl groups and 8-11 ppm for NH protons) and IR spectroscopy (carbonyl stretches at 1700-1750 cmâ»Â¹).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4dqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[24]</sup> These refinements ensure minimal impurities without introducing heavy metal catalysts, maintaining the method&#x27;s viability for research-scale production despite barbital&#x27;s limited current therapeutic use.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8dqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup></span>
<h2 id="pharmacology" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Pharmacology<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="mechanism-of-action" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Mechanism of Action<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Barbital exerts its central nervous system (CNS) depressant effects primarily through positive allosteric modulation of the GABA_A receptor, a ligand-gated ion channel that mediates fast inhibitory neurotransmission. Upon binding to a distinct allosteric site on the GABA_A receptorâ€”separate from the GABA binding site and benzodiazepine recognition siteâ€”barbital prolongs the duration of chloride channel opening in response to GABA, facilitating greater chloride influx into neurons. This hyperpolarizes the neuronal membrane, reducing excitability and propagating inhibition across neural circuits.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4fabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[26]</sup> Unlike competitive agonists such as benzodiazepines, which increase channel opening frequency, barbital&#x27;s action emphasizes extended channel dwell time, as demonstrated in single-channel patch-clamp electrophysiological studies on recombinant GABA_A receptors and native neuronal membranes.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8fabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[27]</sup> Direct channel activation by barbital at higher concentrations further contributes to this inhibitory cascade, independent of GABA presence.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cfabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[28]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The dose-dependent nature of barbital&#x27;s effects arises from its graded suppression of CNS arousal pathways. At low therapeutic doses, sedation predominates via selective inhibition of thalamocortical relay neurons, dampening sensory gating and cortical activation without widespread brainstem involvement. Escalating doses shift toward hypnosis and anesthesia through broader suppression of the ascending reticular activating system in the brainstem, where mutual inhibitory interactions between excitatory and inhibitory neuronal populations are disrupted, leading to global reduction in vigilance and responsiveness.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4fqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[29]</sup> This progression reflects barbital&#x27;s non-selective enhancement of GABAergic tone across brain regions, with minimal direct agonism at other neurotransmitter systems such as dopamine or serotonin receptors, as confirmed by radioligand binding assays showing negligible affinity for monoaminergic targets.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8fqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[30]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Empirical support from electroencephalographic (EEG) recordings underscores these mechanisms, revealing dose-related increases in low-frequency delta waves (0.5â€“4 Hz), indicative of synchronized hyperpolarization and slowed neuronal firing akin to deep sleep states. These spectral shifts occur without altering fast oscillatory bands tied to monoamine modulation, aligning with barbital&#x27;s targeted GABA_A potentiation rather than broader neuromodulatory interference.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4gabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[26]</sup> Binding and kinetic studies further validate the causal link, quantifying barbital&#x27;s prolongation of mean channel open time by 2â€“5 fold in voltage-clamp experiments on cortical and hippocampal neurons.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8gabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[31]</sup></span>
<h3 id="pharmacokinetics-and-metabolism" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Pharmacokinetics and Metabolism<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Barbital is rapidly and completely absorbed from the gastrointestinal tract following oral administration, with bioavailability approaching 100%. <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4habav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup> Peak plasma concentrations are typically attained within 1 to 2 hours post-ingestion. <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8habav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The drug exhibits high lipid solubility, facilitating rapid distribution across the blood-brain barrier and into other tissues. <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4hqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[32]</sup> Its volume of distribution ranges from 0.6 to 1 L/kg in mammalian models, consistent with moderate tissue penetration. <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8hqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[33]</sup> Protein binding is relatively low at approximately 40%, allowing a substantial unbound fraction available for distribution and elimination. <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_chqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Metabolism of barbital is minimal and primarily hepatic, with limited involvement of cytochrome P450 enzymes such as CYP2C19; the majority of the dose remains unchanged. <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4iabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[34]</sup> Elimination occurs predominantly via renal excretion, with 80-90% of the administered dose recovered unchanged in urine, leading to a prolonged plasma half-life of 50-100 hours. <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8iabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[35]</sup> This renal-dependent clearance contributes to drug accumulation in patients with impaired kidney function or advanced age, where reduced glomerular filtration prolongs exposure. <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ciabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup></span>
<h2 id="therapeutic-applications" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Therapeutic Applications<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="historical-indications" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Historical Indications<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Barbital, introduced clinically in 1903 as Veronal, served primarily as a hypnotic agent for treating insomnia, with oral doses of 100-200 mg typically inducing sleep lasting 6-8 hours in adults. Early self-experiments and clinical observations, such as those by psychiatrist Hermann von Husen in 1904, demonstrated its reliability in promoting sleep onset and maintenance among insomniacs, with short-term efficacy reported as high in inducing restful sleep without significant residual effects upon awakening.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4jqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> By the 1920s, it had become a cornerstone of sedative-hypnotic therapy, dominating insomnia management for decades alongside other barbiturates, based on empirical data from therapeutic trials emphasizing its central nervous system depressant properties.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8jqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[36]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In addition to its hypnotic role, barbital found adjunctive application as an anticonvulsant in epilepsy management, leveraging its enhancement of GABAergic inhibition to suppress seizure activity, though phenobarbital largely supplanted it by the 1910s for more potent control. It was also routinely administered for preoperative sedation to alleviate anxiety and facilitate smoother induction of anesthesia, including in obstetric procedures where it aided in labor sedation despite subsequent recognition of potential neonatal impacts. Historical records from the early 20th century indicate its use in reducing patient agitation prior to surgery, contributing to procedural tolerance.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4kabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6kabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Within psychiatric settings from the 1920s to 1940s, barbital was employed to mitigate agitation in manic or excited states, with clinical reports noting its calming effects and utility in narcotherapy protocols involving prolonged sedation, as pioneered by Jacob Klaesi in 1920 for psychotic disorders. Data from this era, including hospital-based observations, showed reduced behavioral disturbances in treated patients, though outcomes were often confounded by concurrent polypharmacy, such as combinations with opioids or other sedatives, limiting attribution to barbital alone.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4kqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6kqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[32]</sup></span>
<h3 id="modern-clinical-uses" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Modern Clinical Uses<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">In modern clinical practice, barbital has no established routine indications in human medicine, having been supplanted by benzodiazepines and other agents with more favorable safety profiles for sedation, hypnosis, and seizure management.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4lqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[37]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6lqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[38]</sup> Its prolonged half-life of approximately 53 hours contributes to risks of accumulation and prolonged sedation, rendering it inferior to shorter-acting alternatives like lorazepam or midazolam for acute applications.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_alqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[34]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Veterinary applications represent one niche persistence, where barbital may be employed for central nervous system depression in select cases, though phenobarbital predominates for seizure control in dogs and cats due to better tolerability and dosing predictability.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4mabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[34]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6mabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[39]</sup> Empirical data from pharmacological references indicate occasional utility in non-epileptic sedation protocols, but no large-scale contemporary studies endorse routine use over established options.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_amabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[40]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In resource-constrained environments, legacy barbiturates including barbital might see sporadic off-label deployment for refractory insomnia or adjunctive anxiolysis, predicated on availability rather than evidence of superiority; however, guidelines from bodies like the World Health Organization prioritize benzodiazepines even in such settings to minimize dependence and overdose risks.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4mqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[41]</sup> No recent peer-reviewed trials (post-2010) demonstrate barbital outperforming alternatives in specific scenarios like refractory status epilepticus or eclampsia, where agents such as phenytoin, levetiracetam, or magnesium sulfate are standard.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8mqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[42]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_amqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[43]</sup></span>
<h2 id="risks-and-adverse-effects" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Risks and Adverse Effects<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="short-term-side-effects" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Short-Term Side Effects<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Common short-term side effects of barbital, observed at therapeutic hypnotic or sedative doses, primarily involve central nervous system depression manifesting as drowsiness, sedation, dizziness, and lightheadedness. These effects typically onset within 30-60 minutes following oral administration and resolve as the drug is eliminated, given barbital&#x27;s half-life of approximately 53 hours, though acute impairment correlates with peak plasma concentrations.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4oabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[38]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6oabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[44]</sup> Ataxia, characterized by impaired coordination and gait instability, along with cognitive effects such as confusion and slowed reaction times, occur due to barbiturate enhancement of GABA_A receptor activity, suppressing neuronal excitability.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_aoabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[45]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_coabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[37]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Gastrointestinal disturbances, including nausea and occasional vomiting, are reported in therapeutic use, likely from direct mucosal irritation or central emetic pathway involvement.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4oqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[44]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6oqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[37]</sup> Paradoxical excitation, such as restlessness or agitation, may arise particularly in the elderly or children, attributed to rapid central nervous system penetration and variable receptor sensitivity, contrasting the typical sedative response.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_aoqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[45]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Respiratory effects at standard therapeutic doses include mild rate reduction, proportional to plasma levels as measured by spirometry, but seldom progress to clinically significant depression without contributing factors like concurrent respiratory disease.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4pabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[46]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6pabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[47]</sup> Cardiovascular changes, such as lowered blood pressure and heart rate via medullary depression, are also dose-related and transient.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_apabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[38]</sup> These effects underscore barbital&#x27;s narrow therapeutic index, necessitating monitoring during initial dosing.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_epabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[46]</sup></span>
<h3 id="overdose-and-toxicity" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Overdose and Toxicity<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Barbital overdose induces profound central nervous system depression through enhancement of GABA_A receptor activity, resulting in medullary suppression that manifests as respiratory arrest, hypotension, and coma.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4qabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[46]</sup> Symptoms typically progress from ataxia, nystagmus, and slurred speech at lower doses to unresponsiveness, hypoventilation, and cardiovascular instability at toxic levels exceeding 5-10 times the hypnotic dose (300-600 mg).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8qabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[48]</sup> The narrow therapeutic index, with fatal oral doses estimated at 2-6 g in non-tolerant adults, underscores the risk, as individual variability in metabolism and co-ingestants like alcohol amplify lethality.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cqabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[49]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Without intervention, survival rates drop below 20% in severe cases due to untreated respiratory failure and secondary complications like aspiration pneumonia.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4qqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> Historical toxicology data from New York City (1957-1963) document 8,469 barbiturate overdoses with 1,165 fatalities, reflecting empirical ties to prescription availability rather than inherent user suicidality, as method substitution occurred post-restrictions.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8qqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Management prioritizes supportive measures: gastrointestinal decontamination with activated charcoal within 1-2 hours of ingestion, mechanical ventilation for respiratory depression, and vasopressors or fluids for hypotension.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4rabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[46]</sup> Hemodialysis accelerates elimination in life-threatening intoxications, leveraging barbital&#x27;s low plasma protein binding (&lt;20%) and moderate volume of distribution, reducing serum levels by 50-70% per session and shortening recovery time compared to conservative care alone.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8rabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[50]</sup> No specific antidote exists, emphasizing early toxicologist consultation for dosing co-interventions like multiple-dose activated charcoal.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_crabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[46]</sup></span>
<h3 id="dependence-tolerance-and-withdrawal" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Dependence, Tolerance, and Withdrawal<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Tolerance to barbital, a long-acting barbiturate, arises from neuroadaptive changes including downregulation of GABA_A receptors in the central nervous system, typically manifesting after weeks of regular therapeutic dosing and prompting dose escalation to maintain efficacy.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4sabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[51]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6sabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[52]</sup> This receptor adaptation reduces the drug&#x27;s potentiation of GABA-mediated chloride influx, diminishing sedative-hypnotic effects over time.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_asabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[53]</sup> Physical dependence emerges in chronic users through these compensatory mechanisms, with longitudinal studies of barbiturate users indicating that 18-35% develop chronic intoxication patterns when combined with other substances, though isolated barbital use shows lower but significant risk tied to duration rather than inevitability.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_esabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[54]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Abrupt discontinuation in dependent individuals precipitates a withdrawal syndrome characterized by heightened anxiety, restlessness, insomnia, tremors, and potentially life-threatening seizures due to unopposed excitatory neurotransmission.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4sqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[55]</sup> Symptoms typically onset within 12-24 hours, intensify over 2-4 days as the long half-life of barbital (up to 50-100 hours) allows gradual clearance, and resolve over 5-10 days with supportive care.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8sqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup> Management strategies emphasize gradual dose tapering to mitigate neuroexcitability or substitution with longer-acting agents like phenobarbital, which permits smoother detoxification by sustaining GABAergic tone.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_csqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[56]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Contemporary recreational abuse of barbital remains rare, with overall barbiturate misuse prevalence under 1% among general populations due to replacement by safer alternatives like benzodiazepines and stricter prescribing.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4tabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup> Historical surges in dependence, such as the 135,000 estimated barbiturate addicts in England by 1965 and widespread U.S. epidemics in the mid-20th century, stemmed primarily from overprescription for insomnia and anxiety rather than unique pharmacological compulsion, as evidenced by sharp declines following regulatory curbs in the 1960s-1970s.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8tabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_atabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[57]</sup> These patterns underscore causal roles of availability and medical practices over intrinsic addictiveness in driving epidemics.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_etabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[36]</sup></span>
<h2 id="legal-status-and-regulation" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Legal Status and Regulation<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="classification-and-controls" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Classification and Controls<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">In the United States, barbital is classified as a Schedule IV controlled substance under the Comprehensive Drug Abuse Prevention and Control Act of 1970, which established the five-tier scheduling system administered by the Drug Enforcement Administration (DEA).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4uqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[58]</sup> This placement acknowledges barbital&#x27;s accepted medical uses, such as in sedation and seizure management, while recognizing a low potential for abuse relative to higher-scheduled drugs and the possibility of limited physical or psychological dependence with restricted prescribing.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8uqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[59]</sup> Schedule IV status imposes requirements for prescriptions via DEA Form 222 for bulk dispensing, secure storage, and record-keeping to mitigate diversion risks.</span>
<span class="mb-4 block break-words text-[1em] leading-7">The evidence-based rationale for Schedule IV derives from barbital&#x27;s pharmacological profile as a long-acting barbiturate, which produces less pronounced euphoria and thus lower recreational misuse rates compared to short-acting barbiturates like secobarbital (Schedule II).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4vabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[60]</sup> National Institute on Drug Abuse (NIDA) surveillance through systems like Monitoring the Future and the National Survey on Drug Use and Health has consistently shown barbiturates overall comprising less than 1% of illicit sedative use reports among adolescents and adults, with long-acting variants like barbital exhibiting even rarer diversion incidents due to slower onset and reduced abuse liability.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8vabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[61]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Under international frameworks, barbital falls under controls harmonized with the 1961 United Nations Single Convention on Narcotic Drugs, where it aligns with Schedule III criteria for substances with moderate abuse potential, therapeutic value, and documented overdose hazards, necessitating import/export licensing and production quotas by signatory states to balance medical access against public health risks.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4vqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[62]</sup> This classification weighs empirical data on barbital&#x27;s narrower therapeutic index against opioids or stimulants, prioritizing regulatory oversight over outright prohibition given its historical role in legitimate pharmacotherapy.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8vqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[63]</sup></span>
<h3 id="international-variations-and-recent-changes" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">International Variations and Recent Changes<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">In the European Union, barbital falls under stringent controls as one of the barbiturates regulated by the 1971 United Nations Convention on Psychotropic Substances, with member states classifying it in high-schedule equivalents (often akin to Schedule IV) that restrict dispensing to authorized medical professionals and require detailed record-keeping to prevent diversion. These measures, harmonized across the bloc since the early 2000s, emphasize low therapeutic indices and abuse potential, resulting in empirical data showing negligible enforcement actions related to barbital specifically, reflective of its obsolescence in favor of safer sedatives.</span>
<span class="mb-4 block break-words text-[1em] leading-7">Asian regulations exhibit variation, with countries like Taiwan implementing tighter oversight in July 2023 by reclassifying barbiturate-containing medications as Schedule 4 controlled substances, mandating enhanced prescription scrutiny and inventory controls amid rising sedative-hypnotic misuse patterns documented in national health surveys.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_51abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[64]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_71abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[65]</sup> This adjustment followed incidents of non-medical diversion, aligning with broader regional trends toward restricting long-acting barbiturates post-2000 to mitigate dependence risks, as evidenced by declining prescription volumes in monitored Asian markets.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_b1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[65]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In Australia, barbital is designated a Schedule 8 prohibited drug for human therapeutic use, subjecting it to federal oversight with severe penalties for unauthorized possession or supply; however, barbiturates as a class receive veterinary exemptions for euthanasia purposes when administered by licensed practitioners, correlating with low human diversion ratesâ€”national data from 2010â€“2020 report fewer than 100 barbiturate-related treatment episodes annually and minimal overdose deaths attributable to such agents.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_51qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[66]</sup> This bifurcated approach has sustained enforcement focus on illicit human markets while permitting controlled animal applications, contrasting with uniform prohibitions elsewhere.</span>
<span class="mb-4 block break-words text-[1em] leading-7">Post-2000 global updates reveal no widespread regulatory relaxation or resurgence for barbital, with International Narcotics Control Board reports highlighting sustained declines in licit use due to superior alternatives; limited niche evaluations in epilepsy contexts (primarily for phenobarbital analogs) have not extended to barbital, amid parallels to opioid crisis-driven scrutiny of high-risk sedatives lacking broad re-adoption evidence from 2021â€“2025 pharmacovigilance studies.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_52abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[67]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_72abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[68]</sup></span>
<h2 id="non-medical-applications" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Non-Medical Applications<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="use-in-biochemical-buffers" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Use in Biochemical Buffers<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Barbital, also known as veronal, serves as a key component in certain biochemical buffers due to its pKa value of approximately 8.0, which enables effective pH control around 8.6 when combined with sodium acetate or sodium barbital.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_53qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[69]</sup> This barbital-sodium acetate buffer system maintains stable ionic strength (typically 0.05â€“0.1 Î¼) and exhibits low interference with protein migration, making it suitable for techniques like serum protein electrophoresis on cellulose acetate or agarose gels.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_93qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[70]</sup> In these applications, the buffer facilitates the separation of serum fractions, including albumin and various globulins, by leveraging differences in electrophoretic mobility under alkaline conditions.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d3qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[71]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The buffer&#x27;s solubility in aqueous solutions and resistance to pH drift during electrophoresis contribute to reproducible band resolution, historically aiding diagnostic assessments of protein abnormalities such as hypogammaglobulinemia or monoclonal gammopathies.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_54abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[72]</sup> Empirical studies have validated its performance in resolving isoenzymes like lactate dehydrogenase alongside serum proteins and lipoproteins.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_94abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[73]</sup> Despite these attributes, barbital&#x27;s inherent pharmacological activity as a barbiturate introduces risks, including potential toxicity from accumulation in high concentrations or prolonged exposure during lab handling.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d4abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[74]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Owing to these safety concerns and regulatory restrictions on barbiturates as controlled substances, non-barbiturate alternativesâ€”such as Tris-barbital hybrids, Tricine-Tris, or hippurate-based systemsâ€”have been developed and adopted for routine protein electrophoresis.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_54qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[75]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_94qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[76]</sup> These substitutes provide comparable buffering capacity at pH 8.6 without the sedative properties or handling hazards of barbital, reflecting a shift toward safer protocols in modern biochemical laboratories while preserving legacy methods in specialized or resource-limited settings.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d4qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[77]</sup></span>
<h2 id="cultural-and-historical-impact" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Cultural and Historical Impact<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="references-in-fiction-and-media" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">References in Fiction and Media<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">In early 20th-century detective fiction, barbital, sold under the trade name Veronal, frequently appears as a hypnotic agent implicated in overdoses or deliberate poisonings, reflecting its era&#x27;s reputation for inducing profound sedation with a narrow therapeutic margin.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_56abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[78]</sup> For instance, Agatha Christie incorporated Veronal in multiple novels, such as <em>Cards on the Table</em> (1936), where a victim&#x27;s death is attributed to an overdose of the drug, and <em>The Murder of Roger Ackroyd</em> (1926), portraying it as a factor in a suspicious demise initially masked as accidental.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_h6abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[79]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_l6abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[80]</sup> These portrayals align with contemporaneous medical reports of Veronal&#x27;s misuse for suicide, given its over-the-counter availability and cumulative toxicity at doses exceeding 1-2 grams.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_p6abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[81]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Similar references occur in other mystery works, including Margery Allingham&#x27;s <em>Dancers in Mourning</em> (1937), where Veronal serves as a plot device for incapacitation or foul play.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_96qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[82]</sup> Such literary uses underscore public awareness of barbital&#x27;s risks without romanticizing its effects, often highlighting detection challenges due to its delayed onset and resemblance to natural sleep.</span>
<span class="mb-4 block break-words text-[1em] leading-7">Film depictions are sparser and typically confined to adaptations of these novels or period dramas evoking 1930s-1940s settings, where barbiturates evoke suicide amid high prescription volumesâ€”reaching millions of doses annually in Europe and the U.S. by the 1930s.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_57abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[83]</sup> Examples include Christie adaptations like the 1992 television film <em>Miss Marple: The Mirror Crack&#x27;d from Side to Side</em>, featuring barbiturate poisoning akin to Veronal&#x27;s profile.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d7abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[84]</sup> Modern media rarely invokes barbital explicitly, signaling its replacement by safer sedatives post-1950s regulations, with no evidence of glorification in contemporary pop culture.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_h7abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[85]</sup></span></article><div id="references" class="min-w-0 scroll-mt-8 overflow-hidden"><div class="text-[16px]"><h2 id="references" node="[object Object]" class="mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden">References</h2></div><ol class="columns-1 gap-x-12 [counter-reset:item] md:columns-2"><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC2424120/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC2424120/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC2424120/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC1079678/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC1079678/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC1079678/</a></span></div></li><li id="https://www.ncbi.nlm.nih.gov/books/NBK539731/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ncbi.nlm.nih.gov/books/NBK539731/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ncbi.nlm.nih.gov/books/NBK539731/</a></span></div></li><li id="https://www.ncbi.nlm.nih.gov/books/NBK548260/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ncbi.nlm.nih.gov/books/NBK548260/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ncbi.nlm.nih.gov/books/NBK548260/</a></span></div></li><li id="https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/barbital" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/barbital" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/barbital</a></span></div></li><li id="https://www.ch.ic.ac.uk/rzepa/mim/drugs/html/barbiturate_text.htm" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ch.ic.ac.uk/rzepa/mim/drugs/html/barbiturate_text.htm" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ch.ic.ac.uk/rzepa/mim/drugs/html/barbiturate_text.htm</a></span></div></li><li id="https://www.chemistryworld.com/podcasts/barbituric-acid/8333.article" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.chemistryworld.com/podcasts/barbituric-acid/8333.article" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.chemistryworld.com/podcasts/barbituric-acid/8333.article</a></span></div></li><li id="https://royalsocietypublishing.org/doi/10.1098/rsnr.2021.0057" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://royalsocietypublishing.org/doi/10.1098/rsnr.2021.0057" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://royalsocietypublishing.org/doi/10.1098/rsnr.2021.0057</a></span></div></li><li id="https://jamanetwork.com/journals/archneurpsyc/fullarticle/650993" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://jamanetwork.com/journals/archneurpsyc/fullarticle/650993" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://jamanetwork.com/journals/archneurpsyc/fullarticle/650993</a></span></div></li><li id="https://www.suicideinfo.ca/resource/siecno-19860249/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.suicideinfo.ca/resource/siecno-19860249/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.suicideinfo.ca/resource/siecno-19860249/</a></span></div></li><li id="https://emedicine.medscape.com/article/813155-overview" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://emedicine.medscape.com/article/813155-overview" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://emedicine.medscape.com/article/813155-overview</a></span></div></li><li id="https://www.ncbi.nlm.nih.gov/books/NBK574544/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ncbi.nlm.nih.gov/books/NBK574544/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ncbi.nlm.nih.gov/books/NBK574544/</a></span></div></li><li id="https://www.deadiversion.usdoj.gov/schedules/orangebook/c_cs_alpha.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.deadiversion.usdoj.gov/schedules/orangebook/c_cs_alpha.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.deadiversion.usdoj.gov/schedules/orangebook/c_cs_alpha.pdf</a></span></div></li><li id="https://www.euda.europa.eu/publications/drug-profiles/barbiturates_en" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.euda.europa.eu/publications/drug-profiles/barbiturates_en" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.euda.europa.eu/publications/drug-profiles/barbiturates_en</a></span></div></li><li id="https://pubchem.ncbi.nlm.nih.gov/compound/Barbital" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubchem.ncbi.nlm.nih.gov/compound/Barbital" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubchem.ncbi.nlm.nih.gov/compound/Barbital</a></span></div></li><li id="https://webbook.nist.gov/cgi/inchi?ID=C57443&amp;Type=IR-SPEC&amp;Index=1" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://webbook.nist.gov/cgi/inchi?ID=C57443&amp;Type=IR-SPEC&amp;Index=1" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://webbook.nist.gov/cgi/inchi?ID=C57443&amp;Type=IR-SPEC&amp;Index=1</a></span></div></li><li id="https://www.chemicalbook.com/ChemicalProductProperty_EN_CB7380141.htm" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.chemicalbook.com/ChemicalProductProperty_EN_CB7380141.htm" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.chemicalbook.com/ChemicalProductProperty_EN_CB7380141.htm</a></span></div></li><li id="https://www.drugfuture.com/chemdata/barbital.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.drugfuture.com/chemdata/barbital.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.drugfuture.com/chemdata/barbital.html</a></span></div></li><li id="https://www.sciencedirect.com/science/article/abs/pii/S0022354915410597" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/abs/pii/S0022354915410597" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/abs/pii/S0022354915410597</a></span></div></li><li id="https://www.sciencedirect.com/science/article/abs/pii/S0022354915334511" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/abs/pii/S0022354915334511" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/abs/pii/S0022354915334511</a></span></div></li><li id="https://prepchem.com/synthesis-of-barbital/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://prepchem.com/synthesis-of-barbital/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://prepchem.com/synthesis-of-barbital/</a></span></div></li><li id="https://scholarworks.uno.edu/cgi/viewcontent.cgi?article=2021&amp;context=td" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://scholarworks.uno.edu/cgi/viewcontent.cgi?article=2021&amp;context=td" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://scholarworks.uno.edu/cgi/viewcontent.cgi?article=2021&amp;context=td</a></span></div></li><li id="https://pubs.acs.org/doi/10.1021/bc9700345" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubs.acs.org/doi/10.1021/bc9700345" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubs.acs.org/doi/10.1021/bc9700345</a></span></div></li><li id="https://edoc.ub.uni-muenchen.de/11562/1/Haque_Nadera.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://edoc.ub.uni-muenchen.de/11562/1/Haque_Nadera.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://edoc.ub.uni-muenchen.de/11562/1/Haque_Nadera.pdf</a></span></div></li><li id="https://www.orgsyn.org/demo.aspx?prep=CV2P0060" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.orgsyn.org/demo.aspx?prep=CV2P0060" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.orgsyn.org/demo.aspx?prep=CV2P0060</a></span></div></li><li id="https://www.ncbi.nlm.nih.gov/books/NBK554443/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ncbi.nlm.nih.gov/books/NBK554443/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ncbi.nlm.nih.gov/books/NBK554443/</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/2482885/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/2482885/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/2482885/</a></span></div></li><li id="https://www.sciencedirect.com/science/article/abs/pii/S0028390806004138" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/abs/pii/S0028390806004138" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/abs/pii/S0028390806004138</a></span></div></li><li id="https://onlinelibrary.wiley.com/doi/pdf/10.5694/j.1326-5377.1970.tb84526.x" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://onlinelibrary.wiley.com/doi/pdf/10.5694/j.1326-5377.1970.tb84526.x" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://onlinelibrary.wiley.com/doi/pdf/10.5694/j.1326-5377.1970.tb84526.x</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/17289092/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/17289092/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/17289092/</a></span></div></li><li id="https://deepblue.lib.umich.edu/bitstream/handle/2027.42/109788/tjp19894171483.pdf?sequence=1" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://deepblue.lib.umich.edu/bitstream/handle/2027.42/109788/tjp19894171483.pdf?sequence=1" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://deepblue.lib.umich.edu/bitstream/handle/2027.42/109788/tjp19894171483.pdf?sequence=1</a></span></div></li><li id="https://www.sciencedirect.com/topics/medicine-and-dentistry/barbital" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/barbital" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/topics/medicine-and-dentistry/barbital</a></span></div></li><li id="https://journals.physiology.org/doi/pdf/10.1152/ajplegacy.1951.168.1.33" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://journals.physiology.org/doi/pdf/10.1152/ajplegacy.1951.168.1.33" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://journals.physiology.org/doi/pdf/10.1152/ajplegacy.1951.168.1.33</a></span></div></li><li id="https://go.drugbank.com/drugs/DB01483" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://go.drugbank.com/drugs/DB01483" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://go.drugbank.com/drugs/DB01483</a></span></div></li><li id="https://academic.oup.com/ajhp/article-pdf/33/4/333/28422855/ajhp0333.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://academic.oup.com/ajhp/article-pdf/33/4/333/28422855/ajhp0333.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://academic.oup.com/ajhp/article-pdf/33/4/333/28422855/ajhp0333.pdf</a></span></div></li><li id="https://www.dovepress.com/the-history-of-barbiturates-a-century-after-their-clinical-introductio-peer-reviewed-fulltext-article-NDT" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.dovepress.com/the-history-of-barbiturates-a-century-after-their-clinical-introductio-peer-reviewed-fulltext-article-NDT" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.dovepress.com/the-history-of-barbiturates-a-century-after-their-clinical-introductio-peer-reviewed-fulltext-article-NDT</a></span></div></li><li id="https://www.drugs.com/drug-class/barbiturates.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.drugs.com/drug-class/barbiturates.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.drugs.com/drug-class/barbiturates.html</a></span></div></li><li id="https://my.clevelandclinic.org/health/treatments/23271-barbiturates" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://my.clevelandclinic.org/health/treatments/23271-barbiturates" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://my.clevelandclinic.org/health/treatments/23271-barbiturates</a></span></div></li><li id="https://vcahospitals.com/know-your-pet/phenobarbital" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://vcahospitals.com/know-your-pet/phenobarbital" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://vcahospitals.com/know-your-pet/phenobarbital</a></span></div></li><li id="https://drugcentral.org/drugcard/289" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://drugcentral.org/drugcard/289" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://drugcentral.org/drugcard/289</a></span></div></li><li id="https://www.sciencedirect.com/topics/neuroscience/barbital" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/topics/neuroscience/barbital" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/topics/neuroscience/barbital</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/37021609/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/37021609/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/37021609/</a></span></div></li><li id="https://www.ncbi.nlm.nih.gov/books/NBK554392/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ncbi.nlm.nih.gov/books/NBK554392/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ncbi.nlm.nih.gov/books/NBK554392/</a></span></div></li><li id="https://americanaddictioncenters.org/barbiturate/side-effects" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://americanaddictioncenters.org/barbiturate/side-effects" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://americanaddictioncenters.org/barbiturate/side-effects</a></span></div></li><li id="https://www.ncbi.nlm.nih.gov/books/NBK532277/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ncbi.nlm.nih.gov/books/NBK532277/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ncbi.nlm.nih.gov/books/NBK532277/</a></span></div></li><li id="https://www.ncbi.nlm.nih.gov/books/NBK499875/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ncbi.nlm.nih.gov/books/NBK499875/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ncbi.nlm.nih.gov/books/NBK499875/</a></span></div></li><li id="https://quizlet.com/explanations/questions/what-adverse-effects-are-caused-by-barbiturates-2558bf91-348dea06-b7a5-467c-a5aa-3d341e8fee41" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://quizlet.com/explanations/questions/what-adverse-effects-are-caused-by-barbiturates-2558bf91-348dea06-b7a5-467c-a5aa-3d341e8fee41" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://quizlet.com/explanations/questions/what-adverse-effects-are-caused-by-barbiturates-2558bf91-348dea06-b7a5-467c-a5aa-3d341e8fee41</a></span></div></li><li id="https://accessmedicine.mhmedical.com/content.aspx?bookid=2284&amp;sectionid=248383642" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://accessmedicine.mhmedical.com/content.aspx?bookid=2284&amp;sectionid=248383642" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://accessmedicine.mhmedical.com/content.aspx?bookid=2284&amp;sectionid=248383642</a></span></div></li><li id="https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/barbiturate-overdose" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/barbiturate-overdose" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/barbiturate-overdose</a></span></div></li><li id="https://emedicine.medscape.com/article/813155-treatment" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://emedicine.medscape.com/article/813155-treatment" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://emedicine.medscape.com/article/813155-treatment</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/8894844/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/8894844/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/8894844/</a></span></div></li><li id="https://proceedings.systemdynamics.org/2008/proceed/papers/KONUR337.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://proceedings.systemdynamics.org/2008/proceed/papers/KONUR337.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://proceedings.systemdynamics.org/2008/proceed/papers/KONUR337.pdf</a></span></div></li><li id="https://www.sciencedirect.com/science/article/abs/pii/0024320596001993" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/abs/pii/0024320596001993" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/abs/pii/0024320596001993</a></span></div></li><li id="https://www.tandfonline.com/doi/pdf/10.3109/10826086909062000" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.tandfonline.com/doi/pdf/10.3109/10826086909062000" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.tandfonline.com/doi/pdf/10.3109/10826086909062000</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/10349206/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/10349206/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/10349206/</a></span></div></li><li id="https://journals.sagepub.com/doi/pdf/10.1177/106002808602000702" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://journals.sagepub.com/doi/pdf/10.1177/106002808602000702" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://journals.sagepub.com/doi/pdf/10.1177/106002808602000702</a></span></div></li><li id="https://www.news-medical.net/health/Barbiturate-History.aspx" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.news-medical.net/health/Barbiturate-History.aspx" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.news-medical.net/health/Barbiturate-History.aspx</a></span></div></li><li id="https://www.law.cornell.edu/uscode/text/21/812" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.law.cornell.edu/uscode/text/21/812" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.law.cornell.edu/uscode/text/21/812</a></span></div></li><li id="https://www.dea.gov/drug-information/drug-scheduling" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.dea.gov/drug-information/drug-scheduling" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.dea.gov/drug-information/drug-scheduling</a></span></div></li><li id="https://www.dea.gov/sites/default/files/2025-01/Barbiturates-2024-Drug-Fact-Sheet.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.dea.gov/sites/default/files/2025-01/Barbiturates-2024-Drug-Fact-Sheet.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.dea.gov/sites/default/files/2025-01/Barbiturates-2024-Drug-Fact-Sheet.pdf</a></span></div></li><li id="https://nida.nih.gov/research-topics/trends-statistics/monitoring-future" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://nida.nih.gov/research-topics/trends-statistics/monitoring-future" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://nida.nih.gov/research-topics/trends-statistics/monitoring-future</a></span></div></li><li id="https://www.unodc.org/documents/commissions/CND/Scheduling_Resource_Material/Scheduling_Control_Regimes.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.unodc.org/documents/commissions/CND/Scheduling_Resource_Material/Scheduling_Control_Regimes.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.unodc.org/documents/commissions/CND/Scheduling_Resource_Material/Scheduling_Control_Regimes.pdf</a></span></div></li><li id="https://www.incb.org/documents/Narcotic-Drugs/1961-Convention/convention_1961_en.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.incb.org/documents/Narcotic-Drugs/1961-Convention/convention_1961_en.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.incb.org/documents/Narcotic-Drugs/1961-Convention/convention_1961_en.pdf</a></span></div></li><li id="https://www.taiwanplus.com/news/taiwan-news/health/230704010/taiwan-tightens-controls-on-barbiturates-and-benzodiazepines" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.taiwanplus.com/news/taiwan-news/health/230704010/taiwan-tightens-controls-on-barbiturates-and-benzodiazepines" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.taiwanplus.com/news/taiwan-news/health/230704010/taiwan-tightens-controls-on-barbiturates-and-benzodiazepines</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC11587671/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11587671/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC11587671/</a></span></div></li><li id="https://www.mja.com.au/journal/2022/216/4/barbiturate-related-hospitalisations-drug-treatment-episodes-and-deaths" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.mja.com.au/journal/2022/216/4/barbiturate-related-hospitalisations-drug-treatment-episodes-and-deaths" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.mja.com.au/journal/2022/216/4/barbiturate-related-hospitalisations-drug-treatment-episodes-and-deaths</a></span></div></li><li id="https://www.incb.org/documents/Publications/AnnualReports/AR2023/Annual_Report/E_INCB_2023_1_eng.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.incb.org/documents/Publications/AnnualReports/AR2023/Annual_Report/E_INCB_2023_1_eng.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.incb.org/documents/Publications/AnnualReports/AR2023/Annual_Report/E_INCB_2023_1_eng.pdf</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/39899099/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/39899099/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/39899099/</a></span></div></li><li id="https://patents.google.com/patent/US4857163A/en" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://patents.google.com/patent/US4857163A/en" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://patents.google.com/patent/US4857163A/en</a></span></div></li><li id="https://www.sciencedirect.com/science/article/pii/S0022030279832737" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/pii/S0022030279832737" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/pii/S0022030279832737</a></span></div></li><li id="https://www.sigmaaldrich.com/US/en/product/sigma/b5934" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sigmaaldrich.com/US/en/product/sigma/b5934" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sigmaaldrich.com/US/en/product/sigma/b5934</a></span></div></li><li id="https://www.sciencedirect.com/topics/nursing-and-health-professions/protein-electrophoresis" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/topics/nursing-and-health-professions/protein-electrophoresis" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/topics/nursing-and-health-professions/protein-electrophoresis</a></span></div></li><li id="https://www.sigmaaldrich.com/deepweb/assets/sigmaaldrich/product/documents/170/711/b5934dat.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sigmaaldrich.com/deepweb/assets/sigmaaldrich/product/documents/170/711/b5934dat.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sigmaaldrich.com/deepweb/assets/sigmaaldrich/product/documents/170/711/b5934dat.pdf</a></span></div></li><li id="https://www.helena.com/Procedures/Pro001Rev6.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.helena.com/Procedures/Pro001Rev6.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.helena.com/Procedures/Pro001Rev6.pdf</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/7389096/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/7389096/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/7389096/</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/568042/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/568042/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/568042/</a></span></div></li><li id="https://academic.oup.com/clinchem/article-abstract/24/10/1825/5669644" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://academic.oup.com/clinchem/article-abstract/24/10/1825/5669644" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://academic.oup.com/clinchem/article-abstract/24/10/1825/5669644</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/38097216/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/38097216/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/38097216/</a></span></div></li><li id="https://ahsweetmystery.com/2016/07/05/no-friendly-drop-agatha-christie-and-poison/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://ahsweetmystery.com/2016/07/05/no-friendly-drop-agatha-christie-and-poison/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://ahsweetmystery.com/2016/07/05/no-friendly-drop-agatha-christie-and-poison/</a></span></div></li><li id="https://www.reddit.com/r/agathachristie/comments/1fcpbl8/does_someone_know_any_stories_by_agatha_christie/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.reddit.com/r/agathachristie/comments/1fcpbl8/does_someone_know_any_stories_by_agatha_christie/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.reddit.com/r/agathachristie/comments/1fcpbl8/does_someone_know_any_stories_by_agatha_christie/</a></span></div></li><li id="https://marymiley.wordpress.com/2013/11/16/veronal-poisoning/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://marymiley.wordpress.com/2013/11/16/veronal-poisoning/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://marymiley.wordpress.com/2013/11/16/veronal-poisoning/</a></span></div></li><li id="https://art-sheep.com/deadly-doses-a-study-of-poisons-in-mystery-literature/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://art-sheep.com/deadly-doses-a-study-of-poisons-in-mystery-literature/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://art-sheep.com/deadly-doses-a-study-of-poisons-in-mystery-literature/</a></span></div></li><li id="https://www.merckgroup.com/en/company/history/corporate-history-stories/corporate-history-stories-v2.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.merckgroup.com/en/company/history/corporate-history-stories/corporate-history-stories-v2.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.merckgroup.com/en/company/history/corporate-history-stories/corporate-history-stories-v2.html</a></span></div></li><li id="https://www.imdb.com/search/title/?keywords=barbiturates" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.imdb.com/search/title/?keywords=barbiturates" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.imdb.com/search/title/?keywords=barbiturates</a></span></div></li><li id="https://www.nbr.co.nz/book-review/pretty-poison-the-rise-and-fall-of-veronal/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nbr.co.nz/book-review/pretty-poison-the-rise-and-fall-of-veronal/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nbr.co.nz/book-review/pretty-poison-the-rise-and-fall-of-veronal/</a></span></div></li></ol></div></div></div><div class="hidden min-[1400px]:block"></div></div></div><!--$--><!--/$--><div role="region" aria-label="Notifications (F8)" tabindex="-1" style="pointer-events:none"><ol tabindex="-1" class="pointer-events-none fixed top-0 z-[100] flex max-h-screen w-full flex-col-reverse p-4 max-sm:left-0 sm:bottom-0 sm:right-0 sm:top-auto sm:max-w-[420px] sm:flex-col pl-16 pr-2 pt-16 sm:px-4"></ol></div><script type="application/json" id="server-client-data-experimentation">{"status":"uninitialized"}</script><script src="/_next/static/chunks/webpack-e121ed42680f327e.js" nonce="YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm" id="_R_" async=""></script><script nonce="YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm">(self.__next_f=self.__next_f||[]).push([0])</script><script nonce="YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm">self.__next_f.push([1,"1:\"$Sreact.fragment\"\n3:I[91363,[],\"\"]\n4:I[23775,[],\"\"]\n5:I[57654,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"3699\",\"static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js\"],\"PageHeaderProvider\"]\n6:I[17618,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"3699\",\"static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js\"],\"HeaderContent\"]\n7:I[25529,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"6751\",\"static/chunks/app/page/%5Bslug%5D/not-found-69a3edc7db5749d6.js\"],\"default\"]\n9:I[6666,[],\"OutletBoundary\"]\nb:I[80415,[],\"AsyncMetadataOutlet\"]\nd:I[6666,[],\"ViewportBoundary\"]\nf:I[6666,[],\"MetadataBoundary\"]\n10:\"$Sreact.suspense\"\n12:I[95909,[\"4219\",\"static/chunks/app/global-error-4d07d20223cd4b4c.js\"],\"default\"]\n"])</script><script nonce="YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm">self.__next_f.push([1,"13:I[51498,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"ConstantsProvider\"]\n"])</script><script nonce="YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm">self.__next_f.push([1,"14:I[91073,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm">self.__next_f.push([1,"15:I[38642,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm">self.__next_f.push([1,"16:I[99648,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"default\"]\n"])</script><script nonce="YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm">self.__next_f.push([1,"17:I[78825,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm">self.__next_f.push([1,"18:I[8550,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"MixpanelProvider\"]\n"])</script><script nonce="YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm">self.__next_f.push([1,"19:I[12290,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"MobileTocProvider\"]\n"])</script><script nonce="YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm">self.__next_f.push([1,"1a:I[53947,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"NuqsAdapter\"]\n"])</script><script nonce="YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm">self.__next_f.push([1,"1b:I[91873,[\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8039\",\"static/chunks/app/error-4a29e9399afba038.js\"],\"default\"]\n1c:I[5091,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"4345\",\"static/chunks/app/not-found-dd95690acf732f18.js\"],\"default\"]\n"])</script><script nonce="YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm">self.__next_f.push([1,"1d:I[16091,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm">self.__next_f.push([1,":HL[\"/_next/static/media/1f2316909698f815.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/3d4419af2cf8609b.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/4dec29efcaeb336c.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/74452ea3ef0f9101.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/904ef0a86fe32a00.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/d886a03bcda7ad8f.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/e1447589d6f59c4b.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/f5a90156f8995c8c.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/css/62c4caba71dfda84.css\",\"style\",{\"nonce\":\"YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm\"}]\n:HL[\"/_next/static/css/eb3d87f98fe1565f.css\",\"style\",{\"nonce\":\"YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm\"}]\n:HL[\"/_next/static/css/1b5e561215938d4d.css\",\"style\",{\"nonce\":\"YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm\"}]\n:HL[\"/_next/static/css/0227d069a630d414.css\",\"style\",{\"nonce\":\"YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm\"}]\n:HL[\"/_next/static/css/f87fff2ab93d05a7.css\",\"style\",{\"nonce\":\"YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm\"}]\n"])</script><script nonce="YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm">self.__next_f.push([1,"0:{\"P\":null,\"b\":\"BpM29AX4fmgcUxZ_6t0le\",\"p\":\"\",\"c\":[\"\",\"page\",\"Barbital\"],\"i\":false,\"f\":[[[\"\",{\"children\":[\"page\",{\"children\":[[\"slug\",\"Barbital\",\"d\"],{\"children\":[\"__PAGE__\",{}]}]}]},\"$undefined\",\"$undefined\",true],[\"\",[\"$\",\"$1\",\"c\",{\"children\":[[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/62c4caba71dfda84.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm\"}],[\"$\",\"link\",\"1\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/eb3d87f98fe1565f.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm\"}],[\"$\",\"link\",\"2\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/1b5e561215938d4d.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm\"}],[\"$\",\"link\",\"3\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/0227d069a630d414.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm\"}]],\"$L2\"]}],{\"children\":[\"page\",[\"$\",\"$1\",\"c\",{\"children\":[null,[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":\"$undefined\",\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}]]}],{\"children\":[[\"slug\",\"Barbital\",\"d\"],[\"$\",\"$1\",\"c\",{\"children\":[null,[\"$\",\"$L5\",null,{\"children\":[[\"$\",\"$L6\",null,{\"maxWidth\":\"full\",\"mobileOptions\":{\"right\":{\"showFixedIssues\":true,\"showThemeSwitcher\":true,\"showSearch\":true,\"showTableOfContents\":true}}}],[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[[\"$\",\"$L7\",null,{}],[]],\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}]]}]]}],{\"children\":[\"__PAGE__\",[\"$\",\"$1\",\"c\",{\"children\":[\"$L8\",[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/f87fff2ab93d05a7.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm\"}]],[\"$\",\"$L9\",null,{\"children\":[\"$La\",[\"$\",\"$Lb\",null,{\"promise\":\"$@c\"}]]}]]}],{},null,false]},null,false]},null,false]},null,false],[\"$\",\"$1\",\"h\",{\"children\":[null,[[\"$\",\"$Ld\",null,{\"children\":\"$Le\"}],[\"$\",\"meta\",null,{\"name\":\"next-size-adjust\",\"content\":\"\"}]],[\"$\",\"$Lf\",null,{\"children\":[\"$\",\"div\",null,{\"hidden\":true,\"children\":[\"$\",\"$10\",null,{\"fallback\":null,\"children\":\"$L11\"}]}]}]]}],false]],\"m\":\"$undefined\",\"G\":[\"$12\",[]],\"s\":false,\"S\":false}\n"])</script><script nonce="YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm">self.__next_f.push([1,"2:[\"$\",\"html\",null,{\"lang\":\"en\",\"className\":\"bg-surface-base antialiased\",\"suppressHydrationWarning\":true,\"children\":[[\"$\",\"head\",null,{\"children\":[[\"$\",\"title\",null,{\"children\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"type\":\"image/x-icon\",\"href\":\"/favicon.ico\",\"sizes\":\"48x48\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"href\":\"/images/icon-dark.png\",\"media\":\"(prefers-color-scheme: light)\",\"type\":\"image/png\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"href\":\"/images/icon-light.png\",\"media\":\"(prefers-color-scheme: dark)\",\"type\":\"image/png\"}],[\"$\",\"link\",null,{\"rel\":\"apple-touch-icon\",\"href\":\"/icon-192x192.png\"}],[\"$\",\"link\",null,{\"rel\":\"manifest\",\"href\":\"/manifest.webmanifest\"}],[\"$\",\"meta\",null,{\"name\":\"robots\",\"content\":\"index, follow\"}],[\"$\",\"meta\",null,{\"name\":\"googlebot\",\"content\":\"index, follow, max-snippet:-1\"}],[\"$\",\"meta\",null,{\"property\":\"og:title\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"property\":\"og:description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"meta\",null,{\"property\":\"og:url\",\"content\":\"https://grokipedia.com\"}],[\"$\",\"meta\",null,{\"property\":\"og:site_name\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"property\":\"og:locale\",\"content\":\"en_US\"}],[\"$\",\"meta\",null,{\"property\":\"og:type\",\"content\":\"website\"}],[\"$\",\"meta\",null,{\"property\":\"og:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:width\",\"content\":\"512\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:height\",\"content\":\"512\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:alt\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:card\",\"content\":\"summary\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:creator\",\"content\":\"@Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:title\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}]]}],[\"$\",\"body\",null,{\"className\":\"flex h-[100svh] w-full flex-col __variable_13c637 __variable_8a0ba0 __variable_779740 __variable_2484fd __variable_525cc3 __variable_13486b\",\"children\":[[\"$\",\"$L13\",null,{\"children\":[\"$\",\"$L14\",null,{\"children\":[\"$\",\"$L15\",null,{\"defaultTheme\":\"dark\",\"nonce\":\"YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm\",\"children\":[\"$\",\"$L16\",null,{\"children\":[\"$\",\"$L17\",null,{\"children\":[\"$\",\"$L18\",null,{\"children\":[\"$\",\"$L19\",null,{\"children\":[\"$\",\"$L1a\",null,{\"children\":[[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$1b\",\"errorStyles\":[],\"errorScripts\":[],\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[[\"$\",\"$L1c\",null,{}],[]],\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}],[\"$\",\"$L1d\",null,{}]]}]}]}]}]}]}]}]}],[\"$\",\"script\",null,{\"type\":\"application/json\",\"id\":\"server-client-data-experimentation\",\"children\":\"{\\\"status\\\":\\\"uninitialized\\\"}\"}]]}]]}]\n"])</script><script nonce="YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm">self.__next_f.push([1,"e:[[\"$\",\"meta\",\"0\",{\"charSet\":\"utf-8\"}],[\"$\",\"meta\",\"1\",{\"name\":\"viewport\",\"content\":\"width=device-width, initial-scale=1, interactive-widget=resizes-content\"}]]\na:null\n"])</script><script nonce="YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm">self.__next_f.push([1,"1e:I[42712,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"HydrationBoundary\"]\n"])</script><script nonce="YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm">self.__next_f.push([1,"21:I[6367,[],\"IconMark\"]\n1f:T9d3c,"])</script><script nonce="YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm">self.__next_f.push([1,"# Barbital\n\n![Barbital chemical structure](./_assets_/Barbital.svg.png)\nBarbital, also known by the trade name Veronal, is a barbiturate compound chemically designated as 5,5-diethylbarbituric acid, recognized as the first barbiturate introduced for clinical use as a long-acting sedative and hypnotic agent. Synthesized in 1902 by Emil Fischer and Heinrich Dresler, its hypnotic properties were demonstrated in 1903 by pharmacologist Josef von Mering, leading to its patenting and marketing by Bayer starting in 1904.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC2424120/)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC1079678/)\n\nBarbital exerts its effects primarily by enhancing the activity of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) at GABA_A receptors in the central nervous system, resulting in generalized depression of neuronal activity that manifests as sedation, hypnosis, and anticonvulsant action. Initially employed for treating insomnia, anxiety, and as a preoperative sedative, its use expanded broadly in the early 20th century but was limited by a narrow therapeutic index, rapid development of tolerance, and severe risks including respiratory depression, dependence, and overdose lethality.[](https://www.ncbi.nlm.nih.gov/books/NBK539731/)[](https://www.ncbi.nlm.nih.gov/books/NBK548260/)\n\nThe drug's historical significance lies in pioneering the barbiturate class, which dominated sedative-hypnotic therapy for decades until safer alternatives like benzodiazepines supplanted it amid growing recognition of abuse potential and adverse outcomes, including contribution to iatrogenic addiction and intentional overdoses.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC2424120/)[](https://www.ncbi.nlm.nih.gov/books/NBK548260/)\n\n## History\n\n### Discovery and Synthesis\n\n![Synthesis of barbital](./_assets_/Barbital_Synthese.svg.png)\nBarbituric acid, the parent compound of barbital, was first synthesized in 1864 by Adolf von Baeyer through the condensation of urea and malonic acid.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC2424120/) This reaction yielded a cyclic structure with no initial pharmacological activity, serving as a foundational scaffold for later derivatives.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC2424120/)\n\nIn 1903, Emil Fischer, a chemist at Bayer, and physician Joseph von Mering developed diethylbarbituric acid (barbital), the first barbiturate with hypnotic properties, by condensing diethylmalonic acid diethyl ester with urea.[](https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/barbital) Fischer patented the compound in January 1903, followed by publication of initial findings in March.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC2424120/) Von Mering's animal experiments demonstrated that oral administration induced prolonged sleep in dogs without significant toxicity, distinguishing it from prior sedatives like chloral hydrate.[](https://www.ch.ic.ac.uk/rzepa/mim/drugs/html/barbiturate_text.htm) This synthesis method enabled scalable production due to barbital's relative stability and solubility in alkaline solutions, facilitating its isolation as a crystalline solid.[](https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/barbital)\n\nThe discovery marked the inaugural application of substituted barbituric acids for medical use, building on Baeyer's earlier work but innovating through alkyl substitution at the 5-position to confer sedative effects.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC2424120/) Bayer named the compound Veronal, evoking the serene associations of Verona, Italy, in recognition of its calming action observed in preclinical tests.[](https://www.chemistryworld.com/podcasts/barbituric-acid/8333.article)\n\n### Early Medical Adoption and Marketing\n\n![Veronal crystals bottle, Germany, 1903-1950](._assets_/Bottle_for_'Veronal'_crystals%252C_Germany%252C_1903-1950_Wellcome_L0057800.jpg)\n\nBarbital, marketed by Bayer as Veronal starting in 1904 following its patent by Emil Fischer in 1903, was introduced as a novel hypnotic agent for treating insomnia and anxiety. The drug was licensed to Winthrop Chemical Company for distribution in the United States. Initial clinical evaluation began with self-experiments by psychiatrist Hermann von Husen in 1904, who administered doses of 0.5 g and 1 g, achieving 8-9 hours of deep sleep with minimal side effects, thereby establishing its efficacy as a sedative.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC2424120/)\n\nContemporary observations highlighted Veronal's advantages over prior sedatives like bromides and chloral hydrate, noting its greater potency, broader therapeutic range, and reduced toxicity profile, which facilitated rapid integration into psychiatric practice for calming manic and melancholic states. By the 1910s, barbital had achieved widespread prescription across Europe and the United States for sedation and neurological disorders, supported by early reports of reliable, dose-dependent hypnotic induction.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC2424120/)\n\nDuring World War I, Veronal emerged as the most commonly prescribed sedative for managing shell shock symptoms such as mental confusion and excitement, administered to approximately 37.5% of affected patients at facilities like the Royal Edinburgh Asylum, demonstrating its practical value in frontline psychiatric care despite the onset of reported overdose incidents.[](https://royalsocietypublishing.org/doi/10.1098/rsnr.2021.0057)\n\n### Decline in Use and Regulatory Shifts\n\nBy the 1920s, reports of barbiturate-related suicides and accidental overdoses began accumulating, with the first documented overdose death appearing in medical literature as early as 1912; from that decade onward, these agents were increasingly employed in intentional self-poisoning due to their accessibility and potent sedative effects.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC2424120/) In the United States, barbiturates were linked to more poisoning deaths than any other pharmaceutical drug except possibly alcohol by the mid-1950s, exacerbated by their narrow therapeutic index, where small dosage excesses could precipitate respiratory failure and lethality.[](https://jamanetwork.com/journals/archneurpsyc/fullarticle/650993) United Kingdom data illustrate the trend's severity: barbiturate suicides rose from 104 cases in 1941â€“1950 to 735 in 1958â€“1962, while accidental overdose deaths climbed from 60 to 285 over the same periods, reflecting both intentional misuse and errors in therapeutic administration.[](https://www.suicideinfo.ca/resource/siecno-19860249/)\n\nThe introduction of benzodiazepines in the early 1960s, starting with chlordiazepoxide in 1960, accelerated the decline in barbiturate prescriptions, as these newer agents demonstrated a wider therapeutic window and reduced risk of fatal respiratory depression owing to a ceiling effect on central nervous system suppression.[](https://emedicine.medscape.com/article/813155-overview) Clinical studies highlighted benzodiazepines' superior safety profile for anxiolysis and hypnosis, with overdose lethality requiring far higher doses or combinations with other depressants, prompting a rapid shift in medical practice away from barbiturates for routine sedative-hypnotic use by the late 1960s.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC2424120/)\n\nRegulatory responses formalized these concerns: the U.S. Controlled Substances Act of 1970 classified barbiturates based on abuse potential and dependence risk, placing short-acting variants like secobarbital in Schedule II, intermediate ones like amobarbital in Schedule III, and long-acting types including barbital in Schedule IV.[](https://www.ncbi.nlm.nih.gov/books/NBK574544/)[](https://www.deadiversion.usdoj.gov/schedules/orangebook/c_cs_alpha.pdf) Internationally, the 1971 United Nations Convention on Psychotropic Substances imposed controls on 12 barbiturates, including barbital, aligning with World Health Organization assessments of their high misuse liability and endorsing restrictions on non-essential hypnotic applications.[](https://www.euda.europa.eu/publications/drug-profiles/barbiturates_en) These measures, grounded in epidemiological data on overdoses and dependence, curtailed over-the-counter and liberal prescription availability, further diminishing barbital's clinical prominence.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC2424120/)\n\n## Chemistry\n\n### Chemical Structure and Properties\n\n![Chemical structure of barbital](./_assets_/Barbital.svg.png)\nBarbital, systematically named 5,5-diethylpyrimidine-2,4,6(1H,3H,5H)-trione, possesses the molecular formula Câ‚ˆHâ‚â‚‚Nâ‚‚Oâ‚ƒ and a molecular weight of 184.19 g/mol. It is a barbituric acid derivative characterized by two ethyl groups substituted at the 5-position of the barbituric acid core, which enhances its lipophilicity relative to the unsubstituted parent compound.[](https://pubchem.ncbi.nlm.nih.gov/compound/Barbital)[](https://webbook.nist.gov/cgi/inchi?ID=C57443\u0026Type=IR-SPEC\u0026Index=1)\n\nAs a white, odorless crystalline powder, barbital has a melting point of 188â€“192 Â°C and is poorly soluble in water (1 g dissolves in approximately 130 mL at 25 Â°C) but more readily soluble in organic solvents, including ethanol (1 g per 14 mL), diethyl ether (1 g per 35 mL), and chloroform (1 g per 75 mL). Its pKâ‚ value is 7.43 at 25 Â°C, indicating weak acidity that permits buffering capacity around neutral pH values.[](https://www.chemicalbook.com/ChemicalProductProperty_EN_CB7380141.htm)[](https://www.drugfuture.com/chemdata/barbital.html)[](https://pubchem.ncbi.nlm.nih.gov/compound/Barbital)\n\nBarbital demonstrates chemical stability under neutral and acidic conditions but degrades via hydrolysis in alkaline media, yielding products such as urea and diethylmalonic acid derivatives, as observed in empirical degradation studies of barbiturates. This pH-dependent instability influences pharmaceutical storage recommendations, favoring dry, acidic or neutral environments to minimize breakdown.[](https://www.sciencedirect.com/science/article/abs/pii/S0022354915410597)[](https://www.sciencedirect.com/science/article/abs/pii/S0022354915334511)\n\n### Laboratory Synthesis Methods\n\n![Barbital synthesis scheme](./_assets_/Barbital_Synthese.svg.png)\n\nBarbital, or 5,5-diethylbarbituric acid, is synthesized in the laboratory through the condensation of diethyl 2,2-diethylmalonate with urea in the presence of sodium ethoxide as a base catalyst.[](https://prepchem.com/synthesis-of-barbital/) This method, originally described by Emil Fischer in 1903, involves dissolving sodium (16 g) in absolute ethanol (300 g) to generate sodium ethoxide, followed by addition of diethyl 2,2-diethylmalonate (50 g) and urea (24 g), with the mixture heated under reflux for several hours to facilitate cyclization and elimination of two equivalents of ethanol.[](https://prepchem.com/synthesis-of-barbital/) The reaction intermediate is then acidified with hydrochloric acid to precipitate the barbital product, which is purified by recrystallization from water or ethanol.[](https://prepchem.com/synthesis-of-barbital/)\n\nThe procedure yields barbital as white crystals with a typical laboratory efficiency of around 70-80% when conducted under anhydrous conditions and controlled temperatures (typically 78-80Â°C during reflux).[](https://scholarworks.uno.edu/cgi/viewcontent.cgi?article=2021\u0026context=td) Variations for scalability include using pre-formed sodium ethoxide solutions to enhance reproducibility, though the core malonic ester-urea condensation remains standard due to its simplicity and high atom economy.[](https://pubs.acs.org/doi/10.1021/bc9700345) Industrial adaptations by Bayer, which commercialized barbital as Veronal starting in 1904, employed analogous ester condensations optimized for larger batches, often incorporating malonic acid derivatives to minimize side products like alkylated ureas.[](https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/barbital)\n\nIn modern laboratory practice, adaptations prioritize safety by avoiding excessive sodium metal handling through commercial sodium ethoxide, and product purity is confirmed via spectroscopic methods such as Â¹H NMR (characteristic signals at Î´ 1.0-1.2 ppm for ethyl groups and 8-11 ppm for NH protons) and IR spectroscopy (carbonyl stretches at 1700-1750 cmâ»Â¹).[](https://edoc.ub.uni-muenchen.de/11562/1/Haque_Nadera.pdf) These refinements ensure minimal impurities without introducing heavy metal catalysts, maintaining the method's viability for research-scale production despite barbital's limited current therapeutic use.[](https://www.orgsyn.org/demo.aspx?prep=CV2P0060)\n\n## Pharmacology\n\n### Mechanism of Action\n\nBarbital exerts its central nervous system (CNS) depressant effects primarily through positive allosteric modulation of the GABA_A receptor, a ligand-gated ion channel that mediates fast inhibitory neurotransmission. Upon binding to a distinct allosteric site on the GABA_A receptorâ€”separate from the GABA binding site and benzodiazepine recognition siteâ€”barbital prolongs the duration of chloride channel opening in response to GABA, facilitating greater chloride influx into neurons. This hyperpolarizes the neuronal membrane, reducing excitability and propagating inhibition across neural circuits.[](https://www.ncbi.nlm.nih.gov/books/NBK554443/) Unlike competitive agonists such as benzodiazepines, which increase channel opening frequency, barbital's action emphasizes extended channel dwell time, as demonstrated in single-channel patch-clamp electrophysiological studies on recombinant GABA_A receptors and native neuronal membranes.[](https://pubmed.ncbi.nlm.nih.gov/2482885/) Direct channel activation by barbital at higher concentrations further contributes to this inhibitory cascade, independent of GABA presence.[](https://www.sciencedirect.com/science/article/abs/pii/S0028390806004138)\n\nThe dose-dependent nature of barbital's effects arises from its graded suppression of CNS arousal pathways. At low therapeutic doses, sedation predominates via selective inhibition of thalamocortical relay neurons, dampening sensory gating and cortical activation without widespread brainstem involvement. Escalating doses shift toward hypnosis and anesthesia through broader suppression of the ascending reticular activating system in the brainstem, where mutual inhibitory interactions between excitatory and inhibitory neuronal populations are disrupted, leading to global reduction in vigilance and responsiveness.[](https://onlinelibrary.wiley.com/doi/pdf/10.5694/j.1326-5377.1970.tb84526.x) This progression reflects barbital's non-selective enhancement of GABAergic tone across brain regions, with minimal direct agonism at other neurotransmitter systems such as dopamine or serotonin receptors, as confirmed by radioligand binding assays showing negligible affinity for monoaminergic targets.[](https://pubmed.ncbi.nlm.nih.gov/17289092/)\n\nEmpirical support from electroencephalographic (EEG) recordings underscores these mechanisms, revealing dose-related increases in low-frequency delta waves (0.5â€“4 Hz), indicative of synchronized hyperpolarization and slowed neuronal firing akin to deep sleep states. These spectral shifts occur without altering fast oscillatory bands tied to monoamine modulation, aligning with barbital's targeted GABA_A potentiation rather than broader neuromodulatory interference.[](https://www.ncbi.nlm.nih.gov/books/NBK554443/) Binding and kinetic studies further validate the causal link, quantifying barbital's prolongation of mean channel open time by 2â€“5 fold in voltage-clamp experiments on cortical and hippocampal neurons.[](https://deepblue.lib.umich.edu/bitstream/handle/2027.42/109788/tjp19894171483.pdf?sequence=1)\n\n### Pharmacokinetics and Metabolism\n\nBarbital is rapidly and completely absorbed from the gastrointestinal tract following oral administration, with bioavailability approaching 100%. [](https://www.ncbi.nlm.nih.gov/books/NBK539731/) Peak plasma concentrations are typically attained within 1 to 2 hours post-ingestion. [](https://www.ncbi.nlm.nih.gov/books/NBK539731/)\n\nThe drug exhibits high lipid solubility, facilitating rapid distribution across the blood-brain barrier and into other tissues. [](https://www.sciencedirect.com/topics/medicine-and-dentistry/barbital) Its volume of distribution ranges from 0.6 to 1 L/kg in mammalian models, consistent with moderate tissue penetration. [](https://journals.physiology.org/doi/pdf/10.1152/ajplegacy.1951.168.1.33) Protein binding is relatively low at approximately 40%, allowing a substantial unbound fraction available for distribution and elimination. [](https://www.ncbi.nlm.nih.gov/books/NBK539731/)\n\nMetabolism of barbital is minimal and primarily hepatic, with limited involvement of cytochrome P450 enzymes such as CYP2C19; the majority of the dose remains unchanged. [](https://go.drugbank.com/drugs/DB01483) Elimination occurs predominantly via renal excretion, with 80-90% of the administered dose recovered unchanged in urine, leading to a prolonged plasma half-life of 50-100 hours. [](https://academic.oup.com/ajhp/article-pdf/33/4/333/28422855/ajhp0333.pdf) This renal-dependent clearance contributes to drug accumulation in patients with impaired kidney function or advanced age, where reduced glomerular filtration prolongs exposure. [](https://www.ncbi.nlm.nih.gov/books/NBK539731/)\n\n## Therapeutic Applications\n\n### Historical Indications\n\nBarbital, introduced clinically in 1903 as Veronal, served primarily as a hypnotic agent for treating insomnia, with oral doses of 100-200 mg typically inducing sleep lasting 6-8 hours in adults. Early self-experiments and clinical observations, such as those by psychiatrist Hermann von Husen in 1904, demonstrated its reliability in promoting sleep onset and maintenance among insomniacs, with short-term efficacy reported as high in inducing restful sleep without significant residual effects upon awakening.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC2424120/) By the 1920s, it had become a cornerstone of sedative-hypnotic therapy, dominating insomnia management for decades alongside other barbiturates, based on empirical data from therapeutic trials emphasizing its central nervous system depressant properties.[](https://www.dovepress.com/the-history-of-barbiturates-a-century-after-their-clinical-introductio-peer-reviewed-fulltext-article-NDT)\n\nIn addition to its hypnotic role, barbital found adjunctive application as an anticonvulsant in epilepsy management, leveraging its enhancement of GABAergic inhibition to suppress seizure activity, though phenobarbital largely supplanted it by the 1910s for more potent control. It was also routinely administered for preoperative sedation to alleviate anxiety and facilitate smoother induction of anesthesia, including in obstetric procedures where it aided in labor sedation despite subsequent recognition of potential neonatal impacts. Historical records from the early 20th century indicate its use in reducing patient agitation prior to surgery, contributing to procedural tolerance.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC2424120/)[](https://www.ncbi.nlm.nih.gov/books/NBK539731/)\n\nWithin psychiatric settings from the 1920s to 1940s, barbital was employed to mitigate agitation in manic or excited states, with clinical reports noting its calming effects and utility in narcotherapy protocols involving prolonged sedation, as pioneered by Jacob Klaesi in 1920 for psychotic disorders. Data from this era, including hospital-based observations, showed reduced behavioral disturbances in treated patients, though outcomes were often confounded by concurrent polypharmacy, such as combinations with opioids or other sedatives, limiting attribution to barbital alone.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC2424120/)[](https://www.sciencedirect.com/topics/medicine-and-dentistry/barbital)\n\n### Modern Clinical Uses\n\nIn modern clinical practice, barbital has no established routine indications in human medicine, having been supplanted by benzodiazepines and other agents with more favorable safety profiles for sedation, hypnosis, and seizure management.[](https://www.drugs.com/drug-class/barbiturates.html)[](https://my.clevelandclinic.org/health/treatments/23271-barbiturates) Its prolonged half-life of approximately 53 hours contributes to risks of accumulation and prolonged sedation, rendering it inferior to shorter-acting alternatives like lorazepam or midazolam for acute applications.[](https://go.drugbank.com/drugs/DB01483)\n\nVeterinary applications represent one niche persistence, where barbital may be employed for central nervous system depression in select cases, though phenobarbital predominates for seizure control in dogs and cats due to better tolerability and dosing predictability.[](https://go.drugbank.com/drugs/DB01483)[](https://vcahospitals.com/know-your-pet/phenobarbital) Empirical data from pharmacological references indicate occasional utility in non-epileptic sedation protocols, but no large-scale contemporary studies endorse routine use over established options.[](https://drugcentral.org/drugcard/289)\n\nIn resource-constrained environments, legacy barbiturates including barbital might see sporadic off-label deployment for refractory insomnia or adjunctive anxiolysis, predicated on availability rather than evidence of superiority; however, guidelines from bodies like the World Health Organization prioritize benzodiazepines even in such settings to minimize dependence and overdose risks.[](https://www.sciencedirect.com/topics/neuroscience/barbital) No recent peer-reviewed trials (post-2010) demonstrate barbital outperforming alternatives in specific scenarios like refractory status epilepticus or eclampsia, where agents such as phenytoin, levetiracetam, or magnesium sulfate are standard.[](https://pubmed.ncbi.nlm.nih.gov/37021609/)[](https://www.ncbi.nlm.nih.gov/books/NBK554392/)\n\n## Risks and Adverse Effects\n\n### Short-Term Side Effects\n\nCommon short-term side effects of barbital, observed at therapeutic hypnotic or sedative doses, primarily involve central nervous system depression manifesting as drowsiness, sedation, dizziness, and lightheadedness. These effects typically onset within 30-60 minutes following oral administration and resolve as the drug is eliminated, given barbital's half-life of approximately 53 hours, though acute impairment correlates with peak plasma concentrations.[](https://my.clevelandclinic.org/health/treatments/23271-barbiturates)[](https://americanaddictioncenters.org/barbiturate/side-effects) Ataxia, characterized by impaired coordination and gait instability, along with cognitive effects such as confusion and slowed reaction times, occur due to barbiturate enhancement of GABA_A receptor activity, suppressing neuronal excitability.[](https://www.ncbi.nlm.nih.gov/books/NBK532277/)[](https://www.drugs.com/drug-class/barbiturates.html)\n\nGastrointestinal disturbances, including nausea and occasional vomiting, are reported in therapeutic use, likely from direct mucosal irritation or central emetic pathway involvement.[](https://americanaddictioncenters.org/barbiturate/side-effects)[](https://www.drugs.com/drug-class/barbiturates.html) Paradoxical excitation, such as restlessness or agitation, may arise particularly in the elderly or children, attributed to rapid central nervous system penetration and variable receptor sensitivity, contrasting the typical sedative response.[](https://www.ncbi.nlm.nih.gov/books/NBK532277/)\n\nRespiratory effects at standard therapeutic doses include mild rate reduction, proportional to plasma levels as measured by spirometry, but seldom progress to clinically significant depression without contributing factors like concurrent respiratory disease.[](https://www.ncbi.nlm.nih.gov/books/NBK499875/)[](https://quizlet.com/explanations/questions/what-adverse-effects-are-caused-by-barbiturates-2558bf91-348dea06-b7a5-467c-a5aa-3d341e8fee41) Cardiovascular changes, such as lowered blood pressure and heart rate via medullary depression, are also dose-related and transient.[](https://my.clevelandclinic.org/health/treatments/23271-barbiturates) These effects underscore barbital's narrow therapeutic index, necessitating monitoring during initial dosing.[](https://www.ncbi.nlm.nih.gov/books/NBK499875/)\n\n### Overdose and Toxicity\n\nBarbital overdose induces profound central nervous system depression through enhancement of GABA_A receptor activity, resulting in medullary suppression that manifests as respiratory arrest, hypotension, and coma.[](https://www.ncbi.nlm.nih.gov/books/NBK499875/) Symptoms typically progress from ataxia, nystagmus, and slurred speech at lower doses to unresponsiveness, hypoventilation, and cardiovascular instability at toxic levels exceeding 5-10 times the hypnotic dose (300-600 mg).[](https://accessmedicine.mhmedical.com/content.aspx?bookid=2284\u0026sectionid=248383642) The narrow therapeutic index, with fatal oral doses estimated at 2-6 g in non-tolerant adults, underscores the risk, as individual variability in metabolism and co-ingestants like alcohol amplify lethality.[](https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/barbiturate-overdose)\n\nWithout intervention, survival rates drop below 20% in severe cases due to untreated respiratory failure and secondary complications like aspiration pneumonia.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC2424120/) Historical toxicology data from New York City (1957-1963) document 8,469 barbiturate overdoses with 1,165 fatalities, reflecting empirical ties to prescription availability rather than inherent user suicidality, as method substitution occurred post-restrictions.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC2424120/)\n\nManagement prioritizes supportive measures: gastrointestinal decontamination with activated charcoal within 1-2 hours of ingestion, mechanical ventilation for respiratory depression, and vasopressors or fluids for hypotension.[](https://www.ncbi.nlm.nih.gov/books/NBK499875/) Hemodialysis accelerates elimination in life-threatening intoxications, leveraging barbital's low plasma protein binding (\u003c20%) and moderate volume of distribution, reducing serum levels by 50-70% per session and shortening recovery time compared to conservative care alone.[](https://emedicine.medscape.com/article/813155-treatment) No specific antidote exists, emphasizing early toxicologist consultation for dosing co-interventions like multiple-dose activated charcoal.[](https://www.ncbi.nlm.nih.gov/books/NBK499875/)\n\n### Dependence, Tolerance, and Withdrawal\n\nTolerance to barbital, a long-acting barbiturate, arises from neuroadaptive changes including downregulation of GABA_A receptors in the central nervous system, typically manifesting after weeks of regular therapeutic dosing and prompting dose escalation to maintain efficacy.[](https://pubmed.ncbi.nlm.nih.gov/8894844/)[](https://proceedings.systemdynamics.org/2008/proceed/papers/KONUR337.pdf) This receptor adaptation reduces the drug's potentiation of GABA-mediated chloride influx, diminishing sedative-hypnotic effects over time.[](https://www.sciencedirect.com/science/article/abs/pii/0024320596001993) Physical dependence emerges in chronic users through these compensatory mechanisms, with longitudinal studies of barbiturate users indicating that 18-35% develop chronic intoxication patterns when combined with other substances, though isolated barbital use shows lower but significant risk tied to duration rather than inevitability.[](https://www.tandfonline.com/doi/pdf/10.3109/10826086909062000)\n\nAbrupt discontinuation in dependent individuals precipitates a withdrawal syndrome characterized by heightened anxiety, restlessness, insomnia, tremors, and potentially life-threatening seizures due to unopposed excitatory neurotransmission.[](https://pubmed.ncbi.nlm.nih.gov/10349206/) Symptoms typically onset within 12-24 hours, intensify over 2-4 days as the long half-life of barbital (up to 50-100 hours) allows gradual clearance, and resolve over 5-10 days with supportive care.[](https://www.ncbi.nlm.nih.gov/books/NBK539731/) Management strategies emphasize gradual dose tapering to mitigate neuroexcitability or substitution with longer-acting agents like phenobarbital, which permits smoother detoxification by sustaining GABAergic tone.[](https://journals.sagepub.com/doi/pdf/10.1177/106002808602000702)\n\nContemporary recreational abuse of barbital remains rare, with overall barbiturate misuse prevalence under 1% among general populations due to replacement by safer alternatives like benzodiazepines and stricter prescribing.[](https://emedicine.medscape.com/article/813155-overview) Historical surges in dependence, such as the 135,000 estimated barbiturate addicts in England by 1965 and widespread U.S. epidemics in the mid-20th century, stemmed primarily from overprescription for insomnia and anxiety rather than unique pharmacological compulsion, as evidenced by sharp declines following regulatory curbs in the 1960s-1970s.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC2424120/)[](https://www.news-medical.net/health/Barbiturate-History.aspx) These patterns underscore causal roles of availability and medical practices over intrinsic addictiveness in driving epidemics.[](https://www.dovepress.com/the-history-of-barbiturates-a-century-after-their-clinical-introductio-peer-reviewed-fulltext-article-NDT)\n\n## Legal Status and Regulation\n\n### Classification and Controls\n\nIn the United States, barbital is classified as a Schedule IV controlled substance under the Comprehensive Drug Abuse Prevention and Control Act of 1970, which established the five-tier scheduling system administered by the Drug Enforcement Administration (DEA).[](https://www.law.cornell.edu/uscode/text/21/812) This placement acknowledges barbital's accepted medical uses, such as in sedation and seizure management, while recognizing a low potential for abuse relative to higher-scheduled drugs and the possibility of limited physical or psychological dependence with restricted prescribing.[](https://www.dea.gov/drug-information/drug-scheduling) Schedule IV status imposes requirements for prescriptions via DEA Form 222 for bulk dispensing, secure storage, and record-keeping to mitigate diversion risks.\n\nThe evidence-based rationale for Schedule IV derives from barbital's pharmacological profile as a long-acting barbiturate, which produces less pronounced euphoria and thus lower recreational misuse rates compared to short-acting barbiturates like secobarbital (Schedule II).[](https://www.dea.gov/sites/default/files/2025-01/Barbiturates-2024-Drug-Fact-Sheet.pdf) National Institute on Drug Abuse (NIDA) surveillance through systems like Monitoring the Future and the National Survey on Drug Use and Health has consistently shown barbiturates overall comprising less than 1% of illicit sedative use reports among adolescents and adults, with long-acting variants like barbital exhibiting even rarer diversion incidents due to slower onset and reduced abuse liability.[](https://nida.nih.gov/research-topics/trends-statistics/monitoring-future)\n\nUnder international frameworks, barbital falls under controls harmonized with the 1961 United Nations Single Convention on Narcotic Drugs, where it aligns with Schedule III criteria for substances with moderate abuse potential, therapeutic value, and documented overdose hazards, necessitating import/export licensing and production quotas by signatory states to balance medical access against public health risks.[](https://www.unodc.org/documents/commissions/CND/Scheduling_Resource_Material/Scheduling_Control_Regimes.pdf) This classification weighs empirical data on barbital's narrower therapeutic index against opioids or stimulants, prioritizing regulatory oversight over outright prohibition given its historical role in legitimate pharmacotherapy.[](https://www.incb.org/documents/Narcotic-Drugs/1961-Convention/convention_1961_en.pdf)\n\n### International Variations and Recent Changes\n\nIn the European Union, barbital falls under stringent controls as one of the barbiturates regulated by the 1971 United Nations Convention on Psychotropic Substances, with member states classifying it in high-schedule equivalents (often akin to Schedule IV) that restrict dispensing to authorized medical professionals and require detailed record-keeping to prevent diversion. These measures, harmonized across the bloc since the early 2000s, emphasize low therapeutic indices and abuse potential, resulting in empirical data showing negligible enforcement actions related to barbital specifically, reflective of its obsolescence in favor of safer sedatives.\n\nAsian regulations exhibit variation, with countries like Taiwan implementing tighter oversight in July 2023 by reclassifying barbiturate-containing medications as Schedule 4 controlled substances, mandating enhanced prescription scrutiny and inventory controls amid rising sedative-hypnotic misuse patterns documented in national health surveys.[](https://www.taiwanplus.com/news/taiwan-news/health/230704010/taiwan-tightens-controls-on-barbiturates-and-benzodiazepines)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC11587671/) This adjustment followed incidents of non-medical diversion, aligning with broader regional trends toward restricting long-acting barbiturates post-2000 to mitigate dependence risks, as evidenced by declining prescription volumes in monitored Asian markets.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC11587671/)\n\nIn Australia, barbital is designated a Schedule 8 prohibited drug for human therapeutic use, subjecting it to federal oversight with severe penalties for unauthorized possession or supply; however, barbiturates as a class receive veterinary exemptions for euthanasia purposes when administered by licensed practitioners, correlating with low human diversion ratesâ€”national data from 2010â€“2020 report fewer than 100 barbiturate-related treatment episodes annually and minimal overdose deaths attributable to such agents.[](https://www.mja.com.au/journal/2022/216/4/barbiturate-related-hospitalisations-drug-treatment-episodes-and-deaths) This bifurcated approach has sustained enforcement focus on illicit human markets while permitting controlled animal applications, contrasting with uniform prohibitions elsewhere.\n\nPost-2000 global updates reveal no widespread regulatory relaxation or resurgence for barbital, with International Narcotics Control Board reports highlighting sustained declines in licit use due to superior alternatives; limited niche evaluations in epilepsy contexts (primarily for phenobarbital analogs) have not extended to barbital, amid parallels to opioid crisis-driven scrutiny of high-risk sedatives lacking broad re-adoption evidence from 2021â€“2025 pharmacovigilance studies.[](https://www.incb.org/documents/Publications/AnnualReports/AR2023/Annual_Report/E_INCB_2023_1_eng.pdf)[](https://pubmed.ncbi.nlm.nih.gov/39899099/)\n\n## Non-Medical Applications\n\n### Use in Biochemical Buffers\n\nBarbital, also known as veronal, serves as a key component in certain biochemical buffers due to its pKa value of approximately 8.0, which enables effective pH control around 8.6 when combined with sodium acetate or sodium barbital.[](https://patents.google.com/patent/US4857163A/en) This barbital-sodium acetate buffer system maintains stable ionic strength (typically 0.05â€“0.1 Î¼) and exhibits low interference with protein migration, making it suitable for techniques like serum protein electrophoresis on cellulose acetate or agarose gels.[](https://www.sciencedirect.com/science/article/pii/S0022030279832737) In these applications, the buffer facilitates the separation of serum fractions, including albumin and various globulins, by leveraging differences in electrophoretic mobility under alkaline conditions.[](https://www.sigmaaldrich.com/US/en/product/sigma/b5934)\n\nThe buffer's solubility in aqueous solutions and resistance to pH drift during electrophoresis contribute to reproducible band resolution, historically aiding diagnostic assessments of protein abnormalities such as hypogammaglobulinemia or monoclonal gammopathies.[](https://www.sciencedirect.com/topics/nursing-and-health-professions/protein-electrophoresis) Empirical studies have validated its performance in resolving isoenzymes like lactate dehydrogenase alongside serum proteins and lipoproteins.[](https://www.sigmaaldrich.com/deepweb/assets/sigmaaldrich/product/documents/170/711/b5934dat.pdf) Despite these attributes, barbital's inherent pharmacological activity as a barbiturate introduces risks, including potential toxicity from accumulation in high concentrations or prolonged exposure during lab handling.[](https://www.helena.com/Procedures/Pro001Rev6.pdf)\n\nOwing to these safety concerns and regulatory restrictions on barbiturates as controlled substances, non-barbiturate alternativesâ€”such as Tris-barbital hybrids, Tricine-Tris, or hippurate-based systemsâ€”have been developed and adopted for routine protein electrophoresis.[](https://pubmed.ncbi.nlm.nih.gov/7389096/) [](https://pubmed.ncbi.nlm.nih.gov/568042/) These substitutes provide comparable buffering capacity at pH 8.6 without the sedative properties or handling hazards of barbital, reflecting a shift toward safer protocols in modern biochemical laboratories while preserving legacy methods in specialized or resource-limited settings.[](https://academic.oup.com/clinchem/article-abstract/24/10/1825/5669644)\n\n## Cultural and Historical Impact\n\n### References in Fiction and Media\n\nIn early 20th-century detective fiction, barbital, sold under the trade name Veronal, frequently appears as a hypnotic agent implicated in overdoses or deliberate poisonings, reflecting its era's reputation for inducing profound sedation with a narrow therapeutic margin.[](https://pubmed.ncbi.nlm.nih.gov/38097216/) For instance, Agatha Christie incorporated Veronal in multiple novels, such as *Cards on the Table* (1936), where a victim's death is attributed to an overdose of the drug, and *The Murder of Roger Ackroyd* (1926), portraying it as a factor in a suspicious demise initially masked as accidental.[](https://ahsweetmystery.com/2016/07/05/no-friendly-drop-agatha-christie-and-poison/) [](https://www.reddit.com/r/agathachristie/comments/1fcpbl8/does_someone_know_any_stories_by_agatha_christie/) These portrayals align with contemporaneous medical reports of Veronal's misuse for suicide, given its over-the-counter availability and cumulative toxicity at doses exceeding 1-2 grams.[](https://marymiley.wordpress.com/2013/11/16/veronal-poisoning/)\n\nSimilar references occur in other mystery works, including Margery Allingham's *Dancers in Mourning* (1937), where Veronal serves as a plot device for incapacitation or foul play.[](https://art-sheep.com/deadly-doses-a-study-of-poisons-in-mystery-literature/) Such literary uses underscore public awareness of barbital's risks without romanticizing its effects, often highlighting detection challenges due to its delayed onset and resemblance to natural sleep.\n\nFilm depictions are sparser and typically confined to adaptations of these novels or period dramas evoking 1930s-1940s settings, where barbiturates evoke suicide amid high prescription volumesâ€”reaching millions of doses annually in Europe and the U.S. by the 1930s.[](https://www.merckgroup.com/en/company/history/corporate-history-stories/corporate-history-stories-v2.html) Examples include Christie adaptations like the 1992 television film *Miss Marple: The Mirror Crack'd from Side to Side*, featuring barbiturate poisoning akin to Veronal's profile.[](https://www.imdb.com/search/title/?keywords=barbiturates) Modern media rarely invokes barbital explicitly, signaling its replacement by safer sedatives post-1950s regulations, with no evidence of glorification in contemporary pop culture.[](https://www.nbr.co.nz/book-review/pretty-poison-the-rise-and-fall-of-veronal/)"])</script><script nonce="YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm">self.__next_f.push([1,"8:[\"$\",\"$L1e\",null,{\"state\":{\"mutations\":[],\"queries\":[{\"dehydratedAt\":1761886851191,\"state\":{\"data\":{\"page\":{\"citations\":[{\"id\":\"1\",\"title\":\"The history of barbiturates a century after their clinical introduction\",\"description\":\"The clinical introduction of barbiturates begun a century ago (1904) when the Farbwerke Fr Bayer and Co brought onto the market the first agent of this type,Â ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC2424120/\",\"favicon\":\"\"},{\"id\":\"2\",\"title\":\"One hundred years of barbiturates and their saint - PMC\",\"description\":\"In 1863, Johan Adolf Baeyer discovered malonylurea, a substance that would become the parent compound of the barbiturates.\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC1079678/\",\"favicon\":\"\"},{\"id\":\"3\",\"title\":\"Barbiturates - StatPearls - NCBI Bookshelf - NIH\",\"description\":\"In addition, these medications are also helpful for inducing anesthesia. Thiopental, introduced in 1934 for general anesthesia induction, served as the primaryÂ ...\",\"url\":\"https://www.ncbi.nlm.nih.gov/books/NBK539731/\",\"favicon\":\"\"},{\"id\":\"4\",\"title\":\"Barbiturates - LiverTox - NCBI Bookshelf - NIH\",\"description\":\"Oct 3, 2021 Â· The barbiturates were introduced into medical practice in the early 20th century, used as a sleeping aid and in treatment of schizophrenia.\u003c|separator|\u003e\",\"url\":\"https://www.ncbi.nlm.nih.gov/books/NBK548260/\",\"favicon\":\"\"},{\"id\":\"5\",\"title\":\"Barbital - an overview | ScienceDirect Topics\",\"description\":\"In 1903 Fischer and von Mering discovered a simple method of producing all manner of substituted barbiturates by condensation of dialkylmalonic acid with urea.\",\"url\":\"https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/barbital\",\"favicon\":\"\"},{\"id\":\"6\",\"title\":\"Barbiturate\",\"description\":\"The medical value of these substances was not realised, however, until 1903 when two other German chemists, Emil Fischer and Joseph von Mering, discovered thatÂ ...\",\"url\":\"https://www.ch.ic.ac.uk/rzepa/mim/drugs/html/barbiturate_text.htm\",\"favicon\":\"\"},{\"id\":\"7\",\"title\":\"Barbituric acid | Podcast - Chemistry World\",\"description\":\"Mar 3, 2015 Â· They patented their invention and named it 'Veronal', either for being a 'true' hypnotic, or for Verona, the most peaceful place von Mering knewÂ ...\",\"url\":\"https://www.chemistryworld.com/podcasts/barbituric-acid/8333.article\",\"favicon\":\"\"},{\"id\":\"8\",\"title\":\"Hysteria, head injuries and heredity: 'shell-shocked' soldiers of the ...\",\"description\":\"Mar 2, 2022 Â· The most commonly prescribed drug was Veronal ... Webb, 'â€œDottyvilleâ€: Craiglockhart War Hospital and shell-shock treatment in the First World WarÂ ...\",\"url\":\"https://royalsocietypublishing.org/doi/10.1098/rsnr.2021.0057\",\"favicon\":\"\"},{\"id\":\"9\",\"title\":\"CHRONIC BARBITURATE INTOXICATION: An Experimental Study\",\"description\":\"Acute intoxication with barbiturates accounts for about 25 per cent of all patients with acute poisoning admitted to general hospitals2; and more deaths areÂ ...\",\"url\":\"https://jamanetwork.com/journals/archneurpsyc/fullarticle/650993\",\"favicon\":\"\"},{\"id\":\"10\",\"title\":\"More and More Barbiturates - Centre for Suicide Prevention\",\"description\":\"... overdose increased from 104 during 1941-50 to 735 during 1958-62, \u0026 for accidental deaths from 60 to 285; since 1943 the female suicide rate from barbituratesÂ ...\",\"url\":\"https://www.suicideinfo.ca/resource/siecno-19860249/\",\"favicon\":\"\"},{\"id\":\"11\",\"title\":\"Barbiturate Toxicity: Practice Essentials, Background, Pathophysiology\",\"description\":\"Jan 16, 2025 Â· In general, sedative-hypnotic drugs are nonselective in their effects. At lower doses, a reduction in restlessness and emotional tension occurs.\",\"url\":\"https://emedicine.medscape.com/article/813155-overview\",\"favicon\":\"\"},{\"id\":\"12\",\"title\":\"Controlled Substance Act - StatPearls - NCBI Bookshelf - NIH\",\"description\":\"Schedule II controlled substances include amphetamines, many barbiturates, cocaine (used as a local anesthetic or to stop severe epistaxis), many opioidsÂ ...\",\"url\":\"https://www.ncbi.nlm.nih.gov/books/NBK574544/\",\"favicon\":\"\"},{\"id\":\"13\",\"title\":\"[PDF] Controlled Substances - Alphabetical Order\",\"description\":\"... Schedule, \\\"CSCN\\\" = Controlled Substance Code Number. Controlled Substances ... Barbiturates not specifically listed. Benzethidine. 9606. Y. Benzphetamine.\",\"url\":\"https://www.deadiversion.usdoj.gov/schedules/orangebook/c_cs_alpha.pdf\",\"favicon\":\"\"},{\"id\":\"14\",\"title\":\"Barbiturates drug profile | www.euda.europa.eu - European Union\",\"description\":\"Medical uses. The original use of barbiturates as sedative/hypnotics is no longer recommended because of their adverse reactions and risk of dependence.Missing:  adoption 1910s\",\"url\":\"https://www.euda.europa.eu/publications/drug-profiles/barbiturates_en\",\"favicon\":\"\"},{\"id\":\"15\",\"title\":\"Barbital | C8H12N2O3 | CID 2294 - PubChem - NIH\",\"description\":\"5,5-diethylbarbituric acid is a member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by two ethyl groups.Missing:  stability | Show results with:stability\",\"url\":\"https://pubchem.ncbi.nlm.nih.gov/compound/Barbital\",\"favicon\":\"\"},{\"id\":\"16\",\"title\":\"Barbital - the NIST WebBook\",\"description\":\"Barbital, also known as 5,5-diethylbarbituric acid, has the formula C8H12N2O3 and a molecular weight of 184.1925.Missing:  physical properties solubility pKa stability\",\"url\":\"https://webbook.nist.gov/cgi/inchi?ID=C57443\u0026Type=IR-SPEC\u0026Index=1\",\"favicon\":\"\"},{\"id\":\"17\",\"title\":\"BARBITAL | 57-44-3 - ChemicalBook\",\"description\":\"Aug 20, 2025 Â· Barbital (CAS 57-44-3) has formula C8H12N2O3, melting point 188-192Â°C, boiling point 318.14Â°C, density 1.2200, and is a solid.Missing:  physical | Show results with:physical\",\"url\":\"https://www.chemicalbook.com/ChemicalProductProperty_EN_CB7380141.htm\",\"favicon\":\"\"},{\"id\":\"18\",\"title\":\"Barbital\",\"description\":\"Barbital, also known as 5,5-Diethyl-2,4,6(1H,3H,5H)-pyrimidinetrione, is a prototype of barbiturate hypnotics, with the formula C8H12N2O3 and molecular weightÂ ...Missing:  physical | Show results with:physical\",\"url\":\"https://www.drugfuture.com/chemdata/barbital.html\",\"favicon\":\"\"},{\"id\":\"19\",\"title\":\"Mechanism of Phenobarbital Degradation - ScienceDirect\",\"description\":\"The degradation pathway in FUâ€“Tris solutions is identical, except that Tris reacts with the aldehydes FOPA and Facet to form oxazolidine adducts stable at pHÂ ...\",\"url\":\"https://www.sciencedirect.com/science/article/abs/pii/S0022354915410597\",\"favicon\":\"\"},{\"id\":\"20\",\"title\":\"Mechanism of Phenobarbital Degradation - ScienceDirect.com\",\"description\":\"Ionic strength effects in the alkaline hydrolyses of amobarbital and phenobarbital increase the rate of barbiturate degradation by the attack of hydroxyl ionÂ ...\",\"url\":\"https://www.sciencedirect.com/science/article/abs/pii/S0022354915334511\",\"favicon\":\"\"},{\"id\":\"21\",\"title\":\"Preparation of barbital - PrepChem.com\",\"description\":\"16 g of sodium are dissolved in 300 g of absolute alcohol, the obtained solution is cooled to room temperature, and 50 g of diethyl diethylmalonate are added.\",\"url\":\"https://prepchem.com/synthesis-of-barbital/\",\"favicon\":\"\"},{\"id\":\"22\",\"title\":\"[PDF] The Design and Synthesis of Novel Barbiturates of Pharmaceutical ...\",\"description\":\"May 21, 2004 Â· substituted barbiturates has changed little from the century old method that uses malonic esters and urea as starting materials.36-38. AlsoÂ ...\",\"url\":\"https://scholarworks.uno.edu/cgi/viewcontent.cgi?article=2021\u0026context=td\",\"favicon\":\"\"},{\"id\":\"23\",\"title\":\"Synthesis of Conjugates for a Barbiturate Screening Assay\",\"description\":\"Sodium (11.3 g, 490 mmol) was carefully dissolved in 150 mL of ethanol, and urea (9.80 g, 163 mmol) was added, followed by diethyl cyclopentylmalonate (32.409 gÂ ...\",\"url\":\"https://pubs.acs.org/doi/10.1021/bc9700345\",\"favicon\":\"\"},{\"id\":\"24\",\"title\":\"[PDF] Coordination Chemistry of Barbituric Acid, its Diethyl Derivative and ...\",\"description\":\"the condensation of urea with diethyl malonoic ester in the presence of sodium ethoxide followed by the elimination of two molecules of ethanol (Scheme 2)Â ...\",\"url\":\"https://edoc.ub.uni-muenchen.de/11562/1/Haque_Nadera.pdf\",\"favicon\":\"\"},{\"id\":\"25\",\"title\":\"\",\"description\":\"\",\"url\":\"https://www.orgsyn.org/demo.aspx?prep=CV2P0060\",\"favicon\":\"\"},{\"id\":\"26\",\"title\":\"GABA Receptor Positive Allosteric Modulators - StatPearls - NCBI\",\"description\":\"Feb 28, 2024 Â· Mechanism of Action Â· Drugs in this class exert their action by increasing an agonist's effects when achieving potentiation. Â· Most generalÂ ...\",\"url\":\"https://www.ncbi.nlm.nih.gov/books/NBK554443/\",\"favicon\":\"\"},{\"id\":\"27\",\"title\":\"Barbiturate regulation of kinetic properties of the GABAA receptor ...\",\"description\":\"GABA alone or with the barbiturates gated the channel open singly and in groups of openings. 5. The barbiturates increased GABA receptor channel mean openÂ ...\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/2482885/\",\"favicon\":\"\"},{\"id\":\"28\",\"title\":\"Barbiturate activation and modulation of GABA A receptors in ...\",\"description\":\"In several regions of the neuraxis, barbiturates enhance synaptic inhibition mediated by receptors for Î³-aminobutyrate (GABA), a major inhibitory transmitter.\",\"url\":\"https://www.sciencedirect.com/science/article/abs/pii/S0028390806004138\",\"favicon\":\"\"},{\"id\":\"29\",\"title\":\"THE PHARMACOLOGY OF BARBITURATES - Wiley Online Library\",\"description\":\"Jun 13, 1970 Â· They have proposed that a system of mutual inhibition operates between these two types of neurones, thereby regulating the level ofÂ ...\",\"url\":\"https://onlinelibrary.wiley.com/doi/pdf/10.5694/j.1326-5377.1970.tb84526.x\",\"favicon\":\"\"},{\"id\":\"30\",\"title\":\"Barbiturate activation and modulation of GABA(A) receptors in ...\",\"description\":\"The ability of phenobarbital at anti-epileptic concentrations to inhibit neocortical firing by direct activation and modulation of GABA(A) receptors relates toÂ ...\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/17289092/\",\"favicon\":\"\"},{\"id\":\"31\",\"title\":\"[PDF] Barbiturate regulation of kinetic properties of the GABAA receptor ...\",\"description\":\"GABA has been shown to activate chloride channel openings to at least fourconductance states (Bormann et al. 1987). Inthe present study, only the moreÂ ...\",\"url\":\"https://deepblue.lib.umich.edu/bitstream/handle/2027.42/109788/tjp19894171483.pdf?sequence=1\",\"favicon\":\"\"},{\"id\":\"32\",\"title\":\"Barbital - an overview | ScienceDirect Topics\",\"description\":\"Barbital is a type of barbiturate that acts as a sedative, increasing GABA activity in the brain to induce sleep and depress the muscular system.\",\"url\":\"https://www.sciencedirect.com/topics/medicine-and-dentistry/barbital\",\"favicon\":\"\"},{\"id\":\"33\",\"title\":\"A Comparison of Effects of Morphine and Barbital on Volume ...\",\"description\":\"i.v. Previously published data in which sodium barbital, 300 mg. per ... The average volume of distribution was 148 per cent. The data for the 2 dogsÂ ...\",\"url\":\"https://journals.physiology.org/doi/pdf/10.1152/ajplegacy.1951.168.1.33\",\"favicon\":\"\"},{\"id\":\"34\",\"title\":\"Barbital: Uses, Interactions, Mechanism of Action | DrugBank Online\",\"description\":\"Jul 31, 2007 Â· The risk or severity of CNS depression can be increased when Barbital is combined with Brotizolam. Buclizine, The risk or severity of adverseÂ ...\",\"url\":\"https://go.drugbank.com/drugs/DB01483\",\"favicon\":\"\"},{\"id\":\"35\",\"title\":\"Current drug therapyâ€”barbiturates\",\"description\":\"Barbital is excreted essentially unchanged in the urine;. 1,7.22,29 approximately ,25% of a dose of phenobarbital or aprobarbital is excreted unchanged.\",\"url\":\"https://academic.oup.com/ajhp/article-pdf/33/4/333/28422855/ajhp0333.pdf\",\"favicon\":\"\"},{\"id\":\"36\",\"title\":\"The history of barbiturates a century after their clinical introduction\",\"description\":\"Dec 15, 2005 Â· Abstract: The present work offers an analysis of the historical development of the discovery and use of barbiturates in the field of psychiatryÂ ...\",\"url\":\"https://www.dovepress.com/the-history-of-barbiturates-a-century-after-their-clinical-introductio-peer-reviewed-fulltext-article-NDT\",\"favicon\":\"\"},{\"id\":\"37\",\"title\":\"List of Common Barbiturates + Uses \u0026 Side Effects - Drugs.com\",\"description\":\"Apr 12, 2023 Â· Historically, barbiturates were used in the treatment of anxiety, epilepsy, to induce sleep, and as anesthetics. Nowadays, their use is limitedÂ ...\",\"url\":\"https://www.drugs.com/drug-class/barbiturates.html\",\"favicon\":\"\"},{\"id\":\"38\",\"title\":\"Barbiturates: Definition, Types, Uses, Side Effects \u0026 Abuse\",\"description\":\"Jun 14, 2022 Â· Barbiturates are medications that cause you to relax or feel drowsy. They can also stop or prevent convulsions and seizures.\",\"url\":\"https://my.clevelandclinic.org/health/treatments/23271-barbiturates\",\"favicon\":\"\"},{\"id\":\"39\",\"title\":\"Phenobarbital | VCA Animal Hospitals\",\"description\":\"Phenobarbital is used to help control seizures in dogs and cats. It may be used alone or with other medication. Learn more at VCA.\",\"url\":\"https://vcahospitals.com/know-your-pet/phenobarbital\",\"favicon\":\"\"},{\"id\":\"40\",\"title\":\"barbital - Drug Central\",\"description\":\"It is used as a hypnotic and sedative and may induce dependence. Barbital is also used in veterinary practice for central nervous system depression.\",\"url\":\"https://drugcentral.org/drugcard/289\",\"favicon\":\"\"},{\"id\":\"41\",\"title\":\"Barbital - an overview | ScienceDirect Topics\",\"description\":\"Barbital is a barbiturate derivative introduced as the first barbiturate hypnotic in 1903, following the synthesis of malonylurea (barbituric acid) by vonÂ ...Missing:  Bayer | Show results with:Bayer\",\"url\":\"https://www.sciencedirect.com/topics/neuroscience/barbital\",\"favicon\":\"\"},{\"id\":\"42\",\"title\":\"Phenobarbital in super-refractory status epilepticus (PIRATE)\",\"description\":\"Apr 16, 2023 Â· This study aimed to evaluate the efficacy and safety of phenobarbital (PB) for the treatment of SRSE.\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/37021609/\",\"favicon\":\"\"},{\"id\":\"43\",\"title\":\"Eclampsia - StatPearls - NCBI Bookshelf\",\"description\":\"Oct 6, 2024 Â· Immediate management, including seizure control with magnesium sulfate and timely delivery, is critical to preventing maternal and fetalÂ ...\",\"url\":\"https://www.ncbi.nlm.nih.gov/books/NBK554392/\",\"favicon\":\"\"},{\"id\":\"44\",\"title\":\"What Are the Side Effects of Barbiturates?\",\"description\":\"Apr 18, 2025 Â· Some users may become irritable or paranoid with high doses of barbiturates. Suicidal thoughts can arise in extreme cases. Barbiturate MisuseÂ ...\",\"url\":\"https://americanaddictioncenters.org/barbiturate/side-effects\",\"favicon\":\"\"},{\"id\":\"45\",\"title\":\"Phenobarbital - StatPearls - NCBI Bookshelf - NIH\",\"description\":\"Feb 28, 2024 Â· Elimination: About 25% to 50% of the unchanged drug is excreted in the urine. Remember that clearance rates vary with patients and theirÂ ...Missing:  percentage | Show results with:percentage\",\"url\":\"https://www.ncbi.nlm.nih.gov/books/NBK532277/\",\"favicon\":\"\"},{\"id\":\"46\",\"title\":\"Barbiturate Toxicity - StatPearls - NCBI Bookshelf - NIH\",\"description\":\"Feb 28, 2024 Â· Barbiturates are sedative-hypnotic drugs. They are derivates of barbituric acid and were introduced clinically in the early 1900s.\",\"url\":\"https://www.ncbi.nlm.nih.gov/books/NBK499875/\",\"favicon\":\"\"},{\"id\":\"47\",\"title\":\"What adverse effects are caused by barbiturates? - Quizlet\",\"description\":\"Barbiturates cause hypoventilation, a slower-than-normal rate of breathing because they suppress the respiratory centers in the brain. What happens to the redÂ ...\",\"url\":\"https://quizlet.com/explanations/questions/what-adverse-effects-are-caused-by-barbiturates-2558bf91-348dea06-b7a5-467c-a5aa-3d341e8fee41\",\"favicon\":\"\"},{\"id\":\"48\",\"title\":\"BARBITURATES | Poisoning \u0026 Drug Overdose, 7e - AccessMedicine\",\"description\":\"In general, toxicity is likely when the dose exceeds 5â€“10 times the hypnotic dose. Chronic users or abusers may have striking tolerance to depressant effects. +Â ...Missing:  Barbital LD50\",\"url\":\"https://accessmedicine.mhmedical.com/content.aspx?bookid=2284\u0026sectionid=248383642\",\"favicon\":\"\"},{\"id\":\"49\",\"title\":\"Barbiturate Overdose - an overview | ScienceDirect Topics\",\"description\":\"For the most commonly abused barbiturates, the ratio of lethal to effective dose ranges between three to one and 30 to 1. View chapterExplore book.\",\"url\":\"https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/barbiturate-overdose\",\"favicon\":\"\"},{\"id\":\"50\",\"title\":\"Barbiturate Toxicity Treatment \u0026 Management - Medscape Reference\",\"description\":\"Jan 16, 2025 Â· Management strategies generally fall into 3 major areas: supportive care, decontamination, and enhancement of elimination.Prehospital Care Â· Emergency Department Care Â· Inpatient CareMissing:  LD50 | Show results with:LD50\",\"url\":\"https://emedicine.medscape.com/article/813155-treatment\",\"favicon\":\"\"},{\"id\":\"51\",\"title\":\"Use-dependent regulation of GABAA receptors - PubMed\",\"description\":\"This downregulation correlates with the establishment of tolerance to and physical dependence on the pharmacological effects of these drugs, suggesting aÂ ...\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/8894844/\",\"favicon\":\"\"},{\"id\":\"52\",\"title\":\"[PDF] Development of Barbiturate Tolerance and Dependence\",\"description\":\"As the drug is continued, the body tries to counteract the increase in inhibitory neurotransmission by down-regulating the GABAA receptors. Unlike enzymeÂ ...\u003c|separator|\u003e\",\"url\":\"https://proceedings.systemdynamics.org/2008/proceed/papers/KONUR337.pdf\",\"favicon\":\"\"},{\"id\":\"53\",\"title\":\"Minireview Pharmacology of barbiturate tolerance/dependence\",\"description\":\"Recent advances in the study of the GABAA receptor/chloride channel complex allow us to examine possible mechanisms that underlie barbiturate tolerance/Â ...\",\"url\":\"https://www.sciencedirect.com/science/article/abs/pii/0024320596001993\",\"favicon\":\"\"},{\"id\":\"54\",\"title\":\"Barbiturate-Sedative Abuse: A Study of Prevalence Among Narcotic ...\",\"description\":\"18.0% of the addict-patients were found to be chronically intoxicated with barbiturates-sedatives. By 1966, however, 35.0% of the narcotic abusers were alsoÂ ...\u003c|separator|\u003e\",\"url\":\"https://www.tandfonline.com/doi/pdf/10.3109/10826086909062000\",\"favicon\":\"\"},{\"id\":\"55\",\"title\":\"[Barbiturate withdrawal syndrome: a case associated with the abuse ...\",\"description\":\"Barbiturates can produce psychological and physical dependence and produce a withdrawal syndrome on the second to fourth day after the drug is suspended.\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/10349206/\",\"favicon\":\"\"},{\"id\":\"56\",\"title\":\"Sedative/Hypnotic Dependence: Patient Stabilization, Tolerance ...\",\"description\":\"Compared to other benzodiazepines and barbiturates, diazepam appears to be the drug of choice for treating dependent patients. Diazepam is rapidly adsorbed andÂ ...\",\"url\":\"https://journals.sagepub.com/doi/pdf/10.1177/106002808602000702\",\"favicon\":\"\"},{\"id\":\"57\",\"title\":\"Barbiturate History - News-Medical\",\"description\":\"In 1864 Adolf von Bayer developed malonylurea from which in the early 20th century came the barbiturates. These agents were first brought to the market in 1904Â ...Missing:  Veronal | Show results with:Veronal\",\"url\":\"https://www.news-medical.net/health/Barbiturate-History.aspx\",\"favicon\":\"\"},{\"id\":\"58\",\"title\":\"21 U.S. Code Â§ 812 - Schedules of controlled substances\",\"description\":\"Phenobarbital. Schedule V. Any compound, mixture, or preparation containing any of the following limited quantities of narcotic drugs, which shall includeÂ ...\",\"url\":\"https://www.law.cornell.edu/uscode/text/21/812\",\"favicon\":\"\"},{\"id\":\"59\",\"title\":\"Drug Scheduling - DEA.gov\",\"description\":\"A Listing of drugs and their schedule are located at Controlled Substance Act (CSA) Scheduling or CSA Scheduling by Alphabetical Order.Missing:  barbiturates | Show results with:barbiturates\",\"url\":\"https://www.dea.gov/drug-information/drug-scheduling\",\"favicon\":\"\"},{\"id\":\"60\",\"title\":\"[PDF] Barbiturates - DEA.gov\",\"description\":\"What is their legal status in the United States? Barbiturates are Schedule II, III, and IV depressants under the Controlled Substances Act. Barbiturates.Missing:  Barbital | Show results with:Barbital\",\"url\":\"https://www.dea.gov/sites/default/files/2025-01/Barbiturates-2024-Drug-Fact-Sheet.pdf\",\"favicon\":\"\"},{\"id\":\"61\",\"title\":\"Monitoring the Future | National Institute on Drug Abuse (NIDA) - NIH\",\"description\":\"Aug 29, 2024 Â· Since 1975 the MTF survey has measured drug and alcohol use and related attitudes among adolescent students nationwide.Missing:  Barbital potential\",\"url\":\"https://nida.nih.gov/research-topics/trends-statistics/monitoring-future\",\"favicon\":\"\"},{\"id\":\"62\",\"title\":\"[PDF] International Drug Control Conventions - Schedules/Tables and ...\",\"description\":\"SINGLE CONVENTION ON NARCOTIC DRUGS OF 1961 â€“ SCHEDULES. Schedule IV. Schedule ... (E.g. barbiturates, including amobarbital, buprenorphine). SCHEDULE IV.\",\"url\":\"https://www.unodc.org/documents/commissions/CND/Scheduling_Resource_Material/Scheduling_Control_Regimes.pdf\",\"favicon\":\"\"},{\"id\":\"63\",\"title\":\"[PDF] SINGLE CONVENTION ON NARCOTIC DRUGS, 1961, - INCB\",\"description\":\"The United Nations Conference for the Adoption of a Single Con vention on Narcotic Drugs met at United Nations Headquarters from 24 January to 25 March 1961. 3.Missing:  Barbital | Show results with:Barbital\",\"url\":\"https://www.incb.org/documents/Narcotic-Drugs/1961-Convention/convention_1961_en.pdf\",\"favicon\":\"\"},{\"id\":\"64\",\"title\":\"Taiwan Tightens Controls on Barbiturates and Benzodiazepines\",\"description\":\"Jul 4, 2023 Â· Taiwan has reclassified medications containing barbiturates and benzodiazepines as schedule 4 controlled substances.Missing:  misuse | Show results with:misuse\",\"url\":\"https://www.taiwanplus.com/news/taiwan-news/health/230704010/taiwan-tightens-controls-on-barbiturates-and-benzodiazepines\",\"favicon\":\"\"},{\"id\":\"65\",\"title\":\"Trends in the use and nonmedical use of sedatives-hypnotics ... - NIH\",\"description\":\"Nov 25, 2024 Â· Many countries, including Taiwan, have tightened regulations on prescribing sedatives-hypnotics over the concern of their associated adverseÂ ...Missing:  barbital | Show results with:barbital\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC11587671/\",\"favicon\":\"\"},{\"id\":\"66\",\"title\":\"Barbiturateâ€related hospitalisations, drug treatment episodes, and ...\",\"description\":\"Nov 1, 2021 Â· The population rate of barbiturateâ€related deaths increased from 0.07 in 2000â€“01 to 0.19 per 100 000 population in 2016â€“17 (AAPC, +9.3%; 95% CI,Â ...\",\"url\":\"https://www.mja.com.au/journal/2022/216/4/barbiturate-related-hospitalisations-drug-treatment-episodes-and-deaths\",\"favicon\":\"\"},{\"id\":\"67\",\"title\":\"[PDF] Report of the International Narcotics Control Board for 2023\",\"description\":\"Jan 21, 2023 Â· The members of the International Narcotics Control Board (INCB) were deeply saddened by the pass- ing of Mr. Bernard Leroy in February 2023.\",\"url\":\"https://www.incb.org/documents/Publications/AnnualReports/AR2023/Annual_Report/E_INCB_2023_1_eng.pdf\",\"favicon\":\"\"},{\"id\":\"68\",\"title\":\"Update on Antiseizure Medications 2025 - PubMed\",\"description\":\"Feb 1, 2025 Â· This article addresses antiseizure medications individually, focusing on key pharmacokinetic characteristics, indications, and modes of use.Missing:  barbital protocols resurgence 2021-2025\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/39899099/\",\"favicon\":\"\"},{\"id\":\"69\",\"title\":\"High resolution electrophoretic gel and method for separating serum ...\",\"description\":\"Barbital buffer, at pH 8.6, is accepted as the standard buffer for routine serum protein electrophoresis. Barbital, also known as veronal, is the bufferÂ ...\",\"url\":\"https://patents.google.com/patent/US4857163A/en\",\"favicon\":\"\"},{\"id\":\"70\",\"title\":\"Rapid Separation of Whey Proteins by Cellulose Acetate ...\",\"description\":\"Tris-barbital-sodium barbital buffer was used at pH 8.6 (ionic strength .097) with a constant current of 225 V for 1 h. Densitometer tracings showedÂ ...\",\"url\":\"https://www.sciencedirect.com/science/article/pii/S0022030279832737\",\"favicon\":\"\"},{\"id\":\"71\",\"title\":\"\",\"description\":\"\",\"url\":\"https://www.sigmaaldrich.com/US/en/product/sigma/b5934\",\"favicon\":\"\"},{\"id\":\"72\",\"title\":\"Protein Electrophoresis - an overview | ScienceDirect Topics\",\"description\":\"Clinical laboratories most commonly use barbital buffers at pH 8.6 to perform the serum protein electrophoresis (SPEP) test. Under these conditionsÂ ...\",\"url\":\"https://www.sciencedirect.com/topics/nursing-and-health-professions/protein-electrophoresis\",\"favicon\":\"\"},{\"id\":\"73\",\"title\":\"\",\"description\":\"\",\"url\":\"https://www.sigmaaldrich.com/deepweb/assets/sigmaaldrich/product/documents/170/711/b5934dat.pdf\",\"favicon\":\"\"},{\"id\":\"74\",\"title\":\"[PDF] Serum Protein Electrophoresis Procedure - Helena Laboratories\",\"description\":\"The buffer contains barbital which, in sufficient quantity, can be toxic. Preparation for Use: Dissolve one package of dry buffer in. 750 mL of deionizedÂ ...\",\"url\":\"https://www.helena.com/Procedures/Pro001Rev6.pdf\",\"favicon\":\"\"},{\"id\":\"75\",\"title\":\"Two new non-barbiturate buffers for electrophoresis of serum ...\",\"description\":\"Two new non-barbiturate buffers have been formulated for serum protein electrophoresis on cellulose acetate membranes.\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/7389096/\",\"favicon\":\"\"},{\"id\":\"76\",\"title\":\"A non-barbital buffer for immunoelectrophoresis and zone ... - PubMed\",\"description\":\"We describe buffer for both immunoelectrophoresis and zone electrophoresis procedures in agarose gels, Tricine [N-tris(hydroxymethyl)methylglycine] and TrisÂ ...\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/568042/\",\"favicon\":\"\"},{\"id\":\"77\",\"title\":\"A non-barbital buffer for immunoelectrophoresis and zone ...\",\"description\":\"We describe buffer for both immunoelectrophoresis and zone electrophoresis procedures in agarose gels, Tricine [N-tris(hydroxymethyl)methylglycine] and TrisÂ ...Missing:  alternatives | Show results with:alternatives\",\"url\":\"https://academic.oup.com/clinchem/article-abstract/24/10/1825/5669644\",\"favicon\":\"\"},{\"id\":\"78\",\"title\":\"[Veronal, in Lord Edgware Dies: A Double-edged Sword of Sedation ...\",\"description\":\"Veronal, introduced during the early 20th century was widely used as a sleeping pill at the time, and this drug is mentioned in Agatha Christie's novels.\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/38097216/\",\"favicon\":\"\"},{\"id\":\"79\",\"title\":\"NO FRIENDLY DROP: Agatha Christie and Poison | Ah Sweet Mystery!\",\"description\":\"Jul 5, 2016 Â· And while we've seen a woman fall victim to a veronal overdose in Cards on the Table, other victims in that novel succumb to anthrax, bacteria,Â ...\",\"url\":\"https://ahsweetmystery.com/2016/07/05/no-friendly-drop-agatha-christie-and-poison/\",\"favicon\":\"\"},{\"id\":\"80\",\"title\":\"Does someone know any stories by Agatha Christie that feature ...\",\"description\":\"Sep 9, 2024 Â· Who killed Roger Ackroyd has veronal (lots of others do too), with drug use blamed for a death. Peril at End House does too. There are lots ofÂ ...\",\"url\":\"https://www.reddit.com/r/agathachristie/comments/1fcpbl8/does_someone_know_any_stories_by_agatha_christie/\",\"favicon\":\"\"},{\"id\":\"81\",\"title\":\"Veronal Poisoning - Mary Miley's Roaring Twenties - WordPress.com\",\"description\":\"Nov 16, 2013 Â· Veronal was an over-the-counter sleeping potion that was occasionally misused for suicide. I needed to know how much it would take to kill someone and how longÂ ...\",\"url\":\"https://marymiley.wordpress.com/2013/11/16/veronal-poisoning/\",\"favicon\":\"\"},{\"id\":\"82\",\"title\":\"Deadly Doses: A Study of Poisons in Mystery Literature - Art-Sheep\",\"description\":\"Aug 23, 2014 Â· Veronal (Barbital): Central to Margery Allingham's â€œDancers in Mourning.â€ Chloral Hydrate: Featured in Raymond Chandler's â€œThe Big SleepÂ ...\",\"url\":\"https://art-sheep.com/deadly-doses-a-study-of-poisons-in-mystery-literature/\",\"favicon\":\"\"},{\"id\":\"83\",\"title\":\"Story: Veronal - Merck Group\",\"description\":\"The medicine is said to have been named in honor of the sleeping potion of the two lovers of Verona, Romeo and Juliet. It hasal so been claimed that theÂ ...\",\"url\":\"https://www.merckgroup.com/en/company/history/corporate-history-stories/corporate-history-stories-v2.html\",\"favicon\":\"\"},{\"id\":\"84\",\"title\":\"barbiturates (Sorted by Popularity Ascending) - IMDb\",\"description\":\"1. Miss Marple: The Mirror Crack'd from Side to Side. 19921h 46mTV-14TV Movie. 7.5 (2.2K) ; 2. The Bell Jar. 19791h 47mR Â· 5.2 (325) ; 3. Rainbow. 19781h 37mTVÂ ...Missing:  Barbital | Show results with:Barbital\",\"url\":\"https://www.imdb.com/search/title/?keywords=barbiturates\",\"favicon\":\"\"},{\"id\":\"85\",\"title\":\"Pretty poison: The rise and fall of Veronal - NBR\",\"description\":\"Apr 14, 2024 Â· A series of sensational criminal trials involved Veronal as a suspected poison. Suspicions raised Scott Bainbridge.\",\"url\":\"https://www.nbr.co.nz/book-review/pretty-poison-the-rise-and-fall-of-veronal/\",\"favicon\":\"\"}],\"images\":[{\"id\":\"16da7011c582\",\"caption\":\"Barbital chemical structure\",\"url\":\"./_assets_/Barbital.svg.png\",\"position\":\"CENTER\",\"width\":0,\"height\":0},{\"id\":\"6c42213b2c3e\",\"caption\":\"Synthesis of barbital\",\"url\":\"./_assets_/Barbital_Synthese.svg.png\",\"position\":\"CENTER\",\"width\":0,\"height\":0},{\"id\":\"016653390f2d\",\"caption\":\"Veronal crystals bottle, Germany, 1903-1950\",\"url\":\"._assets_/Bottle_for_'Veronal'_crystals%252C_Germany%252C_1903-1950_Wellcome_L0057800.jpg\",\"position\":\"CENTER\",\"width\":0,\"height\":0},{\"id\":\"16da7011c582\",\"caption\":\"Chemical structure of barbital\",\"url\":\"./_assets_/Barbital.svg.png\",\"position\":\"CENTER\",\"width\":0,\"height\":0},{\"id\":\"6c42213b2c3e\",\"caption\":\"Barbital synthesis scheme\",\"url\":\"./_assets_/Barbital_Synthese.svg.png\",\"position\":\"CENTER\",\"width\":0,\"height\":0}],\"fixedIssues\":[],\"slug\":\"Barbital\",\"title\":\"Barbital\",\"content\":\"$1f\",\"description\":\"Barbital\\n\\nBarbital chemical structure\\nBarbital, also known by the trade name Veronal, is a barbiturate compound chemically designated as 5,5-diethylbarbituric acid, recognized as the first...\",\"metadata\":{\"categories\":[\"Veronal\"],\"lastModified\":\"1761583129\",\"contentLength\":\"40252\",\"version\":\"1.0\",\"lastEditor\":\"system\",\"language\":\"en\",\"isRedirect\":false,\"redirectTarget\":\"\",\"isWithheld\":false},\"stats\":{\"totalViews\":\"82388\",\"recentViews\":\"82388\",\"dailyAvgViews\":2746.2666015625,\"qualityScore\":1,\"lastViewed\":\"1761886850\"},\"linkedPages\":null},\"found\":true},\"dataUpdateCount\":1,\"dataUpdatedAt\":1761886851187,\"error\":null,\"errorUpdateCount\":0,\"errorUpdatedAt\":0,\"fetchFailureCount\":0,\"fetchFailureReason\":null,\"fetchMeta\":null,\"isInvalidated\":false,\"status\":\"success\",\"fetchStatus\":\"idle\"},\"queryKey\":[\"page\",\"Barbital\"],\"queryHash\":\"[\\\"page\\\",\\\"Barbital\\\"]\"}]},\"children\":\"$L20\"}]\n"])</script><script nonce="YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm">self.__next_f.push([1,"c:{\"metadata\":[[\"$\",\"title\",\"0\",{\"children\":\"Barbital\"}],[\"$\",\"meta\",\"1\",{\"name\":\"description\",\"content\":\"Barbital, also known by the trade name Veronal, is a barbiturate compound chemically designated as 5,5-diethylbarbituric acid, recognized as the first barbiturate introduced for clinical use as a long-acting sedative and hypnotic agent. Synthesized in 1902 by Emil Fischer and Heinrich Dresler, its hypnotic properties were demonstrated in 1903 by pharmacologist Josef von Mering, leading to its patenting and marketing by Bayer starting in 1904. Barbital exerts its effects primarily by enhancing...\"}],[\"$\",\"meta\",\"2\",{\"name\":\"author\",\"content\":\"system\"}],[\"$\",\"link\",\"3\",{\"rel\":\"manifest\",\"href\":\"/manifest.webmanifest\",\"crossOrigin\":\"$undefined\"}],[\"$\",\"meta\",\"4\",{\"name\":\"keywords\",\"content\":\"Veronal\"}],[\"$\",\"meta\",\"5\",{\"name\":\"robots\",\"content\":\"index, follow\"}],[\"$\",\"meta\",\"6\",{\"name\":\"googlebot\",\"content\":\"index, follow, max-snippet:-1\"}],[\"$\",\"link\",\"7\",{\"rel\":\"canonical\",\"href\":\"https://grokipedia.com/page/Barbital\"}],[\"$\",\"meta\",\"8\",{\"property\":\"og:title\",\"content\":\"Barbital\"}],[\"$\",\"meta\",\"9\",{\"property\":\"og:description\",\"content\":\"Barbital, also known by the trade name Veronal, is a barbiturate compound chemically designated as 5,5-diethylbarbituric acid, recognized as the first barbiturate introduced for clinical use as a long-acting sedative and hypnotic agent. Synthesized in 1902 by Emil Fischer and Heinrich Dresler, its hypnotic properties were demonstrated in 1903 by pharmacologist Josef von Mering, leading to its patenting and marketing by Bayer starting in 1904. Barbital exerts its effects primarily by enhancing...\"}],[\"$\",\"meta\",\"10\",{\"property\":\"og:url\",\"content\":\"https://grokipedia.com/page/Barbital\"}],[\"$\",\"meta\",\"11\",{\"property\":\"og:site_name\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",\"12\",{\"property\":\"og:locale\",\"content\":\"en\"}],[\"$\",\"meta\",\"13\",{\"property\":\"og:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"meta\",\"14\",{\"property\":\"og:image:width\",\"content\":\"512\"}],[\"$\",\"meta\",\"15\",{\"property\":\"og:image:height\",\"content\":\"512\"}],[\"$\",\"meta\",\"16\",{\"property\":\"og:image:alt\",\"content\":\"Barbital\"}],[\"$\",\"meta\",\"17\",{\"property\":\"og:type\",\"content\":\"article\"}],[\"$\",\"meta\",\"18\",{\"property\":\"article:modified_time\",\"content\":\"1970-01-21T09:19:43.129Z\"}],[\"$\",\"meta\",\"19\",{\"name\":\"twitter:card\",\"content\":\"summary\"}],[\"$\",\"meta\",\"20\",{\"name\":\"twitter:creator\",\"content\":\"@Grokipedia\"}],[\"$\",\"meta\",\"21\",{\"name\":\"twitter:title\",\"content\":\"Barbital\"}],[\"$\",\"meta\",\"22\",{\"name\":\"twitter:description\",\"content\":\"Barbital, also known by the trade name Veronal, is a barbiturate compound chemically designated as 5,5-diethylbarbituric acid, recognized as the first barbiturate introduced for clinical use as a long-acting sedative and hypnotic agent. Synthesized in 1902 by Emil Fischer and Heinrich Dresler, its hypnotic properties were demonstrated in 1903 by pharmacologist Josef von Mering, leading to its patenting and marketing by Bayer starting in 1904. Barbital exerts its effects primarily by enhancing...\"}],[\"$\",\"meta\",\"23\",{\"name\":\"twitter:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"link\",\"24\",{\"rel\":\"icon\",\"href\":\"/favicon.ico\",\"type\":\"image/x-icon\",\"sizes\":\"16x16\"}],[\"$\",\"$L21\",\"25\",{}]],\"error\":null,\"digest\":\"$undefined\"}\n"])</script><script nonce="YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm">self.__next_f.push([1,"11:\"$c:metadata\"\n"])</script><script nonce="YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm">self.__next_f.push([1,"22:I[61172,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"PageEditorProvider\"]\n"])</script><script nonce="YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm">self.__next_f.push([1,"23:I[63493,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"default\"]\n"])</script><script nonce="YzU2ZTJiMDgtNjk3Ni00NWNhLTkwN2ItZDk4NjdjYTViNjJm">self.__next_f.push([1,"20:[\"$\",\"$L22\",null,{\"children\":[\"$\",\"$L23\",null,{\"slug\":\"Barbital\"}]}]\n"])</script></body></html>